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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
Organisms are in constant contact to potentially harmful exogenous influences. Therefore, 
mechanisms have evolved that aim to protect the host. They are referred to as the immune system.  
The word “immune” is derived from the Latin in munos meaning “to be unaffected”. As biological 
term the designation “immune” describes the insusceptibility of an organism towards foreign or 
abnormal structures. Protozoa as well as metazoa possess an inbred innate immune system, which 
comprises various immediate nonspecific defense mechanisms, but do not lead to an immunological 
memory. Vertebrates developed additional, more complex immune processes that adapt to the specific 
stimulus. This acquired immunity persists as immunological memory after stimulus removal and 
allows a faster and more efficient response in case of a reinfection. 
1.2 INNATE IMMUNITY 
Innate immune responses are characterized by a rapid onset, a limited specificity and no formation of 
an immunological memory.  
 
Microorganisms, which summarize bacteria, viruses, fungi and multicellular eukaryotic parasites, are 
permanently in contact with the human body on external and internal epithelial surfaces. The epithelial 
barrier is a first protection shield that keeps away the vast majority of potentially harmful 
environmental agents. Next to mechanical protection, epithelia also possess chemical defense 
mechanisms to protect against microorganisms by secreting antimicrobial peptides e.g. defensins or 
lysozyme onto external epithelial surfaces. Microorganisms that overcome the epithelial barrier and 
invade the organism, e.g. through epithelial lesions, face a first line of specialized phagocyting cells, 
namely macrophages (Mϕ) and dendritic cells (DCs), that reside in the underlying tissues. Both carry 
special inherited receptors on their outer surface that recognize evolutionary conserved 
pathogen-associated molecular patterns (PAMPs) and are therefore called pattern recognition receptors 
(PRR).  
Ligand recognition by distinct PRRs activates Mϕs as well as DCs to phagocytose the encountered 
microorganism. Other PRRs are secreted into the extracellular fluids and are part of the humoral innate 
immunity. They bind foreign pattern and thereby opsonize invading microorganisms for subsequent 
phagocytosis. The elimination by phagocytosis starts immediately upon microorganism invasion and is 
the prominent innate mechanism within the first four hours after microbial penetration. The response 
is able to remove invading microorganisms before any signs of infection might even develop 
(Janeway, 2005). 
 
Microorganisms that cannot be repelled at this immediate early stage lead to the induction of early 
induced responses and are called pathogenic microorganisms or pathogens. These responses are the 
main defense at 4-96 hours post infection. They are also induced by PRRs. These do not only induce 
phagocytosis, but also generate intracellular signals that lead to the expression of pro-inflammatory 
cytokines and chemokines, which in turn initiate a local inflammation. 
Inherited innate responses are further indispensable for the induction of precise adaptive mechanisms 
(Janeway, 2005). 
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1.2.1 EARLY INDUCED RESPONSES: INFLAMMATION & CYTOKINES 
Inflammation is a physiological reaction towards potentially harmful stimuli like invading 
microorganisms or irritating substances. It can also be directed against self molecules leading to auto-
inflammatory disorders.  
Under steady state conditions, monocytes from the blood migrate into the tissues, where they 
differentiate into Mϕs and phagocytose self and foreign material within the extracellular compartment. 
Mϕs can initiate an inflammation via their PRRs. Activated Mϕs produce and secrete pro-
inflammatory cytokines especially tumor necrosis factor alpha (TNFα), interleukin 1 beta (IL-1β) and 
IL-6. TNFα and IL-1β potently activate the surrounding endothelial cells leading to vasodilatation and 
hence an upregulation of blood flow into the infected area. The increased perfusion causes redness 
(rubor) and heating (calor), two of the five cardinal features of inflammation. Vessels increase their 
permeability allowing the leakage of fluid and plasma proteins from the blood into the infected tissues. 
This causes tissue swelling (tumor) and the sensation of pain (dolor). Aching is further induced by 
prostaglandins, which are rapidly produced by activated Mϕs together with other lipid mediators as 
leukotrienes and platelet activating factor (PAF). PAF mediates increased coagulation in the 
surrounding efferent vessels, which prevents that the infection spreads through the blood stream. 
Moreover, inflammation is characterized by a functional loss within the affected area (functio laesa). 
Activated Mϕs produce chemoattractant cytokines, so called chemokines. These drive a chemotactic 
invasion of specific leukocytes into the inflamed area. TNFα induces an increased vessel diameter and 
the expression of special adhesion molecules on the endothelium. In combination with the chemokines 
CXCL8 (IL-8, murine: KC) and CCL2 this enables leukocyte extravasation. Within the tissue 
leukocytes move further along a chemokine gradient towards the origin of inflammation. CXCL8 is a 
very early induced chemokine mediating the attraction and extravasation of neutrophil granulocytes 
and naïve T lymphocytes. Later, CCL2 is secreted to attract monocytes and immature DCs into the 
inflamed tissue. These cell types do not only phagocytose, but also present antigen and therefore 
convey a pivotal role in the developing adaptive responses. 
 
Mϕs and neutrophils are part of the cellular innate immunity and potently phagocytose and digest 
foreign material. Neutrophils are the most abundant type of polymorphnuclear leukocytes in the 
bloodstream making up about 50% of all circulating leukocytes, but are never seen in the tissue unless 
an inflammatory response is induced. During an inflammation neutrophils are recruited to the site of 
infection or injury and make up the most frequent cell type. Neutrophils are short lived and die during 
the inflammatory response within the tissue thereby leading to pus formation. Mϕs do not only destroy 
pathogens by digestion, but also initiate adaptive responses by antigen presentation. Mϕs do not die 
during the infection, but can convey subsequent immune responses (Janeway, 2005). 
 
The induced pro-inflammatory cytokines TNFα, IL-1β and IL-6 initiate various further mechanisms, 
which aim to efficiently remove invading pathogens by acting on different local as well as distant cell 
types and tissues throughout the body.  
They for instance initiate the generation and mobilization of neutrophils in the bone marrow and 
function as endogenous pyrogens, which accelerates the formation of adaptive responses. Locally 
secreted TNFα and IL-1β activate endothelial cells to express altered cellular adhesion molecules, 
which initiates immune cell extravasation. TNFα induces intravascular coagulation. Moreover, IL6 
induces an acute phase response that leads to the secretion of collectins, which are secreted PRRs that 
opsonize microorganisms. 
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Interferons (IFNs) comprise a cytokine subgroup with potent antiviral functions. Accordingly, they are 
predominantly produced during viral infections. IFNα is mainly secreted by leukocytes, IFNβ by 
fibroblasts. Secreted type I IFNs induce an antiviral state in the producing cell itself (autocrine) as well 
as in neighboring cells (paracrine). 
IFNs signal via the JAK-STAT signaling pathway and lead to the induction of IFN-stimulated 
genes (ISG). These turn on mechanisms that interfere with viral replication and block a spreading of 
the infection to uninfected cells. Type I IFNs induce e.g. 2´-5´oligoadenylate syntethase (OAS), an 
enzyme that activates the internal RNase L to degrade intracellular viral, but also host ribonucleic 
acids (RNAs). Furthermore, protein kinase R (PKR) is induced, which phosphorylates the eukaryotic 
translation initiation factor 2 alpha (eIF2α) and thereby inactivates the viral and host protein synthesis 
within the cell. Type I IFNs also initiate the production of interferon gamma (IFNɣ), a type II IFN, 
which is mainly secreted by T lymphocytes and natural killer (NK) cells. IFNɣ potentiates the antiviral 
mechanisms of type I IFNs, but has its greatest importance by shaping adaptive responses.  
Beyond the induction of cytokines and chemokines pathogens recognition via PRRs also leads to the 
expression of co-stimulatory molecules on Mϕs and DCs. Surface molecules like CD80 (B7.1) and 
CD86 (B7.2) are indispensable co-receptors for the activation of adaptive responses (Janeway, 2005).  
1.2.2 PATTERN RECOGNITION RECEPTORS – INNATE IMMUNE SENSORS 
In 1989 Charles Janeway postulated the concept of distinct microbial pattern that are recognized by 
specific receptors of the innate immune system (Janeway, 1989). Until then, innate immunity was 
thought to be basically composed of nonspecific phagocytosis and the main immunological research 
focused on adaptive mechanisms. Today we know that there are evolutionary conserved patterns on 
microbes, so called pathogen-associated microbial patterns (PAMPs) that are recognized by germline-
encoded receptors termed pattern recognition receptors (PRRs). Next to PAMPs PRRs also recognize 
endogenous danger-associated molecular patterns (DAMPs) that originate e.g. from injury or cell 
death.  
A great variety of PRRs has been discovered until now. There are phagocytosis-inducing PRRs (e.g. 
scavenger receptors and C-type lectin receptors (CLRs) and signaling PRRs, which convey 
downstream signals that initiate early induced innate responses as inflammation. Four major families 
of these signaling PRRs have been classified: the TOLL-like receptor (TLR), RIG-I like 
receptor (RLR), AIM2-like receptor (ALR) and NOD-like receptor (NLR) family.  
All PRRs have inherited and invariable receptor specificity. Therefore, innate mechanisms can react 
immediately to invading microorganisms, but they can only recognize a limited spectrum of PAMPs in 
contrast to the antigen receptors of the adaptive immune system, which can bind an infinite 
multiplicity of antigens. However, PRRs can recognize a broad spectrum of pathogens as PAMPs are 
shared by several microorganisms e.g. viral double stranded RNA (dsRNA), flagellin in the bacterial 
flagellum as well as lipopolysaccharid (LPS) in the cell wall of gram negative bacteria. Moreover, 
PAMPs are vital microbial structural or nucleic acid components that cannot be altered to escape this 
PRR immune recognition.  
A combination of different PRRs is expressed on immune as well as on non immune cells. The 
composition is cell type-specific. Different receptors elicit diverse innate responses and shape the 
innate as well as the developing adaptive immune response (Janeway, 2005; Mogensen, 2009). 
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1.2.3 TLRS – TOLL-LIKE RECEPTORS 
TLRs are membrane bound PRRs that scan the extracellular and luminal fluids for microbial patterns. 
These are recognized by the leucine-rich repeats (LRR)-containing ectodomain, while the intracellular 
TOLL/IL-1 receptor (TIR) domain exerts the downstream signal transduction. All TLR members 
except TLR3 signal via the adaptor protein myeloid differentiation primary response gene 88 
(MyD88) to induce nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) as well as 
mitogen-activated protein kinases (MAPK) signaling. Both result in the induction of pro-inflammatory 
cytokines. TLR3 signals MyD88-independent via the adaptor TIR-domain-containing adapter inducing 
IFNβ (TRIF). This TRIF-dependent TLR signaling pathway leads to the activation of NF-κB as well 
as IFN regulatory factor 3 (IRF3), which next to NF-κB target genes also induces type I IFNs. TLR4 is 
the only TLR protein that can signal spatially separated via both pathways (Kawai and Akira, 2010). 
The TLR members TLR3, TLR7, TLR8 and TLR9 are located on intracellular membranes of 
endosomes, lysosomes and endolysosomes as well as the endoplasmic reticulum, while all other TLRs 
are located at the plasma membrane. TLR4 is unique as it switches between both localizations upon 
activation. The plasma membrane bound TLRs recognize mainly microbial membrane components 
(e.g. TLR5 recognizes flagellin of the bacterial flagellum), while TLRs on intracellular membranes 
recognize microbial nucleic acids (e.g. TLR3 recognizes dsRNA) (Kawai and Akira, 2010).  
1.2.4 NLRS – NUCLEOTIDE-BINDING DOMAIN AND LEUCINE-RICH REPEATS-
CONTAINING RECEPTORS 
1.2.4.1 DISCOVERY & PLANT HOMOLOGUES 
The nucleotide-binding domain (NBD) and leucine-rich repeat (LRR)-containing gene family is the 
largest known family of intracellular PRRs so far. It was initially found by database search for 
homologous structures to plant resistance genes (R genes). R genes-encoded proteins detect the 
presence of pathogens within plants and induce defense responses via MAPK signaling or cell death. 
The encoded proteins are either cytosolic or membrane bound and their largest know subgroup 
contains a nucleotide-binding site as well as an LRR domain and is therefore called NB-LRR 
subfamily of R genes (Jones and Takemoto, 2004).  
In the human genome 22 R gene homologues were found that share strong structural and functional 
similarities to NB-LRR genes (Aravind et al., 2001; Tschopp et al., 2003). To emphasize the 
evolutionary conserved domains and the similarity to plant NB-LRR genes, the new gene family was 
named NBD and LRR-containing (NLR; also NOD-like receptor) gene family (Ting et al., 2008). 
1.2.4.2 STRUCTURE & SUBFAMILIES 
All NLRs have a typical tripartite domain structure (Fig. 1-1). Two domains, the LRR and the NBD, 
are conserved among plants and vertebrates and shared by almost all NLR members. The LRR domain 
at the carboxy-terminal end of the NLR protein senses specific ligands in analogy to the TLRs LRR 
domain.  
The centrally located NBD is also referred to as NOD (nucleotide-binding and oligomerization 
domain) or NACHT domain, which is an acronym for NAIP, CIITA, HET-E and TP1 (see table of 
abbreviations). The NBD is required for NLR oligomerization and hence activation. It is part of a 
P-loop NTPase with nucleotide triphosphatase activity (Martinon and Tschopp, 2004). 
The NLR amino-terminus harbors the effector domain, which upon NLR oligomerization leads to 
homotypic protein-protein interactions. These interactions link the receptor to downstream adaptor and 
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effector proteins that convey signal transduction. Four different effector domains are known today that 
are shared by various NLR members. NLR members are subclassified by these N-terminal effector 
domains. NLRAs contain an acidic activation domain (AD; also: acidic transactivation or acidic 
domain), NLRBs a baculoviral inhibitory repeat-like domain (BIR), NLRCs a caspase activation and 
recruitment domain (CARD) and NLRPs a pyrin domain (PYD). NLRs that do not share any effector 
domain homology are classified as NLRX (Tab. 1).  
 
N-terminal effector domains NLR subfamilies Former classified as Representatives 
Acidic activation domain (AD) NLRA  CIITA 
Baculoviral inhibitory repeat-like domain (BIR) NLRB NAIPs, BIRC NAIP 
Caspase activation and recruitment domain (CARD) NLRC NODs, CARDs NOD2, NLRC5 
Pyrin domain (PYD) NLRP NALPs, PAN, PYPAF NLRP3 
No strong homology to other NLR subfamilies NLRX  NLRX1 
Tab. 1: NLR subfamilies classified by effector domain homology.  
Until the agreement on a generally accepted nomenclature of the NLR members in 2008 there was a 
confusing diversity of names for individual NLR members. CARD-containing NLR members were 
referred to as NODs or CARDs, while PYD-containing NLRs were denoted NALPs. Four NLR 
members were not renamed according to the new classification due to intense research and a vast 
amount of publications ahead of the consensus of a common NLR nomenclature. These are the NLRA 
protein CIITA (MHC class II transactivator), the NLRB protein NAIP (neuronal apoptosis inhibitory 
protein) and the NLRC proteins NOD1 and NOD2 (nucleotide-binding oligomerization domain-
containing protein 1 and 2), respectively (Ting et al., 2008).  
Up to date there are 22 known human and 34 murine NLR members. Not for all of them ligands have 
been identified so far and despite structural similarities some family members might actually not even 
have receptor functions (Martinon and Tschopp, 2005). 
1.2.4.3 SIGNALING 
In the inactive state, NLRs are autorepressed by the LRR domain, which hinders the NBD sterically 
from oligomerization. This prevents spontaneous oligomerization and activation in the absence of 
proper ligands. Furthermore, endogenous NLR concentrations are low to prevent activation by 
aggregations. Ligand sensing induces a conformational change that exposes the NBD and hence 
allows NLR oligomerization. Depending on the NLR member, homo- as well as hetero-oligomers are 
known. Effector domains become exposed and corresponding adaptor proteins are recruited via 
homotypic interactions. Adaptors are mutually activated by close vicinity and a signal is conveyed 
downstream (Martinon and Tschopp, 2005).  
CARD-containing NLR members (NLRCs) recruit CARD-containing adaptors as the serine threonine 
kinase RIP2, which is recruited e.g. to NOD1 and NOD2. Subsequently, this activates NF-κB and 
MAPK signaling and the production of inflammatory cytokines (Girardin et al., 2001; Inohara et al., 
2000; Park et al., 2007). In contrast, PYD-containing NLRs (NLRPs) recruit PYD-containing 
adaptors. NLRPs that lead to the formation of caspase-1 activating inflammasomes (e.g. NLRP1, 
NLRP3, NLRP4) associate e.g. with the PYD-containing inflammasome adaptor apoptosis-associated 
speck-like protein containing a CARD (ASC), which is encoded by the PYCARD gene. ASC recruits 
caspase-1 via a CARD-CARD interaction. Oligomerization of NLRPs and their interaction with 
adaptors and effectors brings inflammatory caspases close together and leads to the activation of the 
inflammasome complex, cleaves IL-1 and IL-18 propeptides into their active forms (Martinon et al., 
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2002). IL-1 and IL-18 subsequently bind to their receptor complexes at the plasma membrane. These 
(like TLRs) have intracellular TIR domains and recruit TIR adaptors as MyD88 to activate NF-κB and 
other inflammatory signaling pathways.  
1.2.4.4 NLR LIGANDS & EXPRESSION 
Diverse ligands of foreign (PAMPs), but also endogenous (DAMPs) nature can be sensed by NLRs. 
NOD1 and NOD2 homo-oligomers e.g. sense fragments of the bacterial cell wall component 
peptidoglycan (PGN). NOD1 detects γ-D-glutamyl-mesopimelic acid (meso-DAP) present in PGN of 
all gram negative and certain gram positive bacteria (Chamaillard et al., 2003a), while NOD2 
recognizes muramyl dipeptide (MDP) present in all (gram negative and positive) bacteria (Girardin et 
al., 2003). NLRP3 instead was shown to form an inflammasome that is activated by a decline in the 
intracellular K+ concentration (Muñoz-Planillo et al., 2013) and therefore by a great variety of 
structurally unrelated ligands that all induce K+ efflux. Among these are e.g. bacterial and viral RNA 
(Kanneganti et al., 2006a, 2006b), monosodium urate (Martinon et al., 2006), nigericin (Mariathasan 
et al., 2006) as well as reactive oxygen species (ROS) that are produced after exposure to silica or 
asbestos (Dostert et al., 2008). The NLRP3 inflammasome leads to activation of caspase-1. Due to the 
variety of ligands NLRP3 is thought to be a general cellular stress receptor.  
NLRs are defined as cytosolic PRRs, but they can also associate to other cellular compartments. 
NOD1 and NOD2 for instance are usually cytoplasmic, but were also found to be attached to the 
plasma membrane upon activation, which seems to be involved in downstream signaling (Barnich et 
al., 2005; Kufer et al., 2008). Furthermore, NLRX1 locates at the mitochondrial membrane (Moore et 
al., 2008) and CIITA within the nucleus (Harton et al., 1999). 
1.2.4.5 NLRS AND DISEASE 
Mutations in NLR genes were found to be involved in the development of a variety of inflammatory 
disorders.  
Missense mutations in the NBD of NLRP3 can e.g. cause different autosomal dominant 
autoinflammatory syndromes: familial cold autoinflammatory syndrome, Muckle–Wells syndrome or 
chronic infantile neurological cutaneous and articular syndrome. These are characterized by periodic 
fever and skin rashes (McDermott, 2002).  
In contrast, loss of function mutations in the CIITA gene severely impede the expression of major 
histocompatibility complex class II (MHC class II, MHC II) receptors. This subsequently causes a 
severe combined immunodeficiency with impaired B and T cell responses towards extracellular 
pathogens and consequently leads to strong inflammations. The vulnerability due to decreased 
MHC class II levels is referred to as Bare Lymphocyte Syndrome (BLS) type II.  
Mutations in NOD2 are associated with two different inflammatory disorders: Blau syndrome and 
Crohn´s disease (CD, Morbus Crohn). CD is a chronic inflammatory disorder of the intestine 
associated with mutations in the NOD2 LRR domain (Hampe et al., 2001; Hugot et al., 2001; Ogura et 
al., 2001). CD-associated mutations impair NOD2-mediated MDP recognition and the subsequent 
NF-κB activation in the presence of bacterial infection (Chamaillard et al., 2003b; Inohara et al., 
2003). Further clinical aspects of CD are introduced below (see 1.4). The rare autosomal dominant 
Blau syndrome is caused by mutations in the NOD2 nucleotide binding domain instead (Miceli-
Richard et al., 2001; Wang et al., 2002), which leads to an overactivation of NOD2 even in the 
absence of bacterial insults (Chamaillard et al., 2003b; Kanazawa et al., 2005). The disease is 
characterized by granulomatouse arthritis, uveitis as well as skin lesions.  
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1.2.5 NLRC5 – AN NLR MEMBER WITH AMBIGUOUS FUNCTIONS 
NLRC5 was previously also referred to as NOD4, NOD27 or CLR16.1 until the NLR nomenclature 
classified the protein to the NLRC subfamily due to structural means (Ting et al., 2008). The NLRC5 
gene is located on chromosome 16q13 and covers a region of 93980 base pairs (bp). It encodes a 
messenger RNA (mRNA) with a length of 6775 bp containing 52 exons (NCBI ID: 84166). This 
mRNA is translated into a 1866 amino acid long peptide chain with a molecular weight of 204,6 kDa 
(Uniprot ID: Q86WI3). 
1.2.5.1 EXPRESSION & INDUCTION 
Initially NLRC5 was reported to be expressed in brain, lung and prostate tissue and only little amounts 
were found in immune tissues (Kuenzel et al., 2010). In contrast, other groups reported NLRC5 to be 
highly expressed in immune tissues and hematopoietic cells (Benko et al., 2010; Neerincx et al., 
2010). 
The protein was found to be strongly upregulated by IFNɣ in hematopoietic as well as 
non-hematopoietic cells (Benko et al., 2010; Kuenzel et al., 2010; Neerincx et al., 2010).  
Secreted IFNɣ binds to the IFNɣ receptor complex on the plasma membrane and induces intracellular 
JAK-STAT signaling. This leads to the phosphorylation of STAT 1 and the formation of 
phosphoSTAT 1 homodimers. These can enter the nucleus and are believed to bind the NLRC5 
promoter region and induce the transcription of NLRC5 (Kuenzel et al., 2010).  
It was also reported that NLRC5 can be moderately induced by IFNβ as well as LPS and the synthetic 
dsRNA analogue polyinosinic acid‑polycytidylic acid (poly(I:C)). The last two are TLR ligands 
capable of inducing IFNβ either via TRIF-dependent TLR4 or TLR3 signaling. Furthermore, some 
viruses were reported to induce NLRC5 by inducing IFNɣ e.g. Sendai virus (Neerincx et al., 2010), a 
single stranded (ss) RNA virus, as well as Cytomegalovirus (Kuenzel et al., 2010), a double 
stranded (ds) deoxyribonucleic acid (DNA) virus.  
1.2.5.2 STRUCTURE 
NLRC5 shares the NLR-typical tripartite domain structure consisting of a C-terminal LRR domain, a 
centrally located nucleotide binding domain and a N-terminal effector domain (Fig. 1-1).  
The extended LRR region harbors 26 LRR motifs and makes NLRC5 the largest of all known NLR 
members. Alternative mRNA splicing within the LRR region generates five distinct NLRC5 isoforms, 
one of them is missing the entire LRR region. Alterations in the length of the LRR region are 
supposed to yield conformational variants and might thereby allow the recognition of different ligands. 
The isoforms could furthermore regulate specific NLRC5 functions in a cell type- or tissue-specific 
manner. Although NLRC5 belongs to the family of PRRs, it is unknown if the protein is capable of 
recognizing a specific yet unknown ligand and if this would occur in a direct or indirect manner 
(Neerincx et al., 2010).  
The NLRC5 NBD region contains a Walker A motif (also called a phosphate or P-loop), which is a 
nucleoside triphosphate (NTP) binding site. It is not known so far if ATP or GTP nucleosids are bound 
to the NLRC5 Walker A motif. Furthermore, the NTP hydrolysis site, called Walker B motif, is 
located within the NBD (Neerincx et al., 2010).  
The N-terminal effector domain of NLRC5 comprises the tertiary structure of a death fold domain 
with its typical α-helical repeats, although it doesn´t share much structural similarities to the known 
death fold domains of other NLRs as e.g. the CARD and PYD domains. Therefore, the NLRC5 protein 
is assigned to the NLRC subfamily and the effector domain is referred to as atypical CARD domain.  
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Wagner and colleagues found that this atypical CARD neither homotypically interacts with the CARD 
of the adaptor protein RIPK2, which is known to activate pro-inflammatory pathways in NOD1 and 
NOD2 signaling; nor did it interact with the CARD or PYD domain of ASC (Wagner et al., 2009). In 
contrast, the group around Davis later reported the interaction of NLRC5 with ASC, an observation 
that links NLRC5 to inflammasomes (Davis et al., 2010). There is only little knowledge on further 
adaptors that interact with the atypical NLRC5 CARD domain. Consequently, there is not much 
known about potential NLRC5 downstream signaling pathways. 
 
Fig. 1-1: Tripartite NLR structure 
Depicted is a simplified illustration of the tripartite NLR structure as well as the human NLRC5 and CIITA domain structure. The N-terminal 
structure can be constituted by AD, BIR, CARD or PYD domains and account for the classification into NLR subfamilies. Length and 
composition of the LRR region varies between individual NLR members. Moreover, accessory domains and motifs exist. The CIITA isoform 
expressed in DCs furthermore bears an N-terminal CARD domain upstream the AD. 
Abbreviations: NBD (nucleotide-binding domain), LRR (leucine-rich repeat), CARD (caspase activation and recruitment domain), aCARD 
(atypical CARD), AD (acidic activation domain), NLS (nuclear localization signal) 
1.2.5.3 PROPOSED FUNCTIONS  
The proposed NLRC5 functions are shortly summarized below and reflect the contradictory results 
published.  
 
Antiviral Function 
Initially NLRC5 was reported to potentiate antiviral signaling, which supports a pro-inflammatory role 
of the protein.  
The infection of human foreskin fibroblasts with CMV induced IFNɣ, which led to an upregulation of 
NLRC5 via the JAK/STAT signaling pathway. NLRC5 subsequently activated the nuclear promoter 
sites IFNɣ activation sequence (GAS) and Interferon‑specific response element (ISRE) and mediated 
the transcription of certain antiviral proteins e.g. IFNα (Kuenzel et al., 2010).  
NLRC5 was further necessary for efficient antiviral responses against SeV. When NLRC5 was 
silenced only diminished amounts of IFNβ as well as CXCL10, ‘regulated on activation, normal T cell 
expressed and secreted’ (RANTES, CCL5) and macrophage inflammatory protein 1α (MIP1α, CCL3) 
were induced in infected THP-1 cells. All of these are crucial to initiate a proper antiviral response. 
However, autoactivation experiments could not confirm an activation of the ISRE promoter regions by 
NLRC5 nor detect an activation of the NF-κB, IFNβ, IRF3 or IRF7 promoter regions (Neerincx et al., 
2010).  
 
Inhibition of NF-κB and IFN signaling pathways 
In contrast, other groups describe NLRC5 be a negative regulator of inflammation as the protein limits 
the duration and intensity of an inflammatory event. 
Benko and colleagues reported that NLRC5 overexpression in HEK293 cells leads to a diminished 
NF-κB, ISRE and AP-1 promoter activity. Furthermore, they observed that the silencing of NLRC5 by 
short hairpin RNAs (shRNAs) in the murine macrophage cell line RAW264.7 reduces the expression 
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of the anti-inflammatory IL-10, while pro-inflammatory cytokines like IL-6, IL-1β and TNFα were 
significantly upregulated (Benko et al., 2010). These results are supported by Cui et al. who reported 
that NLRC5 is a potent negative regulator of the NF-κB signaling pathway supposedly by binding to 
the IκB kinase complex (IKKα/IKKβ). Furthermore, they found NLRC5 to inhibit IFNβ promoter 
activity via an interaction with retinoic acid‑inducible gene 1 (RIG-I) and melanoma differentiation 
associated gene 5 (MDA5). Consequently, the group around Cui (in contrast to others) proposes 
NLRC5 to negatively regulate type I IFN responses. A transient knockdown of NLRC5 by small 
interfering RNAs (siRNAs) enhanced innate immune responses as the induction of pro-inflammatory 
mediators e.g. TNFα as well as IFNβ was elevated (Cui et al., 2010). In accordance, the group around 
Kumar found NLRC5 to suppress NF-κB activation using reporter gene assays (Kumar et al., 2011). 
These results collectively support an anti-inflammatory NLRC5 function. 
However, in vivo and ex vivo experiments based on Nlrc5-deficient mice could not verify any of the in 
vitro overexpression and silencing data described by any group before. Nlrc5-deficient primary cell 
cultures showed a normal generation of pro-inflammatory cytokines, chemokines and type I IFNs if 
stimulated with various TLR or RLR ligands as well as dsDNA. Neither viral infections with 
Newcastle disease virus (NDV, ssRNA) or Herpes simplex virus 1 (HSV-1, dsDNA) nor bacterial 
infections with the gram positive Francisella tularensis, Salmonella enterica ssp. enterica ser. 
Typhimurium or the gram negative Listeria monocytogenes led to an altered production of pro-
inflammatory mediators in Nlrc5-deficient cells (Kumar et al., 2011).  
 
Inflammasome Activation 
Kumar and colleagues further observed that NLRC5 overexpression activates caspase-1 and induces 
the production of IL-1β in vitro. Activation of the NLRP3, NLRC4 and absent in melanoma 2 (AIM2) 
inflammasome was tested in Nlrc5-deficient primary cultures using various specific ligands, but no 
effect on the IL-1β production was found. Therefore, they concluded that NLRC5 does not participate 
in the formation of any of these inflammasomes, but might rather comprise an own NLRC5 
inflammasome with yet unassigned ligands (Kumar et al., 2011). The group around Jenny Ting also 
found implications for NLRC5 in inflammasome activation. They observed a reduced production of 
IL-1β in NLRC5-silenced cells during infections with different bacteria and proposed NLRC5 has a 
pro-inflammatory function as it promotes the generation of mature IL-1β. The tested bacterial strains 
Escherichia coli, Shigella flexneri and Staphylococcus aureus typically lead to inflammasome 
activation in an NLRP3- and ASC-dependent fashion, which was impaired upon NLRC5 deletion. 
Other NLRP3 activators like monosodium urate or alum also lead to a diminished IL-1β production in 
NLRC5-silenced cells, while the activation of the NLRP3 inflammasome by the pore forming toxins 
nigericin and α-hemolysin was not altered. Co-immunoprecipitation studies found NLRC5 to interact 
directly with the NBD of NLRP3 and the adaptor protein ASC (in contrast to observations made by 
(Wagner et al., 2009). Hence, it was concluded that NLRC5 is possibly a component of the NLRP3 
inflammasome or a newly discovery inflammasome itself (Davis et al., 2010). 
 
NLRC5 As Transcriptional Regulator In The Nucleus 
While NLRC5 was initially described to be located within the cytosol (Kuenzel et al., 2010; Neerincx 
et al., 2010), a shuttling mechanism was discovered between the cytosol and the nucleus later on 
(Benko et al., 2010; Meissner et al., 2010). Using sequence analysis and deletion mutants Meissner et 
al. discovered a nuclear localization signal at the transition between CARD and NBD domain, which 
controls the subcellular localization of NLRC5. Nuclear import is conveyed by importin α, while the 
export was found to depend on exportin 1, also known as chromosome maintenance region (Crm1 or 
CrmA) (Meissner et al., 2010). A comparable mechanism is used by another NLR member, CIITA, 
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which also shuttles in an exportin 1-dependent fashion between the cytosol and the nucleus acting as a 
transcriptional coactivator for MHC class II coding genes within the nucleus (Spilianakis et al., 2000; 
Steimle et al., 1994).  
Accordingly, the group around Meissner postulated a rather nuclear NLRC5 function and identified 
genes that were differentially regulated by the NLR member. Most strikingly NLRC5 was found to 
influence the expression of those human leukocyte antigen (HLA) genes that code for MHC class I 
molecules (HLA-A, -B, -C, -E) as well as genes that are associated with MHC class I antigen 
presentation and processing (e.g. β2M, LMP2, TAP1). They further identified NTP binding within the 
Walker A motif to be required for the induction of MHC class I, while NTP hydrolysis at the 
Walker B site was not. Mutations in the Walker A motif prevented NTP binding, while mutations 
within the nuclear localization signal (NLS) prevented proper importin α binding. Both abrogated the 
nuclear import of NLRC5 and thereby gene induction. Using reporter gene and chromatin precipitation 
assays it was further discovered that NLRC5 directly binds and transactivates the promoter regions of 
HLA and HLA-associated genes (Meissner et al., 2010, 2012a). 
1.3 ADAPTIVE IMMUNITY 
Adaptive defense mechanisms are precise and combat intruding pathogens efficiently if innate 
responses alone fail to entirely clear the infection. They start delayed, approximately 4-7 days post 
infection, because antigen-specific adaptive effector cells need to be generated first (Janeway, 2005). 
1.3.1 GENERATION & MATURATION OF LYMPHOCYTES 
Adaptive responses are initiated in secondary lymphoid organs, namely the spleen that collects 
antigens from the blood, the lymph nodes that collect antigens from the tissues and the 
mucosa-associated lymphoid tissues (MALTs) that encounter antigen from epithelial surfaces.  
Key players of adaptive responses are the lymphocytes, which derive from lymphoid precursors in the 
bone marrow and mature in the central (primary) lymphoid organs. Two types of lymphocytes exist: 
T lymphocytes (T cells, TCs) that mature in the thymus and B lymphocytes (B cells, BCs) that mature 
in the bone marrow. During lymphocyte development a single lymphoid progenitor gives rise to a vast 
number of naïve lymphocytes that all bear antigen receptors, either T (TCR) or B cell receptors (BCR) 
with a unique specificity. Developing immature lymphocytes that strongly bind self antigens are 
potentially self-reactive and are therefore removed from the lymphocytes receptor repertoire, a process 
termed clonal depletion. Naïve T and B lymphocytes leave the primary lymphoid organs to circulate 
continuously through the blood and the peripheral (secondary) lymphoid organs until their surface 
bound lymphocyte antigen receptors encounters their specific antigen. Upon antigen recognition naïve 
lymphocytes stop migrating. They start to proliferate and differentiate into distinct effector cells, 
which clonally expand to generate progeny with identical antigen receptor specificity as well as equal 
effector functions. 
Next to the recognition of their specific antigen naïve lymphocytes need a second, co-stimulatory 
signal to be activated for maturation. This controls the initiation of adaptive responses and prevents the 
onset of defense mechanisms against harmless antigens. Missing co-stimulation leads to the induction 
of anergy as the presented antigen is considered as “self”. This loss of reactivity towards the presented 
peptide cannot be restored if the antigen is encountered again (Janeway, 2005). 
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1.3.2 VARIANT LYMPHOCYTE ANTIGEN RECEPTORS 
A vast variety of innate PRRs can be expressed on different cell types to convey innate immune 
responses. In contrast, lymphocytes express only one type of adaptive antigen receptor that possesses 
only one particular antigen-binding specificity to initiate adaptive responses. All naïve lymphocytes 
recognize different antigens, but several lymphocytes can encounter diverse antigens on the same 
pathogen.  
Contrary to the invariant innate pathogen receptors (PRRs) lymphocyte antigen receptors are not 
germline-encoded. They have individual variant antigen-binding properties and recognize only a very 
distinct antigen on a precise pathogen. A vast variety of TC and BC receptor specificities (1 x 108 in 
humans) exist, because a huge individual receptor repertoire is generated by somatic recombination 
during lymphocyte development. 
However, different from PRRs there is only a limited number of naïve lymphocytes that bear a 
particular antigen-binding receptor. Clonal expansion upon antigen recognition is therefore essential 
for an effective adaptive response. 
The majority of effector cells undergo apoptosis after the antigen has been successfully cleared from 
the system, but some effector cells bearing that receptor specificity persist. These constitute the 
immunological memory and facilitate a faster response towards this exact antigen in case of 
reinfection (Janeway, 2005).  
1.3.3 B LYMPHOCYTES & HUMORAL ADAPTIVE IMMUNITY 
T and B lymphocytes differ in the architecture of their antigen receptors, in the way they recognize 
antigens and the effector functions they mediate.  
 
B cells, DCs and Mϕs are professional antigen presenting cells (APCs). They constitutively express 
MHC class II receptors on their surface and present extracellular antigens to T lymphocytes (see 
1.3.4). Furthermore, naïve B lymphocytes recognize unprocessed antigens in the extracellular space 
via their BCRs.  
Simultaneous signaling of the BCR and a surfacial MHC class II induces the maturation of naïve 
B lymphocytes to antibody secreting plasma cells. These antibodies are directed against the native 
BCR-bound antigen (antigen: antibody generating). 
Antibody-binding neutralizes extracellular pathogens and bacterial toxins and prevents a spreading of 
the infection. It further tags pathogens for phagocytosis, a process known as opsonization.  
Intracellular infections are not recognized by the adaptive humoral responses, because antibodies are 
only directed against native antigens and bacterial-derived toxins in the extracellular room. Additional 
cell-mediated adaptive mechanisms are required for a proper immune surveillance, which depends on 
the effector functions of T lymphocytes (Janeway, 2005). 
1.3.4 T LYMPHOCYTES & CELL-MEDIATED ADAPTIVE IMMUNITY 
Naïve T lymphocytes detect processed peptide antigens that are presented by MHC molecules on the 
surface of APCs. Co-stimulatory signals, which are needed for T lymphocyte activation, are also 
delivered by APCs. Their expression is induced by innate mechanisms e.g. upon PRR recognition. 
Accordingly, innate immunity plays a pivotal role in the generation of adaptive responses. 
The presentation of endogenous and exogenous peptides by MHC receptors and their recognition by 
T lymphocytes is essential for the generation of adaptive responses. Accordingly, T lymphocytes are 
screened for their ability to bind self peptides on MHC molecules during development in the primary 
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lymphoid organs. Immature T cells receive survival signals if their TCR is able to interact with 
MHC-peptide complexes (positive selection). Cells that strongly interact with MHC-bound self-
peptides are retrieved these survival signals (negative selection) to prevent the development of 
autoreactive T lymphocytes. 
MHC class I molecules, which present intracellular peptides, are bound by the TCR in combination 
with the CD8 co-receptor. CD8+ T lymphocytes mature to cytotoxic effector cells. These cytotoxic 
T lymphocytes (CTLs) convey a cell-specific killing towards attached cells if the particular antigen is 
encountered again. CTLs thereby eliminate infected, but also malignant cells. 
Extracellular peptides are presented on MHC class II molecules and recognized by TCRs that carry a 
CD4 co-receptor. CD4+ T lymphocytes mature to T helper cells, which are activated to convey their 
effector function upon encounter of the particular antigen on a MHC class II receptor. Different 
CD4+ T cell populations exist that encompass distinct effector functions. 
For instance, Th1 cells mainly secret IFNɣ, TNFα and IL-2. They potently induce Mϕ activation and 
differentiation. In contrast, Th2 cells are not involved in cell-mediated innate responses. They convey 
the co-stimulatory signal to activate naïve BCs and are therefore indispensable for the adaptive 
humoral immunity (Janeway, 2005). 
1.3.5 ANTIGEN PRESENTATION 
Antigens are generated inside the cell and presented on major histocompatibility complexes (MHC) at 
the plasma membrane. They are recognized by T lymphocytes via their TCR. Two distinct MHC 
classes exist called MHC class I and II (also MHC I and MHC II), which both share a comparable 
three dimensional structure as well as similar biological functions. MHC class I and II components are 
collectively encoded within the HLA gene cluster. Their heavy chains are highly polymorphic. Both 
classes differ in their expression pattern and in the origin, generation and loading of bound peptides. 
Both MHC complexes induce different adaptive defense mechanisms (Neefjes et al., 2011) (see also 
1.3.4). 
1.3.5.1 MHC CLASS II COMPLEX 
MHC class II molecules are heterodimers that consist of two homogenous heavy chains (designated α 
and β). Each of these chains is encoded by one of the highly polymorphic genes HLA-DR, HLA-DQ or 
HLA-DP. The α and β chain are assembled in the ER and associate with an invariant chain, Ii, which 
mediates a rapid transport of the MHC II-Ii complex to the late endosomal compartment for peptide 
loading. MHC class II complexes present exogenous antigens, which are derived from the extracellular 
space or the endosomal compartment. Self or foreign proteins are taken up by phagocytosis and 
degraded to peptides by proteases in the late endosome. The invariant chain binds the MHC II peptide 
binding groove that forms between the α and β chain. This prevents ER peptides from binding to the 
MHC II molecule. In the late endosomal compartment Ii is digested by cathepsins, just the class II-
associated Ii peptide (CLIP) region is preserved within the MHC II peptide binding groove. It is 
exchanged with a suitable peptide by HLA-DM, an MHC-like molecule that acts as a chaperone. The 
late endosomal compartment containing the MHC II α/β complex, HLA-DM and cathepsins is also 
termed the MHC class II peptide loading compartment (MIIC) (Hartman et al., 2010). Peptide-loaded 
MHC class II complexes are transported from the late endosome to the plasma membrane for antigen 
presentation (Neefjes et al., 2011). 
The expression of the MHC class II α and β chain and proteins involved in MHC II presentation e.g. Ii 
and HLA-DM is regulated by the NLR family member CIITA. CIITA is strongly induced by IFNɣ. It 
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does not directly bind to the DNA, but is recruited to the enhanceosome that assembles around the 
SXY motif within the MHC class II promoter region. CIITA recruits the transcription machinery and 
thereby regulates the transcriptional regulation of MHC class II expression (Reith et al., 2005). 
The expression of MHC class II is restricted to professional APCs in the steady state, but IFNɣ 
induces MHC class II molecules also on other cell types like fibroblasts, endothelial and epithelial 
cells during the course of inflammation or infection (Bland, 1988; Geppert and Lipsky, 1985). 
MHC class II-peptide complexes are bound by CD4+ T lymphocytes and initiate their maturation to 
effector cells as well as their subsequent activation. 
 
Fig. 1-2: Generation and presentation of antigenic peptides 
a) Intracellular proteins are degraded by proteasomes within the cytosol, imported into the ER and bound onto MHC class I:β2M complexes. 
Loaded MHC class I:peptide complexes are presented to CD8+ T cells at the plasma membrane. b) Extracellular proteins are degraded within 
endosomes and loaded onto MHC class II complexes in the MIIC, which is part of the late endosomal compartment. 
Figure adapted after: “NLRC5: a key regulator of MHC class I-dependent immune responses.” Kobayashi & van den Elsen, Nature Reviews 
Immunology, 2012 December  
Abbreviations: β2M (beta-2- microglobulin), CLIP (class II-associated li peptide), HLA (human leukocyte antigen), MIIC (MHC class II 
peptide loading compartment), MHC (major histocompatibility complex), TAP2 (transporter associated with peptide binding 2), TCR (T cell 
receptor) 
1.3.5.2 MHC CLASS I COMPLEX 
MHC class I molecules are ubiquitously expressed on the surface of all nucleated cells. NF-κB and 
ISRE binding sites are located in the promoter regions of MHC class I coding genes. Accordingly, 
MHC I expression is further upregulated during inflammatory responses (Gobin et al., 1998a, 1999).  
The MHC class I complex predominantly presents cytosolic and nuclear peptides to the T cell receptor 
of CD8+ T lymphocytes. Cytosolic proteins are either endogenous or derived from intracellular 
pathogens. They are mainly degraded by the cytosolic 26S proteasome, while nuclear proteins are 
degraded by nuclear proteasomes and generated peptides diffuse through the nuclear pores into the 
cytosol (Reits et al., 2003). Besides the 26S proteasome immune cells express an immune proteasome. 
Its proteolytic subunits are incorporated into the 20S core barrel of the 26S proteasome and alter the 
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degradation pattern. The immune proteasome selectively generate immunogenic peptides and thereby 
improve the antigen presentation by MHC class I complexes (Toes et al., 2001). Immune proteasomes 
exhibit an enhanced activity to better cope with the increasing amounts of misfolded proteins 
generated during immune stress or IFNɣ responses (Seifert et al., 2010). 
MHC class I molecules are heterodimers that consist of a polymorphic transmembrane heavy chain 
encoded by either HLA-A, HLA-B or HLA-C and a light chain called beta-2-microglobulin (β2M). 
Both chains assemble in the ER. They are stabilized by chaperones until a suitable 8 – 9 aa long 
peptide is bound in their peptide binding groove. Approximately 8 – 16 aa long peptides are pumped 
from the cytosol into the ER lumen by the transporter associated with peptide binding (TAP), which is 
located in the ER membrane. These peptides are further N-terminally trimmed until they adequately fit 
the peptide binding groove. The MHC class I peptide loading complex ensures efficient peptide 
binding. It is constituted of the MHC class I heterodimer, TAP and various chaperons e.g. TAP-
associated glycoprotein (tapasin) that stabilize the complex until a proper peptide is bound. Upon 
peptide binding the complex achieves intrinsic stability, the chaperones dissociate and the 
MHC I-peptide complex is transported via the Golgi network toward the plasma membrane where 
MHC class I exposes its bound peptide to the extracellular room (Neefjes et al., 2011). 
CIITA was reported to induce the transcription of MHC class I in addition to MHC class II molecules 
in vitro (Gobin et al., 1997, 1998b, 2001; Martin et al., 1997), but a major role of CIITA in regulating 
MHC I transcription could not be confirmed in vivo as Ciita ko mice showed normal basal 
MHC class I expression (Itoh-Lindstrom et al., 1999). NLRC5 has recently been reported to be the 
master regulator of the transcription of genes coding for MHC class I molecules as well as proteins 
involved in MHC class I loading (Meissner et al., 2010). 
1.4 INFLAMMATORY BOWEL DISEASE 
The term inflammatory bowel disease (IBD) summarizes a group of intestinal inflammatory disorders 
of which ulcerative colitis (UC) and Crohn´s disease (CD) are the most frequent and best characterized 
forms. Both diseases are highly prevalent in the western civilization (Kaser et al., 2010). 
1.4.1 CLINICAL MANIFESTATION 
UC and CD are recurrent or chronic inflammatory conditions that typically have their onset in the 2nd 
and 3rd decade of life. They are characterized by similar clinical signs e.g. abdominal pain, cramps, 
vomiting, diarrhea and rectal bleeding followed by anemia and body weight loss. Both forms are 
diagnosed via inflammatory markers in the stool and the endoscopic examination of the large intestine 
(coloscopy). UC and CD are mainly distinguished by the location of the inflammation and the kind of 
inflammatory changes (Podolsky, 2002).  
CD can affect the entire gastrointestinal tract from the mouth to the anus. The inflammation is 
transmural, involving all layers of the bowel wall, and occurs discontinuous with segmental 
inflammatory patches (so called skip lesions) that are separated by healthy tissue. CD affects the colon 
and the terminal part of the small intestine, the ileum. In contrast, UC is characterized by a continuous 
inflammation in the mucosal and submucosal tissue. It is usually restricted to the colon and the rectum 
and histologically characterized by neutrophil influx into the lamina propria, goblet cell depletion and 
crypt abscesses (Xavier and Podolsky, 2007). 
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1.4.2 PATHOGENESIS 
IBD is an idiopathic disease. Its pathogenesis is supposedly multifactorial. A general genetic 
susceptibility in combination with a dysregulated immune system, an altered microbial gut flora as 
well as other environmental factors are thought to favor the development of disease (Kaser et al., 
2010). 
Genome-wide association studies (GWAS) discovered more than 163 IBD susceptibility regions 
related to 300 known genes so far (Jostins et al., 2012), but individual IBD risk loci confer only a 
modest risk for disease development.  
Sporadic occurring IBD results from an accumulation of a great quantity of interacting single 
nucleotide polymorphisms (SNPs), which alone only have minor biological effects. In contrast, a 
familial heritability of IBD is due to rare genetic variants, which have a major biological impact and 
are modified by further SNPs (Kaser et al., 2010). Mutations in the autophagy gene ATG16L1 (Hampe 
et al., 2007; Rioux et al., 2007) as well as the NLR gene family member NOD2 were e.g. identified as 
major risk loci for the development of CD in the Caucasian population (Hampe et al., 2001; Hugot et 
al., 2001; Ogura et al., 2001).  
Cytokines are involved in the pathogenesis of IBD as they drive and control the inflammation and 
convey the clinical symptoms (Strober et al., 2002). Several IBD risk loci were found to encode for 
cytokines as well as their receptors or signaling pathways (Jostins et al., 2012). Th1-associated 
cytokines like IFNɣ and IL-2 are upregulated in CD patients, while UC rather favors a Th2 phenotype 
with an elevated secretion of IL-5 and IL-13 (Fuss et al., 1996). The neutralization of cytokines during 
the course of IBD has been an intense field of research and the antibody-mediated blockage of TNFα 
is a successful therapeutical option today (Danese and Fiocchi, 2011).  
An important environmental factor in the development of IBD is the composition of the gut 
microbiota. Intestinal microorganisms usually coexists in balance with the immune system of the host 
(Round and Mazmanian, 2009). Defects in mucosal immune mechanisms as well as an altered enteric 
colonization can disrupt this balance. This can favor excessive responses towards commensals, 
colonization with potentially pathogenous microorganisms or bacterial invasion. IBD patients were 
found to have a less complex microbial pattern within the gut (Frank et al., 2007). The composition of 
the enteric microbiota can be affected by diet, antibiotic treatment or gut infection, facts that have also 
been associated with the onset of IBD (Kaser et al., 2010). 
1.4.3 THERAPY 
UC and CD are not medically curable. Both diseases need to be treated individually with 
immunosuppressive and anti-inflammatory drugs to relief symptoms and control the inflammation. UC 
can be eliminated by the removal of the large bowel, as the disorder is strictly limited to colon tissue. 
In contrast, surgery will not abolish CD as it affects the entire gastrointestinal tract and often flares up 
again after the removal of severely affected parts at the junction of the combined healthy intestinal 
sites (Karimuddin, Gilles, 2015; Tresca, 2015).  
Due to its clinical manifestations IBD restricts the life quality of affected patients. The disease is rarely 
fatal, but complications can occur like toxic megacolon or gut perforation, which can be lethal. 
Furthermore, patients have an elevated risk to develop colorectal cancer (Berg et al., 2002; Itzkowitz 
et al., 2005). 
 
Introduction 
21 
 
1.4.4 DSS-INDUCED COLITIS  
A MURINE MODEL TO INITIATE INNATE AND ADAPTIVE IMMUNE PROCESSES 
Dextran sodium sulphate (DSS), a sulphated polysaccharide, induces experimental colitis in rodents 
when administered orally (Chassaing et al., 2014; Perse et al., 2012). DSS is directly cytotoxic to 
intestinal epithelial cells (IEC) of the basal crypts. Thereby it disrupts the epithelial barrier and allows 
the infiltration of microorganisms and antigens from the gut lumen into the bowel wall, which 
subsequently induces an inflammatory response (Ni et al., 1996). 
The induction of experimental colitis by DSS is simple, inexpensive, has an immediate onset and a 
well controllable progression of inflammation. Accordingly, it is a very common method. Acute, 
chronic or relapsing disease can be induced depending on the concentration, duration and frequency of 
DSS administration. Furthermore, the model is dependent on the depicted mouse strain (Mähler et al., 
1998) and the bacterial colonization of the gut (Bylund-Fellenius et al., 1994; Nell et al., 2010). 
DSS-induced colitis shares common clinical and histological features of human IBD. Therefore, it is 
used as an animal model to investigate IBD pathogenesis and potential therapies. Acute murine DSS 
colitis is mainly characterized by diarrhea, weight loss and traces of blood in the feces. Intestinal 
inflammation is histologically characterized by neutrophil influx into the lamina propria and 
submucosa, cryptitis as well as crypt abscesses and the subsequent necrosis within the epithelial layer. 
Epithelial degeneration is further accompanied by mucin depletion. Upon chronification the 
inflammation becomes transmural, lymphoid follicles appear in the subserosa and especially 
mononuclear leukocytes infiltrate the bowel wall. Preceding erosions can regenerate and reepithalize 
with squamous epithelium that is normally only found in the anal mucosa (Perse et al., 2012). 
DSS-induced colitis affects especially the rectum similar to UC. However, focal lesions, disseminated 
lymphoid follicles and transmural inflammation found in the chronic state rather reassemble the 
pathogenesis of CD (Perse et al., 2012). 
Innate immune mechanisms are indispensable for the genesis of DSS-induced colitis in mice. In 
contrast, adaptive responses, which also evolve and exacerbate disease, are dispensable for the onset 
and progression of the DSS-induced intestinal inflammation (Dieleman et al., 1994; Garrett et al., 
2007).  
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1.5 OBJECTIVE 
This project focused on the characterization of a specific NLR gene family member that was barely 
characterized when this work started: the ‘NLR family, CARD domain containing 5’ (NLRC5).  
The aim was to investigate and characterize the role of NLRC5 in immune processes.  
 
In detail, the following questions were addressed: 
 
I. Does the expression pattern of NLRC5 indicate a functional relevance of the protein in 
immune organs, tissues or cells? 
Is the expression of NLRC5 regulated during immune responses? 
 
II. Is NLRC5 involved in innate immune processes comparable to other NLR members?  
a. Is the protein involved in innate signaling pathways and the induction of cytokines? 
b. Has NLRC5 an impact on the generation and / or migration of innate immune cells? 
 
III. Is NLRC5 involved in adaptive responses? 
a. Has it an effect on the generation and differentiation of lymphocyte populations? 
b. Is the protein implicated in antigen presentation as reported for CIITA? 
 
IV. What is the phenotype of Nlrc5-deficient (ko) mice? 
a. Does the ko affect viability and fertility? 
b. Does the ko influence the normal development of tissues and organs? 
c. Do ko mice show an altered susceptibility or progression towards DSS-induced 
intestinal inflammation? 
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2 MATERIALS & METHODS 
Used abbreviations are listed in alphabetical order in the appendix. 
2.1 EXPERIMENTAL MICE 
Genetically engineered mice are an important method to study the function of genes e.g. those that 
were identified by sequencing, but whose biological roles have not been elucidated. Their specific 
protein functions might be evaluated by observing an altered phenotype upon gene inactivation. The 
knockout technique was first published in 1989 and is best established for laboratory mice until now 
(Thomas and Capecchi, 1987). 
2.1.1 GENERATION OF NLRC5 KNOCKOUT MICE 
A constitutive Nlrc5 knockout mouse line (Nlrc5 ko, Nlrc5-/-) was generated by the company genOway 
to obtain a model organism to investigate the biological function of the Nlrc5 gene ex vivo and in vivo. 
The ko mouse has a targeted gene deletion. Due to the extensive size of the Nlrc5 gene (~56 kb) it was 
not possible to delete the entire gene using homologous recombination. Only the exons 4–7 were 
removed. Exon 4 contains the ATG start codon necessary for the initiation of transcription. 
Furthermore the CARD and NACHT domain are encoded within the deleted region. The deletion 
resulted in the absence of any Nlrc5 transcript. 
A targeting vector was designed in which the exons 4-7 were replaced by a loxP-flanked neomycin 
resistance cassette. It contained two homology arms isogenic to the used embryonic stem (ES) cell line 
129Sv/Pas. This facilitated homologous recombination and therefore the targeting and replacement of 
the coding sequence at exons 4–7 with the manipulated vector construct. The two loxP sites allowed 
the later deletion of the neomycin selection cassette using Cre recombinase. A diphtheria 
toxin A (DTA) negative selection marker reduced the isolation of non-homologous recombined ES 
cell clones. 
 
Tab. 2: Nlrc5 knockout strategy 
Displayed is the Nlrc5 targeting strategy for the deletion of exon 4–7. The diagram is not depicted to scale. Hatched rectangles represent 
putative Nlrc5 coding sequences (Ex1-40), grey rectangles indicate non coding exon portions, the solid line represents the chromosome 
sequence. LoxP sites are represented by blue triangles. The size of the Nlrc5 sequence to be deleted is shown. (Figure adapted after 
genOway) 
ES cells were obtained from the blastocyst of 129Sv/Pas mice and the designed linearized targeting 
vector was inserted by electroporation. A positive selection was carried out by gentamicin (G418) to 
identify recombinant ES cell clones. These were injected into the blastocyst of C57BL/6J mice and 
reimplanted into pseudo pregnant females. Chimeras were born and the males mated with C57BL/6J 
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females to generate the F1 generation that was imported into the central animal facility (ZTH; Zentrale 
Tierhaltung) of the University Hospital Schleswig Holstein in Kiel. 
The generated Nlrc5 knockout mice were further back crossed on C57BL/6N background 
(B6;129Sv/Pas-Nlrc5tm1geno). Genotypes were analyzed by polymerase chain reaction (PCR). 
Heterozygous offspring was crossed to yield -/- and +/+ genotypes, which will be referred to as 
Nlrc5 knockout (ko; -/-) and wild type (wt; +/+) below. 
2.1.2 ANIMAL HUSBANDRY 
Animals were bred and kept in individually ventilated cages (IVC) in the ZTH under specific 
pathogen-free (SPF) standard conditions as defined by the Federation of European Laboratory Animal 
Science Associations (FELASA) (Nicklas et al., 2002) with a light/ dark rhythm of 12/12 h and 
temperatures of 20-24 °C. Water and food were given ad libitum. Mice were separated from the 
mother at the age of 4 weeks and tail- or ear-clipped to allow genotyping.  
During colitis experiments mice were kept under SPF conditions in the Victor Hensen animal facility 
(VHH) on the university campus, Kiel. 
All experiments were approved by the Ministry of Agriculture and Environment Schleswig-Holstein 
and the commissary of animal welfare of the Christian Albrechts University, Kiel. 
 
License number Designation 
V 312-72241.121-33 / 554 Characterization of the Nlrc5 knockout mouse - killing for tissue withdrawal 
V 312-72241.121-33 (26-3/10) Characterization of the Nlrc5 knockout mouse  - acute and chronic DSS-induced colitis 
Tab. 3: Animal experiment license numbers  
(From the Ministry of Agriculture and Environment Schleswig-Holstein for conducted animal experiments) 
2.1.3 GENOTYPING 
Mouse DNA was isolated from tail or ear clips (DNA extraction 2.7.1) and endpoint PCRs were 
performed using DreamTaq Green DNA Polymerase (Fermentas) and primers recommended by 
genOway to evaluate murine genotypes (Tab. 4, Tab. 5, PCR 2.7.2).  
 
Gene Name Sequence Species Amplicon (bp) 
Nlrc5 ko ROS2-I2_PCR#1_F GCCAGACAGCATAGACCAGATAGTGG Mus musculus 2197 
 ROS2-H2_PCR#1_R CTACTTCCATTTGTCACGTCCTGCACG Mus musculus  
Nlrc5 wt ROS2-I3_PCR#2_F  GAGTCACTCACTCTCCAGGGACAGTGG Mus musculus 2113 
 ROS2-N_PCR#2_R CTGTTGAGCTGACGGTGGATGACC Mus musculus  
Tab. 4: Nlrc5 Genotyping Primer Sequences 
 
Dream Taq PCR Reaction Mix 
  
Components Quantity 
Template DNA 1 µg 
Primer Fw 0.25 µl 
Primer Rev 0.25 µl 
dNTP Mix 0.5 µl 
Buffer 2 µl 
DEPC H2O 15.8 µl 
Polymerase 0.2 µl 
  
Tab. 5: Genotyping of Nlrc5-/- mice 
PCR Cycler Program 
   
Temperature Time  
95 °C 4 min  
95 °C 30 s  
65 °C 1 min 35x 
72 °C 3 min  
72 °C 8 min  
4 °C ∞  
   
   
 
GT Amplicons on Agarose Gel 
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2.1.4 WITHDRAWAL OF MURINE MATERIAL FOR EX VIVO ANALYSES 
Animals were sacrificed by cervical dislocation before organs were removed. During experimental 
colitis experimental animals were anaesthetized by a mixture of ketamine (Ketavet, Pfizer) and 
xylazine (Rompun, Bayer) given intraperitoneally. A maximal volume of blood was taken by cardiac 
puncture. Blood was given immediately into blood collection tubes filled with lithium heparin-gel 
(Microvette 500 LiHepGel; Sarstedt) and centrifuged for 5 min at 10 000 x g at RT to obtain the serum 
for further analyses. 
Organs were either fixed in 10% formalin for histological embedding or deep-frozen in liquid nitrogen 
for later RNA, DNA or protein isolation. Frozen tissues were homogenized in the corresponding 
lysing buffers using the tissue homogenizer (Tissue Lyser II, QIAGEN) and the desired compounds 
were extracted after standard protocols (2.7.1; 2.8.1; 2.9.1). 
2.1.5 EXPERIMENTAL DSS COLITIS 
Dextran sodium sulfate (DSS) chemically induces intestinal inflammation in rodents if applied orally 
(Ohkusa, 1985; Okayasu et al., 1990) and is therefore a widely used model to study IBD, in specific 
Colitis ulcerosa or Morbus Crohn. 
Male wt and Nlrc5 ko mice at comparable ages were given DSS dissolved in autoclaved drinking 
water at indicated concentrations, while control groups were given autoclaved water only. Beverages 
were renewed every second day to prevent bacterial contamination especially in the DSS-containing 
bottles. Weight, stool consistency, rectal bleeding and overall behavior were monitored every 1-2 days 
to study disease progression and to meet animal welfare conventions. Mice were excluded from the 
experiment if weight loss exceeded 20% of the initial body weight or if the overall health conditions 
were unacceptable after FELASA guidelines. Stool samples were collected from each mouse and 
smeared on paper to evaluate consistency. Intestinal bleeding was evaluated by testing for occult blood 
in stool with the Guajak test modified after Greegor (Greegor, 1971) as instructed by the manufacturer 
(Haemoccult, Beckman Coulter). The study design was double blind until the end of data analyses. All 
experimental groups were handled and analyzed equally. The precise treatment plan for the acute as 
well as the chronic colitis were modified after the “Chemically induced mouse models of intestinal 
inflammation” (Wirtz et al., 2007) to adapt disease progression to the individual conditions in the 
VHH animal facility as well as the C57BL/6J mouse strain and the laboratory DSS lot. An overview of 
DSS treatment is given prior to the results (Fig. 3-15, Fig. 3-26). After successful induction of colitis, 
mice were sacrificed and blood as well as organs were removed and prepared as described above 
(2.1.4).  
2.2 HISTOLOGY 
Organs were removed from the sacrificed mice, fixed in 10% formalin for 24 h, dehydrated by an 
increasing alcohol–xylol series (STP 120; Thermo Scientific) and embedded in paraffin (TES 99; 
MEDITE). Paraffin blocks were cut into 3.5 µl thick sections with a microtome (RM2255; Leica 
Microsystems) and deposed on microscopic slides. Prior to staining, slides were deparaffinized and 
rehydrated in a decreasing xylol–alcohol dilution series.  
2.2.1 HEMATOXYLIN & EOSIN STAINING  
Hematoxylin and eosin (HE) staining is a widespread staining technique for the evaluation of tissue 
slides. It is a combination of two different staining methods. Hematoxilin is a natural dye. Oxidized to 
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hemalaun it stains basophile cellular structures blue like e.g. the DNA-containing nucleus and the 
rough endoplasmic reticulum, which is rich in ribosomes. In contrast, the synthetic acidic dye eosin 
stains acidophil cellular structures red like e.g. proteins within the cytoplasm and mitochondria. 
Deparaffinized tissue sections were stained with hemalaun (Carl Roth, #T865.3) and blued in tap 
water. Subsequently, sections were stained with eosin (Carl Roth, #X883.2) and washed briefly under 
tap water. Slides were dehydrated in an ascending ethanol series and finally preserved under a cover 
lid using Roti®-Histokitt (Carl Roth, 6638.1). 
2.2.2 PERIODIC ACID – SCHIFF STAIN 
The Periodic Acid–Schiff (PAS) reaction stains polysaccharides and mucosubstances. Glycol groups 
in polysaccharides are oxidized by periodic acid to aldehyde groups. These can bind sulfite from 
Schiff´s reagent to generate fuchsins, which give the red color to the mucopolysaccharides.  
Deparaffinized tissue sections were stained with 0.5% periodic acid (Merck, #1.00524.0025) and 
washed in tap water. Then sections were stained with 0.5% Schiff´s reagent (Sigma-Aldrich, 
#3952016) and washed thoroughly with tap water. Afterwards sections were counterstained with 
hemalaun (see 2.2.1), blued with tap water, dehydrated in an ascending ethanol series and preserved 
under a cover lid using Roti®-Histokitt (Carl Roth, 6638.1). 
2.2.3 MICROSCOPY 
Slides were examined with the Axio Imager.Z1 (Zeiss) and pictures taken using the AxioVision 
Rel.4.8 software supplied by the manufacturer. Magnifications are indicated in the results section.  
2.3 CELL CULTURE 
Immortal as well as primary mortal cells were cultured, stimulated and analyzed.  
2.3.1 CELL LINES & PASSAGE 
Cell lines were cultured in the indicated formats and media (Tab. 6). Full media were supplemented 
with 10% fetal calf serum (FCS) at 37 °C and 5% CO2. Cells were washed and diluted in fresh media 
twice a week. Adherent cell lines were pretreated with trypsin/ EDTA for 5-10 minutes at 37 °C in 
order to detach cells from cell culture dishes. This is further referred to as “culture under standard 
conditions”. 
 
Cell Line Description Basic Media DSZM No. 
Immortal Cell Lines 
DB-2 Human B cell RPMI 1640 
 
HEK-293 Human embryonic kidney DMEM ACC-305 
HeLa Human cervix carcinoma (from Henrietta Lacks) RPMI 1640 ACC-57 
HT-29 Human colon adenocarcinoma DMEM ACC-299 
Jurkat Human T cell leukemia RPMI 1640 ACC-282 
THP-1 Human acute monocytic leukemia RPMI 1640 ACC-16 
Generated Primary Cell Lines 
BMDM Murine bone marrow-derived macrophages  MMM + DMEM* 
 
Splenocytes Murine mixed splenocytes RPMI 1640* 
 
Tab. 6: Cultured immortal and primary cell lines 
             *see Tab. 7 for medium details 
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2.3.2 PRIMARY CELL CULTURE 
Primary splenocyte culture  
Mice were sacrificed and spleens removed immediately. All further steps were performed under sterile 
conditions. Spleens were grinded through a 70 µm cell strainer (Sarstedt) and taken up in splenocytes 
medium (Tab. 7). Gained single cell suspensions were carefully layered on an equal volume (5 ml) of 
room tempered Ficoll gradient (Pancoll mouse, PAN-Biotech) and centrifuged in 15 ml reaction tubes 
for 20 min at 1200 x g without bracket. The interphase, containing the leukocytes, was isolated, 
washed in PBS and the mixed murine splenocytes were seeded into the desired format. 
 
Standard Culture Media 
 
RPMI 1640 / MEM / DMEM; all from PAA Laboratories GmbH  
10% (v/v ) FCS Gold, PAA Laboratories GmbH 
 
Splenocyte & BMDC Medium 
 
RPMI 1640 + L-Glutamin + 25 mM HEPES, PAA Laboratories GmbH  
10% (v/v) FCS Gold, PAA Laboratories GmbH 
1% (v/v) Penicillin/Streptomycin, PAA Laboratories GmbH 
1% (v/v) Amphotericin B, PAA Laboratories GmbH 
0.01% (v/v) β-Mercaptoethanol, Sigma 
 
Only for BMDCs: Add fresh: 20 ng/ml rmGM-CSF, Immunotools 
 
BMDM Medium 
 
44% (v/v) MMM, PAA Laboratories GmbH  
44% (v/v) DMEM, PAA Laboratories GmbH 
10% (v/v) FCS Gold, PAA Laboratories GmbH 
1% (v/v) Penicillin/Streptomycin , PAA Laboratories GmbH 
1% (v/v) Fungizone®Antimycotic, Gibco®  
 
Add fresh: 20 ng/ml recombinant mouse (rm) M-CSF, Immunotools 
 
Tab. 7: Cell culture media 
Primary Bone Marrow-Derived Macrophages (BMDMs) 
After sacrificing the mice, the bone marrow was isolated by flushing ice cooled BMDM-medium 
through the bones of the hind legs under sterile conditions. Afterwards bone marrow was pipetted 
through a cell strainer (Sarstedt) to gain single cell suspensions that were seeded in large 25 ml cell 
culture plates. Medium was supplemented with fresh M-CSF (macrophage colony-stimulating factor; 
20 ng/ml; Immunotools) and changed regularly. Mϕs were harvested, counted and seeded into the 
desired experimental formats, when plate bottoms were filled with adherent differentiated Mϕs 
(approximately after 10 days). Mϕs were not trypsinized but scraped off culture plates for passage. 
 
Primary Bone Marrow-Derived Dendritic Cells (BMDCs) 
Bone marrow was gathered and prepared as described in the BMDM protocol above. Cells were 
cultured in BMDC medium supplemented with fresh GM-CSF (granulocyte macrophage colony-
stimulating factor; 20 ng/ml; Immunotools) until DCs were generated (10–21 days). Medium was 
changed regularly. Adherent mature DCs were scraped off the cell culture plate, counted and seeded 
into the desired format prior to the experiments. 
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2.3.3 HARVESTING CULTURED CELLS 
Medium was taken off and cells were washed with PBS. After PBS was removed thoroughly cells 
were broken up by specific lysing buffers to extract DNA, RNA or proteins (see 2.7.1, 2.8.1, 2.9.1). 
Non adherent (suspension) cells were spun down, the supernatant was removed and the pellet lysed 
with the desired buffer. 
2.3.4 CELL STIMULATIONS 
Stimuli were diluted in culture-specific media before they were given onto cells.  
 
Stimulus Product name Company Catalog number 
rm M-CSF Recombinant Mouse Macrophage Colony Stimulating Factor Immunotools 12343118 
rm GM-CSF 
Recombinant Mouse Granulocyte Macrophage Colony 
Stimulating Factor 
Immunotools 12343125 
rh IFNγ Recombinant Human Interferon gamma  Biosource aa24-166 
rh TNFα Recombinant Human Tumor Necrosis Factor alpha R&D systems®  210-TA  
rm IL-2 Recombinant Mouse Interleukin 2 Immunotools 12340024 
PHA Phytohemagglutinin PHA-L Sigma L2769 
PMA Phorbol 12-myristate 13-acetate Sigma-Aldrich 79346 
Iono Ionomycin calcium salt  Sigma-Aldrich I0634 
ATP Adenosine 5′-triphosphate disodium salt  Sigma-Aldrich A65509 
LPS Lipopolysaccharid from Escherichia coli Nissle 1917 DMSO Provided by the Research Center Borstel 
ssRNA Single stranded (ss) RNA40 / LyoVec™ InvivoGen tlrl-lrna40 
poly(I:C) Polyinosinic Acid - Polycytidylic Acid Calbiochem 528906 
Brefeldin A Brefeldin A Sigma-Aldrich B6542 
Tab. 8: List of utilized stimuli  
2.4 FLOW CYTOMETRY 
Flow cytometry is used to characterize high quantities of single cells within a liquid medium. It is a 
rapid multiparameter laser-based technology to analyze cell numbers and cell properties like size and 
granularity, cell death status as well as extracellular and intracellular markers.  
Cell size and granularity can be determined by the scattering of visible light. The diffraction of light at 
a single cell is expressed in the forward scatter (FSC) and depends on cell volume, while the refraction 
is expressed in the sideward scatter (SSC) and depends on cell granularity. Further information can be 
collected by excitation of fluorescent dyes using different lasers and detection of the emitted 
fluorescent light of every individual cell passed by the laser e.g. information about cell death and cell 
cycle can be gained if cells were pretreated with DNA intercalators like propidium iodide (PI). Here, 
fluorophore-bound antibodies were used to bind specific cell-associated molecules. 
Cultured cells were harvested and transferred to 96-well plates (2 x 105 cells per well; BD Falcon 96-
well 340 µl storage plate V bottom; BD Bioscience). All further steps were conducted at 4 °C. Cells 
were washed with flow cytometry washing buffer (FWB; Tab. 16). Fc receptors, which are present 
especially on Mϕs and DCs were blocked for 20 min with anti mouse (α ms) CD16/ CD32 
(BD Pharmingen) to reduce nonspecific immunoglobulin binding. Afterwards, cells were stained with 
target-specific fluorophore coupled antibodies diluted in FWB (30 min). Additional samples were 
stained with isotype controls to evaluate nonspecific antibody binding that generates nonspecific 
fluorescence signals. In advance of intracellular staining, cells were fixed and permeabilized with the 
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BD Cytofix/ Cytoperm™ Kit (BD Bioscience) as indicated by the manufacturer. To prevent 
fluorophore bleaching, stainings and all following steps were conducted in the dark. Before the flow 
cytometric measurement cells were washed thoroughly with FWB.  
 
Data Analysis 
Cells were analyzed using the BD FACS Calibur™ flow cytometer (BD Bioscience). They were 
measured either in FACS tubes (Sarstedt) or directly in the 96-well format using the High Throughput 
Sampler (BD Bioscience). Data analysis was performed with the BD CellQuest Pro™ Software 
(BD Bioscience) and the Flowing Software 2.5.1 (Perttu Terho, University of Turku, FI; Turku 
Bioimaging). 
 
Geometric Mean 
The geometric mean is defined as the nth root of the product of n numbers and was used – instead of 
the mean – to describe the “mean fluorescence intensity” if data were scaled logarithmically. It can 
also be denoted as geometric mean fluorescence intensity (gMFI) and was used to compare 
fluorescence intensities when the focus of the analysis was not on the number of stained cells, but the 
fluorescence intensity of individual cells. 
2.5 ENZYME-LINKED IMMUNOSORBENT ASSAY 
The enzyme-linked immunosorbent assay (ELISA) is an antibody based technique used to detect and 
quantify e.g. proteins, hormones and viruses in liquid media like culture supernatants or blood serum. 
Here, sandwich ELISAs were performed. Thereby target-specific “capture” antibodies were attached 
via their Fc part to adsorbing 96-well plates. Then samples were incubated on the antibody coated 
plate before a second biotin-labeled “detection” antibody was added.  
The target protein is immobilized at the plate bottom by the capture antibody. The detection antibody 
binds the target protein. Subsequently, horseradish peroxidase (HRP)-coupled streptavidin is added, 
which binds and crosslinks the biotins coupled to the detection antibody. 3,3’,5,5’-
Tetramethylbenzidine (TMB) substrate is added, a chromogen that is oxidized by the bound HRP 
leading to a color change from colorless to blue. The reaction is stopped with acid and the absorption 
measured with a spectrophotometer at a wavelength of 450 nm. The absorption is proportional to the 
amount of bound target protein and measured protein concentrations can be calculated in relation to a 
standard curve. 
All performed ELISAs were conducted according to the manufacturer’s protocol. See also product 
sheets (Tab. 9). 
 
Target Product Company Cat. No 
ms IFNγ IFN-gamma Mouse Antibody Pair Invitrogen CMC4033 
ms IL1-β IL1-beta Mouse Antibody Pair Invitrogen CMC0813 
ms TNFα TNF-alpha Mouse Antibody Pair Invitrogen CMC3013 
Tab. 9: Enzyme-linked immunosorbent assays 
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2.6 MULTIPLEX ASSAY 
Bead-based multiplex immunoassays were performed to measure multiple mediators within the same 
sample of serum or supernatant. 
Color-coded beads are precoated with mediator-specific capture antibodies and added to the sample. 
Due to differently coded beads, several mediators can be detected in the same sample. Capture 
antibodies bind the specific mediator of interest. A secondary biotinylated detection antibody is added 
that is specific for the mediator to be analyzed. Antibody–antigen complexes form, similar to the 
ELISA technique. Afterwards phycoerythrin (PE)-conjugated Streptavidin is added and binds the 
biotinylation sites. Samples are measured in a dual-laser flow-based detection instrument. The bead 
and therefore the analyte detected is evaluated by one laser, while the second laser determines the PE 
signal intensity, which is proportional to the amount of detected analyte.  
The assays were purchased from Bio-Rad and technically performed as well as analyzed by the 
Bioglobe GmbH, Hamburg. 
2.7 ISOLATION & ANALYSES OF DNA 
Deoxyribonucleic acid (DNA) is extracted to analyze individual genetic and epigenetic features. Here 
genetic analyses were mainly performed to identify murine genotypes, which is required for animal 
breeding and animal experiments. 
2.7.1 DNA EXTRACTION 
DNA was extracted using the DNeasy Blood & Tissue Kit (QIAGEN) according to the manufacturer´s 
instructions. Tissues were lysed with Proteinase K, afterwards DNA was precipitated by adding 
ethanol and bound to a silica membrane in a spin column. After several washing steps the DNA was 
eluted by DNA Elution buffer (Tab. 16). 
2.7.2 POLYMERASE CHAIN REACTION 
The polymerase chain reaction (PCR) is used to exponentially amplify genetically material, which can 
subsequently be further analyzed. It is a cyclic process based on a repeated enzymatic reaction with 
three major steps today carried out in fully automated thermocylers (Saiki et al., 1985):  
1. Denaturation of the double stranded genetic material (DNA, RNA, cDNA) into single stranded 
templates at 95 °C. A longer denaturation step for initial break up is necessary, especially for 
genomic DNA. 
2. Annealing of specific short single stranded oligonucleotides (primers) on complementary 
DNA templates. The annealing temperature is dependent on the melting temperature of the 
specific primers. 
3. Primer extensions by a DNA-dependent DNA polymerase, which is stable at high 
temperatures. For instance, the Taq polymerase has its enzymatic optimum at 72 °C. The 
enzyme was originally found in the thermophile bacteria Thermus aquaticus, hence its name. 
There are also other thermostable enzymes, which can amplify templates of varying length 
thereby making more or less mistakes. Depending on the initial template and the desired 
amplicon also RNA-dependent DNA polymerase (reverse transcriptases) or RNA-dependent 
RNA polymerases are used. A prolonged terminal extension phase yields more products. 
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These three consecutive PCR steps are repeated 25–35 times. The amount of amplicon approximately 
doubles during each cycle until the capacity on free dNTPs and primers or polymerase activity is 
exhausted and the accumulation of product terminates. PCR amplicons can be separated on an agarose 
gel by electrophoresis. Different amplicons can be compared by size. Amplicons can also be isolated 
for sequencing and sequential cloning. The signal strength of an amplicon band after gel 
electrophoresis describes only the “endpoint” of the amplification process (endpoint PCR) and does 
not provide information about the initially inserted amount of template. Therefore, quantifications are 
only possible in comparison with an amplicon of a housekeeping template.  
There are more specialized PCR methods used for quantifications, which are called quantitative PCRs 
were template amplification is monitored during the entire cycling process, virtually in “real time”. 
Therefore, these specialized quantitative PCR forms are called real-time quantitative PCR (RT–qPCR; 
see also 2.8.4). 
Here end-point PCRs were performed to evaluate RNA contaminations with genomic DNA (gDNA), 
to test the successful synthesis of complementary DNA (cDNA) and to determine the genotype of the 
experimental animals. The exact protocols are given in the referring method sections. 
2.7.3 AGAROSE GEL ELECTROPHORESIS 
PCR products were separated by size on agarose gels. The polymer agarose builds a gel matrix after 
been heated up in an aqueous solution. The gel matrix is used for separating macromolecules like 
nucleic acids (DNA, RNA, cDNA) by electrophoresis. Nucleic acids move to the anode (+) within an 
electrical field due to their negatively charged phosphate backbone. Because their base pair content is 
proportional to the chain length and approximately proportional to the molecular mass shorter bp 
chains can move faster through the agarose meshwork than longer ones. So nucleic acids are separated 
by size during electrophoresis and the molecular mass is determined in comparison to a DNA marker 
with nucleic acids of know sizes 
Here, PCR products were separated on gels containing 1% (w/v) agarose, 0.5x TAE (Tris–Acetat–
EDTA) buffer and 0.5x Sybr®Safe DNA Gel Stain (Life Technologies), a DNA intercalator excitable 
by ultra violet (UV) light. The gel was covered with TAE puffer, pockets were loaded with either 
15 µl amplicon or 5 µl marker (SmartLadder, Eurogentec) and a voltage of 120 V was applied until 
samples were separated to the desired extent. Amplified nucleic acid bands were visualized under UV 
light in the BioDocAnalyze (Biometra). 
2.8 ISOLATION & ANALYSES OF RNA 
Ribonucleic acids, in specific mRNAs, are transcribed from DNA templates and are translated into 
amino acid chains. Gene expression was studied by analyzing mRNA quantities. 
2.8.1 RNA ISOLATION & DETERMINATION OF CONCENTRATION 
Total RNA was isolated with the RNeasy®Mini kit (QIAGEN) from cell pellets or tissue homogenates 
following the instructions of the manufacturer. Cells were lysed and homogenized on the QIAGEN 
shredder columns in the presence of a highly denaturing guanidine–thiocyanate-containing buffer that 
immediately inactivates RNA-degrading enzymes called RNases. Ethanol was added for precipitation 
before the mixture was given on spin columns with silica based membranes. Genomic DNA 
contaminations were digested by DNases on the column as described by the manufacturer using the 
RNase-Free DNase set (QIAGEN). The high salt buffer system allowed RNA with more than 200 bp 
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to bind to the membrane. Therefore, especially mRNAs were enriched in the eluate, while smaller 
RNA molecules were mostly lost in the process. After the elution of RNA from the columns by 
nuclease-free water RNA, concentrations were measured using the NanoDrop®ND1000 
spectrophotometer (Thermo Fisher Scientific) and stored at –80 °C. 
2.8.2 GENOMIC DNA CONTAMINATIONS & RNA CLEAN UP 
Extracted RNAs were tested for contamination with genomic DNA (gDNA) using endpoint PCR. 
Exon-intron spanning glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers were used, 
which only anneal to DNA templates as RNA does not contain intros anymore. Therefore, only 
gDNA-encoded GAPDH will amplify during a PCR and can be visualized on an agarose gel.  
Upon gDNA detection RNA clean up was performed as described in the RNeasy®Mini kit manual 
(QIAGEN). The RNA sample was bound again onto a silica column and DNase digestion was 
repeated using the RNase-Free DNase set (QIAGEN). 
 
Go Taq PCR Reaction Mix 
  
Components Quantity 
Template 1 µg 
Primer Fw 0.25 µl 
Primer Rev 0.25 µl 
dNTP Mix 0.5 µl 
Buffer 4 µl 
H2O* 13.8 µl 
Polymerase 0.2 µl 
  
Tab. 10: Endpoint PCR 
*nuclease-free water 
 
PCR Cycler Program 
   
Temperature Time  
94 °C 4 min  
94 °C 30 sec  
58 °C 30 sec 20-25x 
72 °C 1 min   
72 °C 4 min   
4 °C ∞  
   
   
   
   
 
2.8.3 REVERSE TRANSCRIPTION PCR  
(RT-PCR) 
The amounts of isolated RNA are low and very fragile. Therefore, mRNA is reverse transcribed to the 
more stable cDNA for further analyses.  
The cDNA synthesis was performed with the RevertAidTMPremium First Strand cDNA Synthesis Kit 
(Fermentas) as instructed by the manual and with the quantities listed below. The supplied reverse 
transcriptase enzyme is an RNA-directed DNA polymerase obtained from the retrovirus Moloney 
Murine Leukemia Virus (MMLV). The used oligo(dT18) primer anneals selectively to the 3’poly(A) 
tail of eukaryotic mRNAs and initiate them to be reverse transcribed into single stranded cDNAs.  
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Reverse Transcription Reaction Mix 
   
 Components Quantity 
Step 1 RNA 1 µg 
 Oligo(dT18) Primer 0.125 µl 
 dNTP Mix 0.5 µl 
 H2O* ad 7.5  µl 
   
Add for Step 2 RT Buffer 2 µl 
 Reverse Transcriptase 0.5 µl 
   
   
Tab. 11: Reverse Transcription 
*nuclease-free water 
 
PCR Cycler Program 
  
Temperature Time 
Step 1:  
65 °C 5 min 
4 °C ∞ 
  
Step 2:  
25 °C 10 min 
50 °C 15 min 
85 °C 5 min 
4 °C ∞ 
 
 
After reverse transcription, cDNAs were diluted with nuclease-free water to a concentration of 
10 ng/µl and preserved at –20 °C. Successful cDNA synthesis was tested by endpoint PCR using 
GAPDH primers, followed by agarose gel electrophoresis. Samples that had no or just very few 
amplicons of the house keeping gene were not used for further analyses. 
2.8.4 QUANTITATIVE REAL TIME PCR 
(RT-qPCR) 
The quantitative real time PCR (RT-qPCR) is an advanced PCR technique were the amplification is 
directly (in “real time”) measured by light emission and the template can be quantified as it is 
proportional to the amount of product in the exponential phase of amplification. Therefore, either a 
fluorescing DNA intercalator or FRET (Förster or fluorescence resonance energy transfer) probes are 
added to the reaction mix. 
 
TaqMan Assay 
RT-qPCRs were performed using TaqMan® Gene Expression Assays as suggested by the 
manufacturer (Life Technologies; Tab. 13). Two specific unlabeled primers and a specific FRET 
labeled probe were added to the reaction mix that also contained the cDNA sample and TaqMan 
master mix. Temperature cycles were performed in a light cycler (7900HT Fast Real Time PCR 
System, 384-well format, Applied Biosystems; software SDSv2.4; Tab. 12) that continuously 
measures the fluorescence within the samples. 
Primers and the labeled probe bind the cDNA template after denaturation. The probe is labeled with a 
fluorophore at the 5’ end and with a quencher at the 3’ end. As long as both are in close vicinity there 
is no fluorescence detectable as the light emitted at the 5’ end is taken up (quenched) at the 3’ end.  
As the primer is prolonged toward the assay probe during the elongation cycle, the probe is 
hydrolyzed from the template by the exonuclease function of the DNA polymerase. Therefore, the 
fluorophore is set free from the quencher and the emitted light is now detectable by the light cycler. 
The fluorescence intensity is proportional to the amount of template just amplified. As a new cycle 
starts a new probe binds to the specific template section to be hydrolyzed in the course of primer 
elongation.
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TaqMan Reaction Mix 
  
Component Quantity 
cDNA (5-10 ng) 0.5 µl 
TaqMan probe and primer  
(see Tab. 13; Life Technologies) 0.5 µl 
TaqMan mastermix  
(MM 4370074; Life Technologies) 4.5 µl 
  
Tab. 12: TaqMan Assay Procedure 
Light Cycler Program  
   
Temperature Time  
50 °C 2 min  
95 °C 10 min  
95 °C 15 sec 45x 
60 °C 1 min   
The TaqMan® Gene Expression Assays were performed as suggested by the manufacturer 
(Life Technologies; Tab. 13). 
 
Target  Full name Species ID 
Actb Actin beta Mouse Mm00607939_s1 
Cd4 CD4 antigen Mouse Mm00442754_m1 
Cd8 CD8 antigen, beta chain 1 Mouse Mm00438116_m1 
Ciita Class II transactivator Mouse Mm00482914_m1 
Cxcl1 
Chemokine (C-X-C motif) ligand 1; KC 
(keratinocyte-derived chemokine) 
Mouse Mm00433859_m1 
Cxcl2 Chemokine (C-X-C motif); Gro2, MIP-2 Mouse Mm00436450_m1 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase Mouse Mm99999915_g1 
Ifnb1 Interferon beta Mouse Mm00439552_s1 
Ifng Interferon gamma Mouse Mm01168134_m1 
Il10 Interleukin 10 Mouse Mm00439614_m1 
Il12a Interleukin 12a; IL-12p35 Mouse Mm00434165_m1 
Il1b Interleukin 1 beta Mouse Mm00434228_m1 
Il6 Interleukin 6 Mouse Mm99999064_m1 
Mhc class II histocompatibility 2, class II antigen A, beta 1; IAb Mouse Mm00439216_m1 
Mpo Myeloperoxidase Mouse Mm01298424_m1 
Nlrc5 NLR family, CARD domain containing 5 Mouse Mm01243039_m1 
Tnfa Tumor necrosis factor alpha Mouse Mm00443258_m1 
Tab. 13: TaqMan Assays obtained from Life TechnologiesTM 
RT-qPCR Data Analyses 
After the RT-qPCR is terminated, a threshold is defined within the exponential phase of the gained 
fluorescence data. Further data analyses use the so called Ct value (cycle threshold), which is the 
defined number of cycles required for the fluorescent signal of one sample to cross this threshold. The 
Ct level is inversely proportional to the amount of initial target nucleic acid within a sample. The 
relative target gene expression in comparison to a housekeeping gene (ΔCt  =  2-Ct Target / 2-Ct Housekeeper) 
as well as the relative and absolute expression of the target gene in comparison to an internal reference 
can be calculated from the Ct values (ΔΔCt = ΔCttarget/ ΔCtreference). 
2.9 ISOLATION & ANALYSES OF PROTEINS  
Proteins are extracted and analyzed e.g. to obtain information about their expression or interacting 
partners. 
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2.9.1 PROTEIN ISOLATION & DETERMINATION OF CONCENTRATION 
Cells or homogenized tissues were lysed using a Nonidet P-40 (Octylphenolethoxylat, NP40; Fluka)-
containing buffer (Tab. 16). Lysates were sonicated (3 x 5 s) and incubated on ice for 1 h before they 
were spun down (4 °C, 10 min, 16 000 x g) to sediment cell debris. The concentration of protein 
within the supernatant was measured using DCTM Protein Assay (Bio-Rad) as indicated by the 
manufacturer. The assay is based on the Lowry protein assay (Lowry et al., 1951), a biochemical assay 
used to assess the total protein concentration. It combines the Biuret test, where peptide bonds form a 
complex with copper II (Cu II) ions under alkaline conditions, with the oxidation of aromatic protein 
residues. Cu II ions are reduced to Cu I, which can subsequently reduce the yellow Folin–Ciocalteu 
reagent to molybdenum blue. After a colorimetric measurement at 490 nm concentrations can be 
defined in comparison to a standard curve. 
2.9.2 SDS–PAGE  
(SODIUM DODECYL SULFATE–POLYACRYLAMIDE GEL ELECTROPHORESIS) 
SDS is an anionic detergent that can dissolve hydrophobic molecules. It binds proteins, denatures and 
linearizes them to their primary structure and transfers an even distribution of negative charge per unit 
mass. Therefore, all SDS-treated proteins are negatively charged (anions) and move to the positively 
charged anode (+) in an electrical field. To separate the proteins by size a gel electrophoresis is carried 
out in a polymerized acrylamide gel (PAGE, polyacrylamide gel electrophoresis). Smaller proteins 
will move faster trough the polyacrylamide meshwork than larger molecules on their way to the anode 
(Laemmli, 1970; Shapiro et al., 1967). 
Proteins were set to equal concentrations before protein lysates were diluted with sodium dodecyl 
sulfate (SDS)-containing loading buffer (5x SDS loading buffer; Tab. 16). Samples were heated at 
95 °C for 5 min, spun down and supernatants were separated on polyacrylamide gels. 
12 µg total protein per sample was loaded on two-parted polyacrylamide gels consisting of an upper 
stacking gel (3% w/v polyacrylamide), which bundles samples within the lanes at the beginning of the 
electrophoresis, followed by a separating gel, which contained 7–15% (w/v) polyacrylamide, 
depending on the protein sizes to be separated (Tab. 14). Gels were run in an ionic Tris/ Glycine/ SDS 
(TGS; Bio-Rad) buffer system at 15 mA per gel for 30 min for stacking and with 30 mA per gel for 
45–75 minutes for separation. 
Sample protein sizes were estimated in comparison to a protein standard (PageRuler Plus Prestained 
Protein Ladder, 10–250 kDa, Thermo Fisher Scientific), which is a mix of proteins with known 
molecular mass, that was loaded on the same gel. 
 
 Stacking Gel Separation Gels 
Protein size  50–200 kDa 30–120 kDa 20–100 kDa 
Acrylamide % (w/v) 3% 7.5% 10% 12% 
Aqua bidestillata                              (ml) 1.95 5 4.15 3.5 
4x Stacking buffer                           (ml) 0.75    
4x Separation buffer                        (ml)  2.5 2.5 2.5 
(Bis) Acrylamide; Bio-Rad             (ml) 0.3 2.5 3.35 4 
TEMED; Sigma-Aldrich                ( µl) 3 10 10 10 
10% APS                                         ( µl) 30 100 100 100 
Tab. 14: Self-casted polyacrylamide gels 
 Materials & Methods 
36 
 
2.9.3 WESTERN BLOTTING (IMMUNOBLOTTING) 
Protein Transfer 
After proteins were isolated and subsequently separated by SDS-PAGE, they were transferred 
(blotted) vertically from the polyacrylamide gel onto a polyvinylidene fluoride membrane (Immun-
Blot®PVDF Membrane; Bio-Rad). PVDF membranes were activated in methanol.  
Then a stack was assembled, by surrounding the polyacrylamide gel and the underlying PVDF 
membrane with buffer soaked Whatman filter papers (Extra Thick Filter Paper, Bio-Rad) in the 
following order: cathode buffered filter – polyacrylamide gel – PVDF membrane – anode I buffered 
filter – anode II buffered filter. For protein transfer the western blot stack was blotted for 20 minutes at 
1 A/ 25 V (TransBlot Turbo Transfer System; Bio-Rad). 
 
Name Target Origin Dilution  Company # Cat. No. 
Primary antibodies 
αNLRC5 3H8 hu Nlrc5 rat 1:250 Courtesy of T. Kufer  
αGAPDH hu/ms GAPDH mouse 1:1000 Santa Cruz Biotechnology, Inc. Sc-59541 
      
Secondary antibodies (HRP-coupled) 
αRat IgG HRP rat immunoglobulins goat 1:2000 SIGMA-ALDRICH A9037 
α ms HRP ms immunoglobulins sheep 1:2000 GE Healthcare NA931-1ML 
      
Flow cytometric antibodies (Fluorophore coupled) 
α ms CD8 FITC ms CD8 rat 1:6 Immunotools 22220083 
α ms CD4 PE ms CD4 rat 1:6 Immunotools 22150044 
α ms CD3ε FITC ms CD3 hamster 1:6 Immunotools 22150033 
α ms CD19 PE ms CD19 rat 1:4 Immunotools 22220194 
α ms CD11b FITC ms CD11b rat 1:4 Immunotools 22159113 
α ms Gr-1 FITC ms Gr-1 rat 1:2 Immunotools 22155243 
α ms H-2Kb APC ms MHCI (H-2Kb) mouse 1:100 eBioscience 17-5958 
α ms H-2Db FITC ms MHCI (H-2Db) mouse 1:50 eBioscience 11-5999 
α ms MHC II (I-A) PE ms MHCII (I-A) rat 1:40 eBioscience 12-5322 
α ms CD25 FITC ms CD25 rat 1:6 Immunotools 22150253 
α ms IL-1β/ IL-1F2  PE ms IL-1 beta  rat  R&D Systems® IC4013P 
α ms CD16/CD32 Fc receptors; Fc Block rat 1:100 BD Pharmingen 553142 
ms IgG2a K Isotype APC Isotype ctrl mouse  eBioscience 17-4724 
ms IgG2a Isotype FITC Isotype ctrl mouse  Immunotools 21275523 
rat IgG2a, κ Isotype FITC Isotype ctrl rat  Biolegend 400506 
rat IgG2b, κ Isotype PE Isotype ctrl rat  BD Pharmingen  555848 
Tab. 15: Antibody List 
Blocking & Antibody Detection 
After western blotting PVDF membranes were incubated with 5% non fat dry milk (NFDM; blocking 
buffer; Tab. 16) for at least 1 h at room temperature (RT) to block all nonspecific protein binding sites 
and prevent nonspecific antibody binding. 
Afterwards membranes were probed with target protein-specific primary antibodies diluted in 
blocking buffer and incubated for 1 h at RT or overnight (o/n) at 4 °C. The primary antibody was 
washed off carefully with TTBS (Tab. 16) and membranes were probed with corresponding 
HRP-coupled secondary antibodies (45 min at RT). Secondary antibodies bind species-specific 
antigens on primary antibodies and lead to signal amplification. Unbound secondary antibodies were 
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washed of carefully with TTBS before membranes were incubated with enhanced chemiluminescent 
substrate (ECL; RPN2134; GE Healthcare). The substrate was activated by the HRP enzyme, which 
generates chemiluminescence. Chemiluminescent signals were detected on light sensitive film 
(Hyperfilm, GE Healthcare; table top film processor Curix 60, AGFA). After the detection of the 
target protein membranes were covered with stripping buffer and incubated in a water bath at 65 °C 
for 45 min to strip off all bound antibodies. After intensive washing in TTBS PVDF membranes can 
be blocked and probed again with a different antibody. Usually membranes are reprobed and 
developed for a housekeeping protein, usually β-ACTIN or GAPDH, which serves as loading control 
and allows a normalization of protein contents in the subsequent densitometric analyses. 
 
Buffer  Composition 
Flow Cytometry 
Flow Cytometry Washing Buffer 
(FWB) 
0.5% (w/v) BSA in PBS 
  
DNA isolation 
DNA Elution buffer Tris/Cl 10 mM; EDTA 0.5 mM; pH 9.0 
  
Protein Lysates 
NP40 buffer 
NP40 1% (v/v) ; Tris 20 mM pH 7.4; NaCl 0.15 M; directly before use 1% (v/v) proteinase 
inhibitor (P2714; SIGMA) and 1% (v/v) phosphatase inhibitor (P5726; SIGMA) were added 
  
SDS-PAGE 
5x SDS loading buffer  Tris 250 mM pH 6.8; Glycerin 50% (v/v); SDS 10% (v/v); DTT 500 mM; bromphenol blue 
Separation buffer  Tris 1.5 M pH 8.8; SDS 0.4% (v/v) 
Stacking buffer  Tris 0.5 M pH 6.8; SDS 0.4% (v/v) 
  
Western Blotting 
Cathode buffer  Tris 25 mM; 6-Aminocaproic acid 40mM; Methanol 20% (v/v) 
Anode buffer I  Tris 30 mM; Methanol 20% (v/v) 
Anode buffer II Tris 300 mM; Methanol 20% (v/v) 
10x TBS Tris 200 mM pH 7.6; NaCl 1.37M 
TTBS 1x TBS; Tween®20 0.1% (v/v) 
Blocking buffer TTBS, nonfat dry milk powder (NFDM, Bio-Rad) 5% (w/v) 
Stripping buffer SDS 2%; Tris 62.5 mM pH 6.8 
Tab. 16: Self-arranged buffers 
Abbreviations are explained in the appendix.  
Densitometric Quantification of Western Blot Signals 
Photographic films with detected western blot signals were digitalized and quantified using the Image 
Studio Lite software (LI-COR Bioscience), which quantitatively measures the optical density. Upon 
background subtraction values were normalized to a housekeeping gene and the relative and absolute 
foldchange was calculated compared to an internal reference (Rel. Signal = Starget/Shousekeeper; 
Rel. Foldchange = rel.STarget/ rel.SRef). 
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2.10 STATISTICAL ANALYSES 
Unpaired, two-tailed Student’s t-tests were performed to compare two data sets having Gaussian 
distribution and homogeneous variances. If the conditions were not given, the non-parametric Mann-
Whitney test was performed instead. 
One-way ANOVAs (one variable) or Two-way ANOVAs (multiple variables) were performed if more 
than two data sets were compared. ANOVAs calculate if there exists a significant difference between 
the means of the tested groups. Bonferroni post-hoc tests were performed afterwards to analyze, which 
of these group differences were significant. 
If One-way ANOVA could not be performed due to heterogeneous variances, the non-parametric 
Kruskal-Wallis test was applied instead. Dunn´s combined testing served as post-hoc test.  
Survival curves were generated and analyzed after Kaplan- Meier. 
All statistical analyses were performed with the GraphPad Prism 5 Software. The probabilities are 
indicated as follows: nsp > 0.05 (not significant); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
2.11 TISSUE PANELS 
Commercially available multiple tissue cDNA panels (Clontech) were used for expression analyses by 
RT-qPCR (0). 
Product Name Catalog Number 
Human MTC™ Panel I #636742 
Human MTC™ Panel II #636743 
Human Digestive System MTC™ Panel #636746 
Human Immune System MTC™ Panel #636748 
Mouse MTC™ Panel I #636745 
Mouse MTC™ Panel III #636757 
Tab. 17: Tissue cDNA panels obtained from Clontech 
2.12 SOFTWARE 
 
   Method Device Software for Data Analyses Company 
Analyses of flow cytometric data BD FACSCalibur™ BD CellQuest Pro™ Software BD bioscience 
  Flowing Software 2.5.1 
Perttu Terho, University of 
Turku, FI; Turku Bioimaging 
Statistical Analyses  GraphPad Prism 5 GraphPad Software 
Light microscopy Axio Imager.Z1 AxioVision Rel.4.8 Zeiss 
Chemiluminescence detection ChemiDoc™ XRS Q Quantity One BIO-RAD 
Western blot quantification Odysee XLS Image Studio Lite software LI-COR Bioscience 
Real Time quantitative PCR 
7900HT Fast Real Time 
PCR System 
SDSv2.4 Applied Biosystems 
Tab. 18: Software used for data analyses and presentation 
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3 RESULTS 
3.1 NLRC5 – EXPRESSION AND INDUCTION 
An initial step in the characterization of a protein is to evaluate its distribution within the organism. 
Cell type- or tissue-specific expression patterns can give clues on probable protein functions. 
Furthermore, factors that influence protein levels can indicate by which signaling pathways the 
investigated protein is regulated. Here the expression and induction of NLRC5 was evaluated on 
mRNA and protein levels. 
3.1.1 NLRC5 RNA IS HIGHLY EXPRESSED IN HUMAN AND MURINE IMMUNE TISSUES 
TaqMan assays were performed on human and murine tissue cDNAs in order to answer the questions 
how NLRC5 is expressed throughout the body, if it is ubiquitously distributed or shows a tissue-
specific expression pattern and if it is abundant or rather rare (tissue panels, Clontech; Tab. 17). 
Furthermore, species-specific differences in the general expression and distribution of NLRC5 were 
evaluated (Fig. 3-1 a, b). 
 
Fig. 3-1: NLRC5 expression in human and murine tissues 
NLRC5 TaqMan assays were performed on commercially available human and murine tissue cDNAs (Clontech, Tab. 17). Columns represent 
the average of technical duplicates. The standard error of the mean (SEM) is indicated by the bars. The expression of NLRC5 was normalized 
to the housekeeper GAPDH (ΔCt  =  2-Ct Target / 2-Ct Housekeeper). NLRC5 mRNA expression was highest in lymphoid tissues, especially 
secondary lymphoid organs. 
NLRC5 was expressed in all tested human and mouse tissues except skeletal muscle. Although it was 
ubiquitously expressed, NLRC5 mRNA levels varied between different tissues. The highest mRNA 
expression was found in human and murine secondary lymphoid organs e.g. spleen and lymph nodes 
as well as peripheral blood (pb) leukocytes. A high expression was detected in human bone marrow 
and murine thymus, which are both primary lymphoid organs. Moderate NLRC5 expression was 
detected e.g. in the lung and in various parts of the intestine. A marginal NLRC5 expression was found 
in e.g. muscle tissues, brain, kidney and liver. The expression patterns were comparable between 
humans and mice. An exception presented the prostate that showed high Nlrc5 expression in mouse, 
but only marginal expression in human tissue. 
NLRC5 mRNA was expressed in virtually all tested human and mouse tissues. The abundance was 
diverse between the tissues and the expression was strikingly elevated in immune-associated tissues 
what could indicate an immune relevant function.  
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3.1.2 NLRC5 PROTEIN WAS DETECTED IN VARIOUS CELL LINES AND IS 
UPREGULATED BY IFNγ 
In order to evaluate if NLRC5 is expressed by different cell types or if it can predominantly be found 
in immune cells, which constitute the lymphoid organs its expression was analyzed in human cell lines 
(Tab. 6) using western blotting. Therefore, cells were cultured under standard conditions. Total protein 
was isolated and analyzed for NLRC5 and β-ACTIN. 
It was also of interest if NLRC5 can be induced or reduced by certain stimuli. Accordingly, cells were 
stimulated with either IFNγ or TNFα for 6 or 10 h and changes in NLRC5 protein content were 
quantified on the developed film after immunobloting. 
 
Fig. 3-2: NLRC5 protein levels and its induction in human cell lines 
Human cell lines were cultured in 6-well plates o/n under standard conditions and were either left untreated or stimulated with IFNγ 
(25 ng/ml; hr IFNγ; Biosource) or TNFα (20 ng/ml; hr TNFα; R&D systems®) for 6 or 10 h. Cells were lysed and western blot was 
performed. The membrane was probed with either anti hu NLRC5 rat IgG or anti hu β-ACTIN mouse IgG. Chemiluminescent signals were 
detected on hyperfilm (GE healthcare; a+b) and quantified using the Image Studio Lite software from LI-COR Bioscience (c-e). The 
immunoblots (a, b) show NLRC5 protein expression in different human cell lines (upper lane). β-ACTIN served as protein loading control 
(lower lane). The crosses below indicate the type and duration of cell treatment. After background subtraction values were normalized to 
β-ACTIN and the absolute NLRC5 increment was calculated (e) in comparison to a blot internal reference (~; c: unstimulated HT-29 cells; d: 
unstimulated DB-2 cells).  
NLRC5 was expressed by different cell lines, predominantly leukocytes. The protein was strongly induced upon IFNγ stimulation. 
NLRC5 was detected in all tested immortal human cell lines (Fig. 3-2). The protein was expressed in 
the leukocytic cell lines derived from human blood (THP-1 monocytes, Jurkat T cells, DB-2 B cells) 
as well as in the epithelial cell lines (HT-29, HeLa; HEK-293) derived from other human tissues 
(colon, cervix, embryonic kidney) (Tab. 6). 
Basal NLRC5 levels showed differences between various cell lines. THP-1 and HeLa cells had high 
basal NLRC5 content, while only little of the protein could be detected in HT-29 cells (Fig. 3-2a, c). 
Jurkat and HEK-293 cells also showed higher basal levels compared to DB-2 (Fig. 3-2 d). 
Stimulation with IFNɣ led to a potent induction of NLRC5 in all cell lines (Fig. 3-2a–e). The NLRC5 
protein level was induced on average 2.7–fold after 6 h and 5.5-fold after 10 h of stimulation (e). The 
most potent induction was seen in DB-2 B lymphocytes (5.2 fold after 6 h; 15.4 fold after 10 h) and 
Jurkat T lymphocytes (3.6 fold after 6 h; 5.3 fold after 10 h; e). TNFα stimulation slightly induced 
NLRC5 in THP-1 as well as in HEK-293 cells, but did not have an effect on other tested cell lines.  
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The highest basal NLRC5 levels as well as the most potent increases in NLRC5 expression were 
observed in human leukocytic cell lines, which convey relevant immune processes. The induction of 
NLRC5 by IFNγ and the consequential mRNA tissue expression pattern support the hypothesis that 
NLRC5 might be involved in immunological processes. 
3.2 ANALYSIS OF SECONDARY IMMUNE ORGANS IN NLRC5 KO MICE 
Secondary lymphoid organs (spleen & lymph nodes) showed the highest NLRC5 mRNA expression in 
humans as well as in mice (Fig. 3-1). This raised the question if NLRC5 has a special function within 
these organs or in the cells that are mostly domiciled there. In human cell lines it was shown that 
NLRC5 is highly expressed in THP-1 monocytes and Jurkat T lymphocytes and that the protein is 
potently induced in leukocytes upon IFNɣ stimulation (Fig. 3-2).  
NLRC5 was further characterized by using Nlrc5-deficient mice. Especially murine spleens and 
mesenteric lymph nodes were further analyzed to evaluate if the deletion of Nlrc5 has any 
phenotypical effects within these organs. 
3.2.1 NO CHANGES IN SPLEEN WEIGHT 
Alterations in spleen size and weight are indicators for inflammatory processes like an infection or an 
unbalanced inflammatory immune response within the body. For instance splenomegaly (lat. enlarged 
spleen) can be caused by diseases of the blood or lymph system, infections, cancer or liver disease 
(MedlinePlus).  
If Nlrc5 is indispensable for proper immune function its deletion might affect spleen size. Therefore, 
spleens from Nlrc5 ko and wt mice were weighted and compared (Fig. 3-3).  
 
Fig. 3-3: Spleen weight in Nlrc5 ko mice 
Mice were sacrificed, spleens removed and weighted (animals: n=7–11 per group; age: 8–16 weeks). Each individual mouse is represented 
by a dot. The median is indicated by the bars and given below. One-way ANOVA with Bonferroni post-hoc tests was performed.  
The spleen weight was not influenced by the Nlrc5 knockout.  
There were no obvious differences in spleen size, weight or color in the Nlrc5 ko compared to wt 
mice. Female animals had a higher median spleen weight (~10 mg) if compared to their male 
counterparts in both genotypes.  
The Nlrc5 deletion did not influence the spleen weight and therefore a normal spleen function is 
assumed under SPF caging conditions. Normal spleen architecture and function was further evaluated 
using histological techniques. 
3.2.2 NO STRUCTURAL ALTERATIONS IN SECONDARY LYMPHOID ORGANS 
There were no obvious macroscopic changes in secondary lymphoid organs of Nlrc5 ko mice if 
compared to their wt counterparts. Murine spleen and mesenteric lymph nodes were further 
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histologically examined to compare immune organ structure. Therefore paraffin sections were stained 
with hematoxilin and eosin and microscopically analyzed. 
Wt and Nlrc5 ko mice showed similar lymph node architecture (Fig. 3-4a, b). The cortex (c), which is 
the B cell zone, was equally interspersed with lymph follicles in wt and ko mice. The homogeneous 
dark primary follicles (pN) and the secondary follicles (sN) with their lighter germinal centers (gc) 
were distinguishable. Also the paracortex (pc), which is the T cell zone, and the medullary zone with 
its medullary cords and sinuses showed normal architecture in Nlrc5 ko mice.  
Wt and Nlrc5 ko mice also had similar spleen architecture (Fig. 3-4 c, d). White and red pulp could 
easily be distinguished. The B cell follicles of the white pulp with their germinal centers showed 
comparable size and structure. Also the red pulp did not show any differences. 
 
Fig. 3-4: Structure of secondary lymphoid organs in Nlrc5 ko mice 
Mice were sacrificed (n=2 per group). Spleens and mesenteric lymph nodes were removed. Formalin-fixed and paraffin-embedded tissues 
were dissected and stained with HE. Light microscopy was carried out with the Axio Imager.Z1 at indicated magnifications. Abbreviations 
are used for clarity and explained in the legend.  
The architecture of the secondary lymphoid organs did not differ in NLRC5 ko mice under basal conditions if compared to the wt.  
Although NLRC5 is highly expressed in immune tissues as lymph nodes and spleen the histological 
comparison of these secondary lymphoid organs did not show any obvious changes under basal 
conditions that could be attributed to the Nlrc5 deficiency. 
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3.2.3 ALTERED IMMUNE CELL POPULATIONS IN THE SPLEEN  
NLRC5 is highly expressed in leukocytes as well as immune tissues (Fig. 3-1, Fig. 3-2) that are 
comprised of these cells. This suggests that the protein function might be closely related to certain 
immune cells.  
In order to assess if Nlrc5 ko mice had normal immune cell populations or if there were differences 
due to impaired generation or differentiation of certain leukocytic cell types, murine splenocytes were 
analyzed for various immune cell populations by flow cytometry. 
 
Fig. 3-5: Immune cell populations in the spleen of Nlrc5-deficient mice 
Mice were sacrificed. Spleens were removed, homogenized and mixed splenocyte cultures were prepared. Cells were stained with 
fluorophore labeled antibodies (anti ms CD3ε FITC anti ms CD4 PE, anti ms CD8 FITC, anti ms CD19 PE, anti ms Gr-1 FITC, 
anti ms CD11b FITC; Immunotools) and analyzed by flow cytometry. The mapped percentage refers to the gated vivid leukocyte population. 
Each individual is indicated by a separate dot. Animals: n = 4–6; sex: mixed; age: 8–16 weeks. The median is indicated by the bars and 
written below. Student’s t test was performed. *p = 0.0149  
Nlrc5 ko mice showed a significant decrease in the CD8+ population. 
NLRC5 deficiency had an impact on certain immune cell populations: While the general CD3 
expression on the T lymphocyte population was not altered (a), the CD8+ cytotoxic T lymphocyte 
(CTL) population was significantly diminished in ko mice (c). In contrast, CD4+ T helper (Th) cells as 
well as neutrophils (Gr1+) were slightly elevated in the knockout (b, e). CD19+ B cell and 
CD11b+ monocyte/Mϕ numbers were not affected in the ko (d, f). 
3.3 THE EXPRESSION OF MHC MOLECULES ON NLRC5-DEFICIENT CELLS 
CD8 and CD4 are important co-receptors of the TCR and involved in the recognition of antigens 
presented by MHC molecules. MHC class I and its bound peptide are recognized by the TCR in 
combination with CD8 leading to the activation of the CD8+ co-expressing cytotoxic T cells, while 
CD4 is a co-receptors for loaded MHC class II molecules leading to the activation of the CD4+ co-
expressing helper T cells.  
Nlrc5 was shown to have a significant impact on the CD8+ CTL and a minor impact on the CD4+ Th 
lymphocyte population in mice (Fig. 3-5). Therefore, also the counterparts of CD8 and CD4, the MHC 
class I and II receptors, were analyzed to assess a possible impact of Nlrc5 on the surface expression 
of these molecules. 
3.3.1 DIMINISHED MHC CLASS I EXPRESSION ON NLRC5-DEFICIENT LEUKOCYTES  
The expression of MHC class I was analyzed by flow cytometry in different primary leukocyte 
cultures prepared from Nlrc5 ko mice. 
 
The Surface Expression of MHC Class I is Diminished on Nlrc5-deficient Murine Macrophages 
The MHC class I expression was analyzed on murine Mϕs. Bone marrow was isolated from wt and 
Nlrc5 ko mice. Bone marrow-derived Mϕs (BMDMs) were generated and analyzed by flow cytometry 
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for their surface expression of the MHC I isotype H-2Kb (Fig. 3-6). Wt and Nlrc5 ko mice express 
H-2Kb. Two distinct H-2Kb positive populations were distinguishable for both genotypes (a). Nlrc5-
deficient BMDMs showed a general reduction of H-2Kb expression on the cell surface (a). This is also 
reflected by the geometric mean fluorescence intensity (geometric mean), which was significantly 
diminished in the ko (b).  
 
Fig. 3-6: MHC class I expression on murine Nlrc5-deficient macrophages 
Mice were sacrificed, bone marrow was isolated and BMDMs were generated in vitro. BMDMs were stained with fluorophore labeled 
antibodies (anti ms H-2Kb APC, ms IgG2a K Isotype Control APC from eBioscience) and analyzed by flow cytometry.  
Animals: n = 6 wt, n = 5 ko; sex: mixed; age: 16 weeks.  
a The histogram compares exemplary the MHC class I surface expression on cells of one wt (black line) to the expression on cells of one ko 
animal (green curve). b Geometric mean fluorescence intensities for all tested animals are depicted. Each individual is indicated by a separate 
dot. The median is represented by the bars and written below. Student’s t test was performed. **p = 0.0070.  
Shown is the expression of MHC class I H-2Kb on the surface of BMDMs generated from wt and Nlrc5 ko mice. Nlrc5-deficient bone 
marrow derived Mϕs (BMDMs) had a greatly reduced MHC class I H-2Kb surface expression. 
The Surface Expression of MHC Class I is Diminished on Nlrc5-deficient Murine Lymphocytes 
The expression of the H-2Kb and the H-2Db MHC class I isotypes was further evaluated on murine 
splenocytes by flow cytometry (Fig. 3-7). 
Nlrc5 ko mice had a reduced MHC class I surface expression for both analyzed MHC class I isotypes 
(Fig. 3-7b, c, f, g). The geometrical mean fluorescence intensity was significantly diminished in ko 
lymphocytes (d+h). 
In contrast to the murine BMDMs only one single MHC I population for each isotype was observed on 
wt lymphocytes. However, Nlrc5-deficient macrophages had two separate H-2Kb expressing 
populations (Fig. 3-7 b, c). Also for H-2Db, a second population with slightly reduced surface 
expression existed.  
 Results 
45 
 
 
Fig. 3-7: MHC class I expression on murine Nlrc5-deficient lymphocytes 
Mixed splenocyte cultures were prepared, stained with fluorophore labeled antibodies and analyzed by flow cytometry (anti ms H-2Kb APC, 
anti ms H-2Db FITC, ms IgG2a K Isotype Control APC from eBioscience; ms IgG2a Isotype control FITC from Immunotools). Animals: 
n=6 wt, 5 ko; sex: mixed; age: 16 weeks. a+e Lymphocytes were gated (R-1; red) from the total spleen population (black). b+f The MHC I 
fluorescence intensity is displayed for the entire lymphocyte population in comparison to the cell size indicated by the FSC. The quadrant 
line is drawn for orientation.  
c+g The histograms display the fluorescence intensity versus the cell number and compare exemplary the MHC class I expression in one wt 
animal (black line) to the expression in one ko animal (green curve). Isotype controls are indicated by dashed lines (black = wt, green = ko). 
d+h Geometric means of the fluorescence intensity of all tested animals are compared in the scatter plots. Each individual is shown as a 
separate dot. Bars indicate the median and are given as numbers. Student’s t test was performed. ****p = < 0.0001.  
Shown is the expression of two different MHC class I isotypes (a–d H-2Kb, e–h H-2Db) on the surface of lymphocytes from wt and Nlrc5 
ko mice. Murine lymphocytes showed a significantly and inhomogenously reduced MHC I surface expression for both isotypes. 
3.3.2 TWO MHC CLASS I EXPRESSING LEUKOCYTES POPULATIONS EXIST 
Nlrc5 ko mice did not only show a reduced MHC class I surface expression, they also displayed a 
second MHC class I expressing population within the analyzed lymphocyte population 
(Fig. 3-7 b, c, g). Especially for the H-2Kb isotype these populations were clearly distinguishable. 
However, a second MHC class I expressing population was absent in wt lymphocytes. In order to 
evaluate population size and, which lymphocyte subclasses they are composed of, further flow 
cytometric analyses were performed using murine splenocytes (Fig. 3-8). 
On average 99% of all wt lymphocytes and 98% of all Nlrc5-deficient lymphocytes expressed H-2Kb 
on their surface (d). Wt lymphocytes showed repeatedly one major H-2Kb-expressing population that 
included 98% of all lymphocytes, while the remaining 2% had only low (1%) or no (1%) H-2Kb on 
their surface (Fig. 3-8 b, d).  
Lymphocytes from Nlrc5 ko mice showed two different H-2Kb-expressing populations. On average 
69% of all lymphocytes expressed moderate to high H-2Kb levels (region name “high”) and 29% 
expressed only very low amounts of the MHC I isotype (Fig. 3-8 c, d). Also within the “high” region 
Nlrc5-deficient lymphocytes showed a strongly reduced H-2Kb expression when compared to the wt 
as indicated by the geometric mean fluorescence of that region (Fig. 3-8 b, c). 
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Fig. 3-8: Identification and analysis of MHC class I (H-2Kb) expressing lymphocyte subpopulations  
Mixed splenocyte cultures were prepared and triple stained with fluorophore labeled antibodies for MHC I H-2Kb, CD8 and MHC II 1-A or 
their corresponding isotype controls (anti ms H-2Kb APC, anti ms MHC II (I-A) PE, ms IgG2a κ Isotype APC, rat IgG2b, κ Isotype PE, 
eBioscience, anti ms CD8 FITC, Immunotools; rat IgG2a, κ Isotype FITC, BioLegend). Cells were analyzed by flow cytometry. Data refer to 
the gated vivid lymphocyte population. Animals: n = 5 wt, n = 5 ko; sex: female; age: 8–9 weeks. 
a–c The surface expression of MHC I H-2Kb on wt (black lines) and ko (green curves) lymphocytes is displayed. a Isotype controls were 
used to check for nonspecific staining (dashed lines; black = wt, green = ko) and to define regions (low, high) for further population analyses. 
b+c Population sizes for the regions are given in percent. The geometric mean is indicated in italics and refers only to the high MHC I 
expressing population. d H-2Kb populations for all tested animals were compared. Given is the mean with SEM. Statistical analysis was 
performed with Two-way ANOVA followed by Bonferroni post-hoc tests. **** p < 0.0001 
e–g Shown is the analysis of the CD8+ lymphocyte population. The size of the gated CD8+ population is given in % and the comparison of all 
animals is shown in g. Bars indicate the median. Student’s t test was performed. ***p = 0.0006 
h–j  CD8+ lymphocytes were gated and analyzed for their MHC I H-2Kb surface expression. The histograms compare exemplary the 
population size for the low and high region for one wt and one ko animal (h+i). j Shown is the comparison of the MHC I expression on the 
CD8+ population giving the mean with SEM. Statistical analysis was performed with Two-way ANOVA followed by Bonferroni post-hoc 
tests. **** p < 0.0001 
k+l MHC II 1-A+ lymphocytes were gated and analyzed for their MHC I H-2Kb surface expression. The histograms depict exemplary 
population sizes for the low and high region in one wt and one ko animal.  
Nlrc5-deficient lymphocytes show an additional H-2Kb population that comprises about 30% of all ko lymphocytes. About 60% of ko 
CD8+ CTLs, but only 10% of MHC class II+ APCs belong to this H-2Kb low expressing lymphocyte subpopulation. 90% of MHC II+ cells 
showed a high MHC I expression on Nlrc5-deficient lymphocytes. 
The gated vivid lymphocyte population was further analyzed for CD8 expression (Fig. 3-8 e–g). On 
average 19% of wt lymphocytes expressed CD8 and were therefore cytotoxic T lymphocytes, while 
only 14% of the Nlrc5-deficient lymphocytes were co-expressed CD8 (see also Fig. 3-5 c). CD8+ 
lymphocytes were subsequently analyzed for their H-2Kb expression pattern (Fig. 3-8 h–j). In the wt 
the majority of all CD8+ CTLs expressed high H-2Kb levels (84%). In contrast, only 30% of Nlrc5-
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deficient CD8+ lymphocytes showed a high H-2Kb expression: The majority (57%) had a greatly 
diminished H-2Kb expression. CD8+ T lymphocytes were therefore one of the lymphocyte 
subpopulations that account for the H-2Kblow expressing population among ko lymphocytes.  
In contrast, the great majority of MHC class II+ lymphocytes (99% in wt and 90% in the ko) expressed 
high H-2Kb levels (Fig. 3-8 k, l). Therefore, MHC II+ cells did account for the cellular subpopulation 
that remained a high MHC I H-2Kb expression among Nlrc5-deficient lymphocytes. 
3.3.3 ENLARGED POPULATION OF MHC CLASS II+ CELLS IN THE SPLEEN 
The deletion of Nlrc5 significantly reduced the expression of MHC class I and diminished the CD8+ 
cell population. Furthermore, CD4+ cell numbers were slightly elevated. Therefore, the surface 
expression of MHC class II was analyzed on splenocytes as well. 
MHC class II was expressed on Nlrc5-deficient as well as on wt leukocytes (Fig. 3-9). The amount of 
MHC II per cell did not strikingly differ between both genotypes (a), but the MHC II expressing cell 
population was enlarged in the ko. Nlrc5-deficient leukocytes had on average 9% more MHC II+ 
leukocytes in the spleen when compared to wt cells (b). 
 
Fig. 3-9: MHC class II expression on Nlrc5-deficient leukocytes 
For experimental procedure see legend to Fig. 3-8. Data refer to the gated vivid leukocyte population.  
a Each curve represents the MHC class II expression of one exemplary animal (continuous lines, black = wt, green = ko). Isotype controls 
are used to check for nonspecific immunoglobulin binding (dashed lines; black = wt, green = ko).  
b MHC class II isotype I-A positive cell populations were compared between Nlrc5 ko and wt leukocytes. Each individual is displayed by a 
separate dot. The median is indicated by the bar and written below. Student’s t test was performed for statistical analyses. ***p = 0.0009  
Nlrc5-deficient leukocytes expressed significantly more MHC class II on the plasma membrane. 
3.3.4 MHC CLASS I IS STILL INDUCIBLE IN NLRC5-DEFICIENT LYMPHOCYTES 
A strong reduction of MHC class I molecules was found on Nlrc5-deficient immune cells. In order to 
evaluate if MHC class I could still be induced in Nlrc5-deficient cells, mixed splenocytes were 
stimulated with Phytohemagglutinin (PHA) and IL-2 and MHC I surface expression was monitored by 
flow cytometry. PHA is a natural lectin from the kidney bean (Phaseolus vulgaris), which agglutinates 
leukocyte surface receptors including the TCR. Thereby it leads to a nonspecific cell activation and 
proliferation of T lymphocytes as well as the release of cytokines via several pathways. 
Interleukin 2 (IL-2) stimulates the proliferation and differentiation of activated lymphocytes (Morgan 
et al., 1976) and was used to stimulate lymphocyte proliferation. 
PHA significantly upregulated the MHC class I expression on the surface of wt and ko 
lymphocytes (Fig. 3-10 a, b, c). This was further increased if IL-2 was added.  
MHC I was more potently induced in Nlrc5-deficient than wt cells (Fig. 3-10 c). However, although 
MHC I could be induced by PHA and IL-2, the total surface MHC I expression was still significantly 
decreased in ko lymphocytes if compared to the wt.  
Nlrc5-deficient lymphocytes furthermore showed a significant increase in the number of MHC I+ cells 
after the stimulation with PHA and IL-2. Without stimulation 96.6% of all wt lymphocytes carried 
MHC I on their surface, while in the ko this population was slightly diminished with 95.6% of all 
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lymphocytes being MHC I+ (Fig. 3-10 d). PHA and more potently PHA/ IL-2 induced a slight 
increased in the number of MHC I+ cells, which was significant in Nlrc5 ko lymphocytes. After 
PHA/ IL-2 stimulation the MHC I+ populations were similar for both genotypes, with 97.5% MHC I+ 
wt and 97.6% MHC I+ ko lymphocytes. 
 
Fig. 3-10: Surfacial MHC class I expression on murine lymphocytes upon stimulation 
Mixed splenocyte cultures were prepared (96-well format, 2 x 105cells/well) and stimulated with PHA (0.5 µg/ml) and IL-2 (25 ng/ml; 
Immunotools) for 20 h. Cells were harvested, stained with fluorophore labeled antibodies (anti ms H-2Kb APC; eBioscience) and analyzed 
by flow cytometry. Data refer to the gated vivid lymphocyte population. Animals: n=6 wt, 5 ko; sex: mixed; age: 16 weeks.  
a+b Histograms show MHC I fluorescence intensities in unstimulated (black), PHA (green) or PHA/IL-2 (red) stimulated lymphocytes of an 
exemplary wt (a) and ko animal (b). The dashed line (b) indicates the unstimulated wt and is shown for comparison. The induction of MHC I 
molecules on the surface of lymphocytes is indicated by the geometric mean fluorescence and compared for all animals in c. Furthermore, 
the MHC I H-2Kb positive population was analyzed in a dot plot (MHC I versus FCS; not shown) and changes in population size upon 
stimulation are displayed in d. One-way ANOVAs with Bonferroni post-hoc tests were performed. *p < 0.05; ***p < 0.001; ****p < 0.0001  
MHC class I can be induced in Nlrc5 ko lymphocytes, as the MHC I surface expression was elevated and the total MHC I+ population 
expanded upon cell activation. 
The overall expression of MHC I was strongly upregulated upon stimulation with PHA and IL-2 in wt 
and ko animals. This was mainly mediated through an elevated expression of MHC I (Fig. 3-10 c) on 
the cell surface and only slightly influenced by an increase in the general MHC I+ cell 
population (Fig. 3-10 d).  
MHC class I can still be potently induced upon stimulation in the Nlrc5-deficient cells, although the 
MHC class I expression remained strongly alleviated in Nlrc5-deficient cells. 
3.4 ALTERED CYTOKINE EXPRESSION IN NLRC5-DEFICIENT CELLS  
The Nlrc5 knockout was shown to influence certain immune populations and the surface expression of 
MHC class I and II molecules. In order to assess how NLRC5 influences these parameters various 
signaling pathways were activated in primary leukocyte cultures and the induction of typical cytokines 
was analyzed to evaluate if NLRC5 might be involved in immune signaling pathways. An altered 
immune signaling can influence the MHC expression or the generation, differentiation or survival of 
certain immune cell populations. 
3.4.1 IMPAIRED INDUCTION OF TYPE I AND II IFNS 
Interferons are important mediators within the immune system, especially in antiviral responses 
(Malmgaard, 2004) and link the innate to the adaptive immune system (Le Bon and Tough, 2002). 
NLRC5 was repeatedly reported to be involved in IFN signaling, but observations remained 
contradictory (Benko et al., 2010; Cui et al., 2010; Kuenzel et al., 2010; Neerincx et al., 2010). 
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Therefore, the induction of type I and type II IFNs was evaluated in Nlrc5-deficient cells by 
stimulating murine splenocytes and BMDMs in vitro. 
 
Type I Interferon: IFNβ 
Murine BMDMs were generated and stimulated with poly(I:C) or single stranded (ss) RNA, which 
both mimic viral infection (Fig. 3-11). A pretreatment with LPS was performed for poly(I:C)-induced 
Ifnb expression. The mRNA induction was analyzed using RT-qPCR. 
There was no Ifnb mRNA detectable in unstimulated BMDMs, but it was induced upon stimulation 
with either LPS, LPS/ poly(I:C) or ssRNA in both genotypes. LPS pretreatment led to an equal 
induction of Ifnb (abs. foldchange LPS: wt = 70.9 vs. ko = 70.4) in wt and ko BMDMs. Additional 
stimulation with the synthetic double stranded RNA analogue poly(I:C) potently induced Ifnb mRNA 
in the wt. Ifnb was also induced in ko BMDMs, but to a lesser extent (abs. foldchange LPS/poly(I:C): 
wt = 261.8 vs. ko = 103.5). BMDM treatment with ssRNA also induced Ifnb gene expression. The 
induction tends to be stronger in wt compared to ko BMDMs (abs. foldchange ssRNA: wt = 282.7 vs. 
ko = 92.6).  
 
Fig. 3-11: Induction of Ifnb in stimulated Nlrc5-deficient primary cell cultures  
Murine BMDMs were cultured in 6-well cell culture plates (0.5 x 106 cells/well ). Cells were either prestimulated for 4 h with LPS 
(100 ng/ml, RC Borstel) before poly(I:C) (10 µg/ml; Calbiochem) was added o/n or they were stimulated only with ssRNA (1 µg/ml; 
InvivoGen) for 6 h. RNA was prepared for Ifnb TaqMan assay. Ifnb expression was normalized to β-Actin and the absolute foldchange was 
calculated in comparison to unstimulated samples. Animals: n = 2 wt, 2 ko; sex: female, age: 9 weeks. Technical duplicates were performed 
and averaged. Depicted is the mean of biological replicates with the SEM. TaqMan assay was obtained from Life TechnologiesTM (Tab. 13).  
Nlrc5-deficient cells fail to induce Ifnb upon viral stimulation with either poly(I:C) or ssRNA. 
Lymphocyte Activation 
Primary murine splenocyte cultures were prestimulated with a mixture of Phorbol 12-myristate 13-
acetate and Ionomycin (PMA/ Iono) or PHA. While PHA agglutinates cell-surface receptors to 
activate leukocytes, the combination of PMA/ Iono raises intracellular Ca2+ levels. Free Ca2+ in the 
cytoplasm binds calmodulin that in turn activates the calmodulin-activated phosphatase calreticulin. 
Calreticulin dephosphorylates members of the transcription factor family nuclear factor of activated T 
cells (NFAT), which can enter the nucleus and induce cell-specific gene transcription (Hogan et al., 
2003). Both stimulations were used to activate resting lymphocytes to produce and release their 
specific cytokines. 
Lymphocyte activation was monitored by the surface expression of CD25, to exclude that differences 
in cytokine expression are due to an altered activation status between wt and Nlrc5 ko lymphocytes. 
CD25 is the alpha chain of the IL-2 receptor and was used as lymphocyte activation marker. 
The expression of CD25 was elevated upon either PMA/ Iono or PHA treatment at comparable levels 
on wt and ko splenocytes, thus cells showed an equal activation status (Fig. 3-12 a). Cells were 
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activated equally upon PHA or PMA/ Iono treatment. No influence of LPS on cell activation was 
detected. 
 
Type II Interferon: IFNγ 
Cytokine production was further induced by subsequent LPS treatment (Fig. 3-12 b, c). The induction 
of Ifng mRNA was analyzed by RT-qPCR (TaqMan assay) and the secreted amounts of IFNɣ were 
measured by enzyme-linked immunosorbent assay (ELISA) in culture supernatants (0; 2.5).  
There was no Ifng mRNA detectable in unstimulated wt and ko cells (Fig. 3-12 b). Upon stimulation 
with LPS, PMA/ Iono or PMA/ Iono/ LPS Ifng was slightly induced in both genotypes with a higher 
absolute foldchange in the wt (average abs. foldchange PMA/ Iono/ LPS: wt = 11.8 vs. ko = 3.6). Ifng was 
potently induced after PHA stimulation and further raised if LPS was administered additionally. 
Overall, the expression of Ifng was higher in wt than in Nlrc5-deficient cells (average 
abs. foldchange PHA/LPS: wt = 124.3 vs. ko = 37.6).  
 
Fig. 3-12: Activation of Nlrc5-deficient splenocytes & induction of IFNγ by LPS  
Mixed murine splenocytes were cultured in 12-well cell culture plates (4x106 cells/well) and prestimulated o/n with PMA/Iono 
(PMA: 10 ng/ml; Iono: 1 µg/ml Sigma-Aldrich) or PHA (0.5 µg/ml). Afterwards they were additionally stimulated with LPS (100 ng/ml, RC 
Borstel) for 24 h before supernatant was taken off for ELISA analysis (c) and cells were analyzed by flow cytometry (a) or TaqMan 
analyses (b).  
a Cells were labeled with anti ms CD25 FITC (Immunotools). Results refer to gated vivid splenocytes. b Ifng TaqMan assay was performed, 
expression normalized to β-Actin and absolute foldchange calculated in comparison to unstimulated samples (Life TechnologiesTM; Tab. 13). 
c IFNγ ELISA was performed as instructed by the manufacturer (CMC4033, Invitrogen).  
Animals: n = 2 wt, 2 ko; sex: female; age: 10 weeks. Technical duplicates were performed and averaged. Depicted are the means of 
biological replicates with the SEM. 
Wt and ko splenocytes were equally activated by PMA/ Iono or PHA, while the activation-induced expression of IFNγ was diminished in 
Nlrc5 ko splenocytes.  
Secreted IFNɣ levels were low in both genotypes in untreated and LPS stimulated cells (Fig. 3-12 c; 
average IFNγ concentration unstim: wt = 20.8 pg/ml vs. ko = 22.0 pg/ml). An increase in IFNɣ secretion 
was observed in the wt upon stimulation with PMA/ Iono (147.8 pg/ml), which was further elevated 
by co-administering LPS (219.5 pg/ml). PHA also induced the secretion of IFNɣ (120.0 pg/ml) in wt 
cells, which was further increased by additional LPS treatment (305.0 pg/ml). Nlrc5-deficient 
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splenocytes produced IFNɣ to a much lesser extent. The secretion of IFNɣ was only slightly induced 
by PMA/ Iono (44.2 pg/ml) and not further augmented by an additive LPS treatment. Also PHA 
treatment induced IFNɣ in Nlrc5-deficient cells (78.7 pg/ml), which was further elevated by the 
addition of LPS (150.1 pg/ml). However, the secreted IFNɣ levels were diminished in ko compared to 
wt cells. 
IFNɣ could be induced and secreted by Nlrc5-deficient splenocytes, but mRNA as well as protein 
levels of the type I IFN were reduced if compared to equally treated wt splenocytes. 
 
Taken together, type I and II IFN responses were impaired in Nlrc5-deficient primary cultures upon in 
vitro stimulations compared to wt cells. 
3.4.2 IMPAIRED INDUCTION OF IL-1β  
The cytokine IL-1β is an important mediator in inflammatory cellular immunity, especially in response 
to lipopolysaccharides. IL-1β is mainly produced in cells of the monocytic lineage. It was observed in 
vitro that NLRC5 might be involved in IL-1β signaling (Davis et al., 2010).  
IL-1β induction and secretion were analyzed in Nlrc5-deficient BMDMs and bone marrow-derived 
dendritic cells (BMDCs) to evaluate a potential role of this NLR member in IL-1β signaling processes. 
Primary BMDM and BMDC cultures were stimulated with LPS to induce the expression of the IL-1β 
propeptide and subsequently treated with ATP to activate caspase-1, which cleaves the pro-IL-1β into 
its active form. RNA was isolated for TaqMan analyses.  
Il1b mRNA was induced by LPS in wt and ko BMDMs (Fig. 3-13 a; abs. foldchange LPS: wt = 16.5 vs. 
ko = 3.0). Interestingly, mRNA levels were further raised upon ATP treatment 
(abs. foldchange LPS/ATP: wt = 63.0 vs. ko = 22.6), but the Il1b expression was significantly diminished 
in Nlrc5-deficient BMDMs when compared to wt cells. 
The amount of secreted IL-1β was determined by performing an IL-1β ELISA using culture 
supernatants. The cytokine was barely detectable in wt and ko supernatants of unstimulated and LPS-
treated culture wells (wt unstim, LPS = 10,7 pg/ml; ko unstim = 7,5 pg/ml; ko LPS = 5,7 pg/ml). IL-1β 
secretion was induced in both genotypes by additional stimulation with ATP upon LPS treatment 
(Fig. 3-13 b), but the amount of secreted IL-1β was alleviated in the ko (wt LPS/ATP = 40.7 pg/ml; 
ko LPS/ATP = 12.1 pg/ml). 
Furthermore, IL-1β production was monitored by staining of intracellular IL-1β and its flow 
cytometric analysis in murine dendritic cells (Fig. 3-13 c). Again cells were stimulated with LPS alone 
or in combination with ATP.  
Already basal intracellular IL-1β concentrations were significantly diminished in the Nlrc5-deficient 
BMDCs when compared to the wt. This tendency was observed for all stimulations. Neither the 
treatment with LPS nor LPS/ATP potently raised intracellular IL-1β concentrations in wt and ko 
BMDCs.  
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Fig. 3-13: Induction and secretion of IL-1β in stimulated Nlrc5-deficient primary cells 
Primary BMDMs and BMDCs were generated from fresh murine bone marrow. a & b . Animals: n = 2 wt, 2 ko; sex: female, age: 9 weeks. 
BMDMs were cultured in 6-well cell culture plates (0.5 x 106 cells/ well ). Cells were prestimulated with LPS (1 µg/ml, RC Borstel) for 4 h 
followed by ATP (10 µM; Sigma-Aldrich) stimulation for 20 h. ELISA was performed with supernatants, while RNA was isolated for 
TaqMan analysis a Il1b TaqMan assay was performed (Life TechnologiesTM; Tab. 13), expression normalized to β-Actin and the absolute 
foldchange calculated in comparison to unstimulated samples. b IL-1β ELISA was performed as instructed by the manufacturer (CMC0813, 
Invitrogen).  
c Animals: n = 6 wt, 5 ko; sex: mixed; age: 9 weeks. BMDCs were cultured in 6-well cell culture plates (1 x 106 cells/well) and prestimulated 
with LPS (100 ng/ml, RC Borstel) for 24 h before ATP (10 µM, Sigma-Aldrich) was added. Simultaneously Brefeldin A (4 µg/ml, Sigma-
Aldrich) was added to all wells to inhibit protein secretion. After 6 h cells were fixed, permeabilized (BD Cytofix/Cytoperm™, BD 
Bioscience), stained for intracellular IL-1β as recommended by the manufacturer (ms IL-1beta mAB PE, R&D Systems®) and analyzed by 
flow cytometry.  
Technical duplicates were performed and averaged. Depicted are the means of biological replicates with the SEM.  
The induction of IL-1β was impaired in Nlrc5-deficient primary cultures upon stimulation. 
Altogether, upon stimulation IL-1β levels were reduced in Nlrc5-deficient cells when compared to the 
wt in vitro. 
3.4.3 ALTERED EXPRESSION OF PRO-INFLAMMATORY CYTOKINES 
Various mediators play a pivotal role in immune processes. For instance TNFα, which is a very early 
induced mediator directing innate inflammatory processes. TNFα activates e.g. NF-κB signaling and 
thereby induces other signaling molecules like IL-1β, IL-6 and CXCL1 (KC, human homologue: 
IL-8). These mediate further steps in the course of inflammation. NLRC5 was reported to inhibit 
NF-κB signaling in vitro (Benko et al., 2010; Cui et al., 2010). To evaluate this, the expression of 
Tnfa, Il6 and Cxcl1 were analyzed ex vivo in murine BMDMs.  
Murine BMDMs were stimulated with LPS (Fig. 3-14 a, b). The induction of pro-inflammatory 
cytokines was investigated on the mRNA level using TaqMan assays. TNFα secretion was further 
measured by performing ELISA assays. 
Tnfa, Il6 and Cxcl1 were induced upon LPS stimulation to a different extent in both genotypes. 
While the mRNA expression of Tnfa was elevated in Nlrc5-deficient BMDMs (Fig. 3-14 a; 
abs. foldchange LPS: wt = 7.4 vs. ko = 15.0), the secretion of TNFα was higher in wt BMDMs 
(Fig. 3-14 b; wt LPS = 808.1 pg/ml; ko LPS = 308.5 pg/ml). Furthermore, Cxcl1 mRNA levels were 
elevated in Nlrc5-deficient BMDMs (Fig. 3-14 d; abs. foldchange LPS: wt = 40.9 vs. ko = 82.4) and Il6 
mRNA was induced to a similar extent upon LPS stimulation in wt and ko cultures (Fig. 3-14 c). 
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Fig. 3-14: Induction of pro-inflammatory mediators in stimulated Nlrc5-deficient BMDMs 
a-d Primary BMDM cultures were generated from murine bone marrow and cultured in 6-well cell culture plates (0.5 x 106 cells/ well ). 
Cells were prestimulated with LPS (1 µg/ml, RC Borstel) for 24 h. TaqMan assays were carried out on isolated mRNAs (a, c, d; Life 
TechnologiesTM) and the ELISA on cell culture supernatants (b; CMC3013; Invitrogen). All assays were performed as instructed by the 
manufacturer. Animals: n=2 wt, 2 ko; sex: female, age: 9 weeks.  
Technical duplicates were performed and averaged. Depicted are the means of biological replicates with SEM. 
The induction of Tnfa was elevated in Nlrc5-deficient cells when compared to the wt; in contrast secreted TNFα concentrations were strongly 
alleviated in the ko. Cxcl1 mRNA levels were elevated in Nlrc5-deficient BMDMs and Il6 was induced at comparable amounts in both 
genotypes. 
Taken together, TNFα and CXCL1 are differentially regulated in Nlrc5-deficient BMDMs if compared 
to wt cells.  
3.5 THE IMPACT OF NLRC5 ON EXPERIMENTAL MURINE COLITIS 
An immunological phenotype was observed in Nlrc5 ko mice. This phenotype was not only restricted 
to innate responses manifesting through an altered cytokine profile, but it had also an impact on 
adaptive mechanisms as there were striking differences in the expression of MHC molecules as well as 
the CD8 co-expressing T lymphocyte population if Nlrc5 was deleted (3.2, 3.3, 3.4).  
These ex vivo results were further evaluated in vivo in murine DSS-induced experimental colitis 
models, which induce strong inflammation in the murine colon and therefore mimic human IBD. An 
acute and a chronic colitis phenotype were induced, which involve innate as well as adaptive immune 
processes (Hall et al., 2011). 
To answer if NLRC5 has an impact on the inflammatory processes disease onset, progression and 
severity were monitored by analyzing clinical parameters. Furthermore, NLRC5-specific parameters 
were examined. 
3.5.1 INCREASED SEVERITY OF ACUTE COLITIS IN NLRC5 KO MICE 
DSS is reported to be toxic to the colon epithelium. It destructs the epithelial barrier allowing luminal 
microorganisms and antigens to enter the colon tissue, which subsequently leads to the development of 
an experimental colitis (Hans et al., 2000a; Tlaskalová-Hogenová et al., 2005). The development of an 
acute DSS colitis is described to be independent of adaptive immune processes (Dieleman et al., 
1994). Therefore, it is a useful model to study the impact of the NLRC5 protein on innate 
inflammatory processes. 
Acute colitis was induced in Nlrc5 ko and wt mice by applying 3% DSS orally for five days, followed 
by three days of water only (Fig. 3-15).  
All acute colitis read outs described below are based on the experimental setup described in Fig. 3-15 
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Fig. 3-15: Treatment of experimental animals to induce acute DSS colitis 
Shown is the model of DSS treatment that was used to induce an acute colitis. Drinking water was autoclaved and contained 3% DSS at the 
indicated time points. The control group solely got autoclaved water at all times.  
Animals treatment groups: n = 10 wt, 10 ko. Animals control groups: n = 4 wt, n = 4 ko; sex: male; age: 10–11 weeks. 
3.5.1.1 DECREASED SURVIVAL DURING ACUTE DSS TREATMENT 
Already at two to three days after DSS treatment mice started to show severe gastrointestinal 
symptoms such as massive diarrhea and bloody feces, which was accompanied by heavy weight loss 
starting at day five (Fig. 3-17). Due to the severity of disease, mice were monitored daily for weight 
loss and overall health state. In accordance with animal welfare guidelines mice were immediately 
taken out of the experiment and sacrificed if body weight loss exceeded 20% of the initially measured 
body weight. The survival rate is therefore an indicator of disease severity. All water-treated control 
animals (wt & ko) as well as all DSS-treated wild type mice survived the entire experiment (100% 
survival), while only 80% of Nlrc5 knockout mice survived until the end of the experiment at day 
seven (Fig. 3-16). 
 
Fig. 3-16: Survival during the course of acute DSS colitis 
The survival curves show the percentage of vivid animals during the course of the experiment. Mice that did not match the animal welfare 
guidelines in the course of the experiment were not further treated and prematurely sacrificed for analyses. None of the control animals had 
to be taken out early (survival 100%, wt and ko; not shown).  
Wt mice had a higher survival rate than Nlrc5 ko mice during the DSS-induced acute colitis. 
3.5.1.2 ELEVATED DISEASE ACTIVITY INDEX 
During colitis gastrointestinal passage is accelerated and water resorption is diminished within the 
colon to clean the gut from invaded pathogens or toxins (Lippert, 2003). Typical clinical signs are 
diarrhea, body weight loss and intestinal bleeding due to a severe inflammation. These clinical signs 
can also be observed in murine colitis models and they are used to evaluate disease severity 
(Fig. 3-17).  
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Fig. 3-17: DAI – A combined score of body weight, stool consistency and fecal occult blood 
To monitor disease progression mice were weighted (a) and stool samples were judged for consistency (b) and occult blood (c) daily. All 
three parameters were scored over time as indicated (d) and summarized to the disease activity index (DAI), which is generally used to 
evaluate colitis severity (e). Mean values of each experimental group are indicated by single dots with SEM. Two-way ANOVA and 
Bonferroni post-tests were performed. Stars indicate the level of significance between DSS-treated wt and ko groups at the indicated days. 
Please note that significances of DSS-treated groups compared to their control groups are not indicated in the figure for clarity, but 
mentioned in the text. **p < 0.01; ****p < 0.0001  
Nlrc5 ko mice showed a more severe weight loss, diarrhea and rectal bleeding during the course of the acute DSS colitis when compared to 
equally treated wt counterparts, hence ko animals had a higher DAI. 
DSS potently induced an acute colitis in all treated animals. A very strong indicator of disease 
progression and murine health status was the loss of body weight, which started slowly on the fifth day 
of DSS treatment, but proceeded rapidly in the course of the remaining two days until the 
experimental endpoint at day seven (Fig. 3-17 a). Starting from day six, DSS-treated wt and ko 
animals had a significantly reduced mean body weight when compared to their water-treated control 
groups.  
Stool consistency started to soften as early as two days after DSS treatment and differences became 
significant between the two treatment groups (H2O, DSS) at day six (Fig. 3-17 b). Nlrc5 ko mice 
showed significantly more severe diarrhea when compared to the wt, including very watery or bloody 
secretions during the last two days of the experiment.  
Intestinal bleeding was assessed by testing for occult blood, which was detectable in feces of DSS-
treated mice already on the second day of DSS treatment (Fig. 3-17 c). The severity of bleeding 
worsened during the course of the experiment, so that blood was also visible on feces or in the perianal 
region of some animals starting on day four. Towards the end of the acute colitis experiment Nlrc5 
knockout mice developed significantly elevated intestinal bleedings if compared to wild type mice. 
Body weight, stool consistency and rectal bleeding were scored (Fig. 3-17 d) and summarized in the 
Disease Activity Index (DAI; Fig. 3-17 e). The DAI was significantly elevated for DSS-treated ko 
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mice when compared to the water-treated ko control group already on the third day. Wt animals 
developed a significant colitis phenotype after four days of DSS treatment. Furthermore, the DAI 
showed significant differences among the DSS-treated groups. Nlrc5 ko mice reached a higher score 
than wt animals, indicating a more severe acute colitis phenotype. 
Overall clinical signs worsened most notably after DSS had been displaced by pure drinking water. 
Water-treated control groups showed only minor fluctuation of body weight (around 100%) as well as 
a stool consistency between hard to soft, but shaped, which was considered healthy. There was no 
occult blood detectable in any stool sample of the water-treated controls. 
3.5.1.3 COMPARABLE COLON SHORTENING  
Alterations in colon length are typical for certain colitis subtypes e.g. ulcerative colitis (muscular 
shortening) and Crohn´s disease (fibrous shortening) and it is also characteristic for DSS-induced 
experimental colitis models (Okayasu et al., 1990). Therefore, colon length was assessed and 
compared between the treatment groups to evaluate disease severity. Colon length was also compared 
between the genotypes to analyze for an Nlrc5-specific phenotype. 
After colon removal from the sacrificed mice, its length was measured before the large intestine was 
flushed with PBS for further analyses.  
 
Fig. 3-18: Colon shortening during acute colitis 
Mice were anesthetized by intraperitoneal ketamine/ xylazine injection and sacrificed by cardiac puncture. To evaluate colitis severity colons 
were removed and length was measured immediately (a). The length for each individual mouse is represented by a separate dot. The median 
is indicated by the bar and written out below. One-way ANOVA and Bonferroni post-tests were performed. ****p < 0.0001  
Nlrc5 and wt mice had comparable colon shortening during acute DSS-induced colitis. 
Water-treated control animals had an equal colon length independent of their genotype. Colons were 
partially filled with formed feces. The cecum appeared normal and was entirely filled with digestive 
remains. 
In contrast, a 40% reduced colon length was observed in both DSS-treated groups when compared to 
the water-treated animals (Fig. 3-18 a, b). Additionally, colons were bloated up and only few hardly 
formed feces were found in the large intestine. The cecum was strikingly reduced in size and barely 
filled with digestive remains (Fig. 3-18 a). Although Nlrc5 knockout mice showed a more severe 
disease phenotype with increased lethality and a higher disease activity index, both genotypes had 
comparable colon shortening, colon bloating, cecum size as well as amounts and shape of feces after 
DSS treatment. 
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3.5.1.4 ALTERED COLONIC INFLAMMATION AND EPITHELIAL DAMAGE 
The severity of colon inflammation was determined histologically by evaluating the extension of 
inflammatory cell influx into the colon and the degree of epithelial alterations and damages. Feces 
were flushed out of the colons with PBS before colons were rolled up, formalin-fixed and paraffin-
embedded for histological analyses. Slices of the rolled up colons were HE stained and the severity of 
inflammation as well as epithelial alterations were evaluated from the rectum up to the beginning of 
the transverse folds in the middle colon (Fig. 3-19). Scoring was performed according to the literature 
(Wirtz et al. 2007; Welz et al. 2011) with phenotype-specific adaptions (Fig. 3-19 d). 
DSS-treated mice showed severe alterations and damage in the colon epithelium (Fig. 3-19 c, d). 
Crypts were shortened or even absent in parts of the colon. Ulcerations with total crypt loss appeared 
mainly in the distal and middle colon parts, while proximal parts were not affected by the acute DSS 
treatment. 
Wt mice had a severe epithelial damage with an average total crypt loss of 29% within the analyzed 
colonic parts. Nlrc5 ko mice showed an even more severe damage with significantly elevated 
ulcerations. On average 82% of the entire colon length showed a total loss of crypts in Nlrc5 ko 
animals.  
Characteristic for the inflammation within the colon is also the influx of inflammatory cells, especially 
neutrophil granulocytes. In both wt and ko mice inflammatory cells were observed within in colon 
tissue after DSS treatment. The inflammation was scored taking into account the expansion of 
inflammatory cells within the colon. Nlrc5-deficient cells showed a confluence of inflammatory cells 
in the lamina propria with only few points of spreading of inflammatory cells into the submucosal 
layer. In contrast, colons of wt animals showed more severe colonic inflammation with an extensive 
expansion of inflammatory cells throughout the submucosa. In both genotypes edematous alterations 
appeared in the submucosal layer. 
Water-treated mice did not show any epithelial alterations (Fig. 3-19 a, b). Irregularities or 
abnormalities in the pictures for water-treated animals below are artifacts caused by sample 
processing, as there are no signs of inflammation visible in the colon. 
Epithelial damage in the colon was more severe in Nlrc5 ko mice, whereas in wt animals a more 
prominent invasion of immune cells was observed. Epithelial damage as well as immune cell influx 
were scored in a blinded fashion and scores were summarized into a combined histological colon score 
(Fig. 3-19 g). This score reflects the significantly increased severity of acute colitis in Nlrc5 ko mice if 
compared to wt animals. This difference is caused by high scores for crypt loss in ko animals, which 
are slightly balanced by the lower inflammatory score in the ko due to a diminished influx of 
inflammatory cells (Fig. 3-19 e, f). 
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Fig. 3-19: Infiltration of inflammatory cells and epithelial damage in the colon during acute colitis 
a–d Murine colons were flushed with PBS and rolled up for formalin fixation and paraffin embedding. Sections were stained with HE. The 
area of total crypt loss was measured in microscopic pictures (red line) and set into ratio (e) with the entire distal and middle colon length 
(yellow line). Magnifications are indicated.  
e The percentage of colon length with a total crypt loss was compared between wt and ko. Medians are given below.  
f+g The epithelial damage as well as the influx of inflammatory cells were scored as indicated in d. The inflammation score is displayed in f 
and the combined inflammation and epithelial damage score is given in g. 
Each individual mouse is represented by a separate dot. Bars indicate the median. In f the mean scores of all animals within a group are 
represented with SEM as bars for clarity. One-way ANOVA and Bonferroni post-hoc tests were performed. *p < 0.05; ****p < 0.0001  
During the acute colitis Nlrc5 ko mice had more severe epithelial damage, but a reduced influx of inflammatory cells into the colon if 
compared to wt mice. 
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3.5.1.5 INCREASED GOBLET CELL HYPOPLASIA IN THE COLON  
Mucins produced by goblet cells build a mucus layer within the intestine, which is of great importance 
for the protection of the underlying epithelium from luminal influences. Goblet cell hypoplasia is a 
typical histological feature in human ulcerative colitis and Crohn´s disease and it is also found in DSS-
induced rodent colitis models (Gersemann et al., 2009; Shinoda et al., 2010). 
Murine colons of DSS-treated and water-treated wt and ko mice were stained by Periodic Acid-Schiff 
reaction (PAS; 2.2.2) and the distribution of goblet cells was evaluated from the rectum up to the 
beginning of the transverse folds within the colon (Fig. 3-20).  
 
Fig. 3-20: Depletion of mucin-containing goblet cells in murine colon during acute colitis 
a–d Murine colons were flushed with PBS and rolled up for formalin fixation and paraffin embedding. Sections were stained by PAS 
reaction to visualize mucin filled goblet cells. The distal and middle colon area with goblet cell-positive crypts was measured and set into 
ratio with the entire length of that colon part (analog to Fig. 3-20). Magnifications are indicated. 
e The occurrence of goblet cells in the colon was evaluated (transverse folds were not incorporated) and the total distance with virtually no 
goblet cell occurrence was set into ratio to the total measured colon length. Each data point represents a measured mouse colon. The median 
is indicated by the bars and written out below. One-way ANOVA and Bonferroni post-hoc tests were performed. ***p < 0.001  
Nlrc5 ko mice had a significantly elevated loss of goblet cells in the middle and distal colon during acute colitis if compared to the wt.  
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Water-treated mice showed intact colon epithelium (Fig. 3-20 a, b; compare also Fig. 3-19) with 
longer crypts at the proximal and shorter crypts within the distal colon. The density of goblet cells was 
especially high in the transverse folds evident by a continuous deep purple PAS staining of mucins in 
that area; while in more distal parts goblet cells were rather interspersed in the crypts in between other 
epithelial cell types. DSS-treated mice showed a significant crypt shortening and crypt loss as well as 
a striking goblet cell loss. Goblet cell destruction mainly occurred in the distal colon, but was also 
observed in other parts including the transverse folds. No goblet cells were detectable in 28% of the 
total distal colon length of wt mice. Nlrc5 ko mice showed a significantly more severe goblet cell 
hypoplasia with 84% of the total distal colon completely lacking mucin producing cells. Crypts in the 
transverse folds were still interspersed with goblet cells in both genotypes, but with reduced density of 
mucus producing cells within the individual crypts when compared to the control groups. 
3.5.1.6 ELEVATED EXPRESSION OF DISTINCT CYTOKINES  
The DSS-induced breaks in the colonic epithelial barrier lead to a strong inflammatory reaction within 
the colon, initially characterized by the induction of pro-inflammatory cytokines. With increasing 
severity the inflammation becomes systemic and inflammatory mediators are detectable within blood 
serum. 
 
Induction of Cytokines in Colon Tissue 
DSS-treated mice developed colonic inflammation characterized by pro-inflammatory cytokine 
expression. RT-qPCR was performed with isolated colon RNA to analyze the induction of these 
cytokines during the acute colitis (Fig. 3-21).  
 
Fig. 3-21: Cytokine expression in murine colon during acute colitis 
A longitudinal piece of colon tissue (proximal to distal) was homogenized in RNA lyses buffer using the Tissue Lyser II (QIAGEN). RNA 
was isolated and transcribed into cDNA for TaqMan analysis. The relative expression of various cytokines compared to Gapdh is 
displayed a–h. Each data point represents the average of a technical duplicate. Bars indicate the median. Due to high variances the non-
parametric Mann-Whitney Test was performed for statistical analysis of the DSS-treated groups. Significances between water and 
DSS-treated groups are not indicated. *p < 0.05; **p < 0.01  
The induction of several cytokines in the colon tissue was significantly elevated in Nlrc5 ko mice if compared to the wt during acute colitis.  
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Nlrc5 ko mice showed a significantly stronger induction of pro-inflammatory cytokines like Il6, 
Cxcl1, Cxcl2 and Il12a compared to the wt (Fig. 3-21 b-f). Also mRNA levels of the anti-
inflammatory cytokine Il10 were upregulated in ko colons during acute colitis (Fig. 3-21 h). Upon 
DSS treatment only in Nlrc5-deficient cells Il1b was significantly induced in the colon. 
Furthermore, Tnfa was potently induced upon DSS treatment, but to a comparable degree in wt and ko 
animals (Fig. 3-21 a). There was only a minor induction of Ifng in both experimental groups during 
acute colitis. Ifng mRNA levels were also comparable (Fig. 3-12). 
 
Cytokine Levels in Murine Serum 
The production of cytokines was further evaluated in serum samples obtained by cardiac puncture at 
the end of the experiment. Several mediators could be measured within the same sample by bead-
based multiplex technique (see 2.6).  
In wt mice none of the analyzed cytokines (TNFα, IL-6, KC, MIP2a, IL-1β, IL-12, IFNγ, IL-10) was 
significantly elevated in the serum upon DSS treatment compared to their controls (Fig. 3-22 a h). In 
contrast, DSS-treated Nlrc5-deficient animals showed significantly upregulated serum concentrations 
of the pro-inflammatory mediators IL-6, KC and IL-1β as well as the anti-inflammatory IL-10 
(Fig. 3-22 b, c, e, h). 
 
Fig. 3-22: Serum cytokine levels during acute colitis 
At day seven of the acute DSS experiment mice were anesthetized by intraperitoneal ketamine/ xylazine injection and blood was taken by 
cardiac puncture. Blood was centrifuged using lithium heparin-gel blood collection tubes (Sarstedt) to obtain serum for further analyses. 
Cytokines were detected using multiplex assay (Bio-Rad). The measured serum concentrations of several mediators are displayed in a–h. 
Data points represent individual mice. Bars indicate the median. Due to high variances the non-parametric Mann-Whitney Test was 
performed for statistical analysis. Significances between water and DSS-treated groups are not indicated. *p < 0.05; **p < 0.01 
Several serum cytokines were significantly elevated in Nlrc5 ko mice if compared to the wt during acute colitis.  
Overall, no altered inflammatory mediator concentrations were observed in the serum of DSS-treated 
wt mice, while Nlrc5 ko animals developed a systemic upregulation of various cytokines. 
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3.5.1.7 ALTERED SPLEEN WEIGHT IN NLRC5 KO AND WT MICE 
Systemic inflammation is not only characterized by pro-inflammatory cytokine expression in the 
serum, but it can also lead to an increased spleen weight (Siegmund et al., 2001a).  
At the end of the experiment mice were sacrificed and spleens weighted. The control groups had a 
median spleen weight of 73 mg in wt and 75 mg in ko mice (Fig. 3-23 a). Upon DSS treatment wt 
mice showed a 25% increased spleen weight (median 91 mg), while ko spleen weights were not 
changed when compared to the control groups. Alterations in the spleen weight were independent of 
the body weight loss during colitis (Fig. 3-23 b). 
 
Fig. 3-23: Murine spleen weight during acute colitis. 
Spleens were removed and weighted. a The absolute spleen weight is depicted. Medians are written below. b The spleen weight in relation to 
the body weight is depicted. a+b Each data point represents an individual mouse. Medians are indicated by the bars. One-way ANOVA with 
Bonferroni post-tests was performed. **p < 0.01  
The absolute and relative spleen weight was significantly higher in wt compared to Nlrc5 ko mice during acute colitis, while under steady 
state conditions spleen weights were comparable between the genotypes.  
3.5.1.8 ELEVATED MYELOPEROXIDASE EXPRESSION  
The enzyme myeloperoxidase (MPO) is mainly expressed in neutrophil granulocytes and its induction 
or activity is directly associated with the presence of neutrophils in the examined tissue. To evaluate 
Mpo expression RNA was isolated from spleen tissue and analyzed using RT-qPCR. 
Mpo was induced in wt and ko spleens during the acute colitis. The expression of Mpo was 
significantly higher in Nlrc5-deficient spleens compared to the wt, indicating that there was a greater 
neutrophil influx in spleens of Nlrc5 ko mice. 
 
Fig. 3-24: Expression of myeloperoxidase during acute colitis 
The induction of myeloperoxidase (MPO) is significantly elevated in Nlrc5 ko, but not in wt mice during acute colitis. Murine spleens were 
homogenized in RNA lyses buffer using the Tissue Lyser II (QIAGEN). RNA was isolated and transcribed into cDNA for TaqMan analysis. 
The relative expression of Mpo compared to Gapdh is displayed. Each data point represents the average of a technical duplicate. Bars 
indicate the median. One-way ANOVA with Bonferroni post-tests was performed. **p < 0.01 
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3.5.1.9 REDUCED CD8 EXPRESSION IN MURINE SPLEEN  
The development of acute colitis is reported to be independent of the presence of T or Β lymphocytes 
(Dieleman et al., 1994), but adaptive responses develop as the inflammation proceeds (Hall et al., 
2011).  
Nlrc5 knockout mice were shown to have significantly diminished CD8+ cytotoxic T cells and slightly 
upregulated CD4+ T helper cell numbers in the spleen (Fig. 3-5). The development of both T cell 
subpopulations and its dependence on NLRC5 expression was analyzed in the experimental acute 
colitis. 
Cd8 as well as Cd4 were expressed in murine splenocytes (Fig. 3-25).  
Water-treated Nlrc5 ko mice showed a diminished, although not significant, Cd8 expression when 
compared to the wt as described before (Fig. 3-25 a, Fig. 3-5, Fig. 3-8). During acute colitis CD8 
levels were strikingly reduced in both genotypes. There were significantly lower CD8 RNA levels 
detectable in Nlrc5-deficient splenocytes compared to the wt.  
The expression of CD4 was also significantly reduced during the acute colitis when compared to the 
healthy controls. However, the expression of Cd4 in murine splenocytes was comparable between the 
genotypes under healthy conditions as well as during acute colitis and therefore not affected by the 
Nlrc5 ko (Fig. 3-25 b). 
 
Fig. 3-25: Expression of Cd8 and Cd4 in murine spleens during acute colitis 
Murine spleens were homogenized using the Tissue Lyser II (QIAGEN), RNA was isolated and TaqMan analysis was performed. Displayed 
is the relative expression of Cd8 as well as Cd4 compared to Gapdh. Each data point represents the average of a technical duplicate. Bars 
indicate the median. One-way ANOVAs with Bonferroni post-tests were performed. **p < 0.01; ****p < 0.0001  
Cd8 and Cd4 mRNA level are strikingly reduced upon DSS treatment. The expression of CD8 is significantly diminished in Nlrc5 ko mice 
compared to the wt (a), while CD4 level are comparable between both genotypes (b). 
Taken together, the mRNA expression of the CD4 and CD8 T cell co-receptors was significantly 
diminished in spleens of wt and Nlrc5 ko animals with acute DSS-induced colitis. While CD4 RNA 
levels were similar in both genotypes, CD8 was significantly lower in Nlrc5 ko mice during colitis if 
compared to the wt. 
3.5.2 INCREASED SEVERITY OF CHRONIC COLITIS IN NLRC5 KO MICE 
While innate immune cell populations like neutrophil granulocytes start expanding after only one day 
of DSS treatment, adaptive T and B lymphocyte populations begin to expand within the murine colon 
only at the transition to chronification (Hall et al., 2011). Chronic colitis was induced in mice to 
evaluate if NLRC5 affects disease severity by influencing adaptive immune mechanisms. 
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Fig. 3-26: Treatment of experimental animals to induce chronic DSS colitis 
Shown is the model of DSS treatment to induce chronic colitis. Mice were kept under SPF conditions. Drinking water was autoclaved and 
contained 1% DSS at the indicated days. The control groups solely got autoclaved water at all times. Animal treatment groups: n = 9 wt, 
10 ko; age: 10–11 weeks; sex: male; Animal control groups: n = 3 wt, n = 3 ko; age: 8–12 weeks; sex: male. 
Chronic intestinal inflammation was induced in mice by repeatedly applying 1% DSS dissolved in 
drinking water alternating with applying water only. One treatment cycle consisted of 5 days DSS 
followed by 5 days of water (Fig. 3-26). The experiment was planned to last four DSS cycles, but had 
to be aborted after the second cycle, due to disease severity in Nlrc5 ko mice.  
All chronic colitis read outs described below are based on the experimental setup described in 
Fig. 3-26. 
3.5.2.1 DECREASED SURVIVAL DURING CHRONIC DSS TREATMENT  
During DSS treatment mice were monitored every 1–2 days for body weight changes, diarrhea and 
their overall state of health. Mice were excluded from further treatments and sacrificed if their body 
weight loss exceeded 20% as animals in this state of disease were expected to die within the next 24 h 
due to disease progression accompanied by further weight loss. 
None of the water-treated control animals (wt, ko) had to be sacrificed early due to weight loss. Upon 
DSS treatment 90% of wild type mice survived until the end of the experiment (Fig. 3-27). Nlrc5 ko 
mice had a strikingly elevated mortality. Only 60% of DSS-treated ko mice survived until day 21 so 
that it was decided to end the experiment at that time point. Early deceased ko mice (n=4) were 
separately evaluated as koabort after preparation and sampling, as they had more severe disease 
progression compared to the remaining kod21 animals. 
 
Fig. 3-27: Survival during the course of chronic DSS colitis 
The Kaplan-Meier survival plot gives the percentage of living animals during the course of the experiment. Mice that did not match the 
animal welfare guidelines due to DSS treatment had to be taken out of the experiment and were sacrificed for analyses. None of the wt or ko 
control animals had to be taken out early (survival 100%; not shown).  
Wt mice had a higher survival rate during chronic DSS colitis when compared to Nlrc5-deficient mice. 
3.5.2.2 PROGRESSION OF BODY WEIGHT LOSS AND DIARRHEA DURING CHRONIC COLITIS 
Over the course of the repeated DSS treatment body weight changes and stool consistency were 
monitored every second day (Fig. 3-28). All DSS-treated mice developed a colitis phenotype. 
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Control animals continuously gained weight until the end of the experiment (day 19–20), which 
reflects their general health state and appropriate housing conditions in the animal facility. DSS-
treated mice gained weight during the initial DSS period, before a slight decline became detectable 
toward the end of the DSS treatment, which continued even after DSS deprivation (on average 1% on 
day 6). The body weight recovered completely in wt and ko mice until the middle of the following 
DSS cycle before it dropped again and reached its minimum during the second DSS break (~90% of 
the initial weight on day 18). This body weight loss was significant in wt and ko DSS-treated mice 
compared to their control groups. The weight started to recover again approximately one week after 
DSS deprivation (around day 19).  
Mean body weight changes were comparable between Nlrc5 ko and wt mice during the development 
of chronic colitis, but ko mice showed very high variances within the treatment group. Four out of ten 
ko animals had to be sacrificed until day 19 due to massive weight loss (> 20%), while the rest had 
only moderate weight loss (around 10%), which was comparable to wt animals.  
 
Fig. 3-28: Body weight changes and diarrhea score 
To monitor disease progression mice were weighted (a) and stool samples were judged (b) every 1–2 days. The graphs show the 
development of body weight as well as diarrhea over the course of time. For further experimental information see also Fig. 3-26. The Stool 
score is explained in Fig. 3-17. All individuals within one group are indicated by a single dot with SEM. Two-way ANOVA and Bonferroni 
post-tests were performed for statistical analyses. *p < 0.05 
Body weight loss during chronic colitis is comparable between DSS-treated Nlrc5-deficient and wt mice, but ko mice develop a more severe 
diarrhea, which is progressive even during DSS breaks.  
Drinking water supplemented with 1% DSS also led to altered stool consistency. Stool started to 
soften after four days of DSS treatment. In the wt stool consistency normalized again upon DSS 
deprivation and worsened during the subsequent DSS treatment to a mucous diarrhea. During the 
water period the severe diarrhea improved again back to unshaped soft feces. In contrast, ko animals 
showed progressive stool softening over the entire time course with no improvements during DSS 
breaks. A mucous diarrhea developed towards the second DSS cycle.  
Overall it was observed that body weight loss and stool consistency worsened most notably after the 
DSS treatment was already terminated and mice were given only drinking water. Nlrc5 ko mice 
suffered severe diarrhea even towards the end of these DSS breaks, while wt animals always recovered 
during that phase.  
During the cyclic DSS treatment mice, especially the ko, showed a high biological diversity with 
strong data variances independent of caging, so that it was decided to divide the Nlrc5 ko treatment 
group into the kod21 subgroup sacrificed at day 21 and the koabort group. 
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3.5.2.3 SEVERE COLON SHORTENING IN NLRC5 KO MICE 
After terminating the experiment colon shortening was determined to evaluate disease severity. 
Therefore, colons were removed from the mice and their length was measured (Fig. 3-29). 
Subsequently, colons were flushed with PBS to be further analyzed. 
Nlrc5 ko animals had slightly elevated median colon lengths in the control a well as in the treatment 
groups (wt vs. kod21). During chronic colitis a minor colon shortening of 6% was observed in DSS-
treated wt and 8% in kod21 mice compared to the control groups. In contrast, colons of early aborted ko 
animals (koabort) showed a median colon shortening of 32% upon DSS treatment if compared to the 
control. Colon shortening was significantly increased in the koabort than in the kod21 subgroup of Nlrc5-
deficient mice.  
Furthermore, colons were bloated upon DSS treatment. They were still filled with feces, but these 
were poorly formed and held more water compared to the control groups. In contrast to the acute DSS 
model, the cecum had normal size and was filled with digestive remains (not shown).  
 
Fig. 3-29: Colon shortening during chronic colitis 
Mice were anesthetized by an intraperitoneal ketamine/ xylazine injection and sacrificed by cardiac puncture. To evaluate colitis severity 
colons were taken out and length was measured. Due to altered disease severity Nlrc5 ko animals that had to be taken out early were 
evaluated separately and are termed koabort. The length of each individual colon is assigned by a separate dot. The median is indicated by the 
bar and written out below. One-way ANOVA and Bonferroni post-tests were performed. *p < 0.05; **p < 0.01  
Colons are significantly shortened in the severely affected Nlrc5 ko subgroup koabort. 
3.5.2.4 ELEVATED CRYPT LOSS IN AN NLRC5 KO SUBGROUP  
Colonic inflammation was determined histologically in the chronic colitis model. Murine colons were 
removed and flushed with PBS before they were rolled up, formalin-fixed and paraffin-embedded for 
histological analyses. After HE staining colons were scored for epithelial alterations and the influx of 
inflammatory cells. The middle colon (distal from the transverse folds) and the terminal colon 
(including the rectum) were histologically analyzed. 
Both control groups (wt and ko) did not show any epithelial alterations (Fig. 3-30 a, b). Crypts were 
intact and there were no signs of inflammation. Histological irregularities in the pictures of water-
treated animals were artifacts caused by sample processing, as there were no signs of inflammation 
visible in the colon of these control mice.  
DSS treatment groups (wt, ko) showed alterations in the architecture of the colon wall, e.g. 
submucosal edema was observed in almost all DSS-treated animals. Areas in which crypts were 
shortened or lost entirely were scattered throughout the colon, but were more abundant in distal 
regions. Also crypt abscesses were observed in approximately half of all DSS-treated mice. 
Furthermore, there were ulcerations and a strong influx of inflammatory cells into the mucosal and 
submucosal layer. It is noteworthy that there were strong interindividual differences in the degree of 
epithelial damage among wt as well as ko animals.  
Distances with complete crypt loss were measured within the colons as described in Fig. 3-19. Wt 
mice had an epithelial damage with a total loss of crypts on 7% of the analyzed colon epithelium 
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(Fig. 3-30 f). Nlrc5 kod21 animals showed a complete crypt loss on 13% of the measured colon length, 
while the koabort group showed a severe destruction of the colonic epithelium with a loss of crypts on 
50-100% of the colon epithelium. This reflects the severity of disease in this ko subgroup. 
DSS treatment led to a severe influx of inflammatory cells into the colon wall. This inflammation was 
comparable among DSS-treated wt and ko animals. Inflammatory cells were dispersed all throughout 
the mucosal layer and spread into the submucosa. In the majority of animals inflammatory cells even 
crossed the Muscularis externus, leading to a transmural inflammation.  
The epithelial damage and the influx of inflammatory cells into the colon were scored as indicated in 
Fig. 3-19 and scores were summarized (Fig. 3-30 f g). The inflammatory score was equal for wt and 
ko animals of both subgroups (median = 3.5) and is not separately shown in Fig. 3-30. DSS-treated wt 
and kod21 animals had a more severe colitis phenotype when compared to control animals. Colitis 
severity was further significantly elevated in the koabort subgroup compared to wt animals. 
 
Fig. 3-30: Infiltration of inflammatory cells and epithelial damage in the colon during chronic colitis 
a–e Murine colons were flushed with PBS and rolled up before formalin-fixation and paraffin-embedding. Sections were stained with HE. 
The total length of crypt loss was measured and set into ratio with the entire colon length from the rectum to the beginning of the transverse 
folds at the proximal colon (f) as described in Fig. 3-19. Magnifications are indicated. f The median distance of crypt loss is written below 
the diagram. g The influx of inflammatory cells into the colon tissue and the epithelial damage were scored as indicated in Fig. 3-19 h and 
summarized. f+g Each individual mouse is represented by a separate dot. Bars show the median. One-way ANOVA and Bonferroni post-
tests were performed. **p < 0.01; ****p < 0.0001  
During chronic colitis the Nlrc5 koabort subgroup had a significantly more severe epithelial damage in the colon compared to wt and kod21 
mice. However, the influx and distribution of inflammatory cells within the colon was not altered when compared to the wt. 
The widespread occurrence of lymphoid follicles in the colons of Nlrc5-deficient as well as wt animals 
upon repeated DSS treatment was noticeable. These lymphoid follicles reached from the Muscularis 
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externus through the submucosal layer. The occurrence of colonic lymph nodes during chronic colitis 
was increased in DSS-treated mice when compared to control groups, but it was also increased when 
compared to animals that suffered an acute DSS-induced colitis (Fig. 3-31). 
 
Fig. 3-31: Lymphatic tissue in murine colons upon repeated DSS treatment 
The occurrence of lymphoid follicles was increased in murine colons upon DSS treatment. Shown is the colon of an Nlrc5-deficient mouse. 
For technical procedure see Fig. 3-30. 
3.5.2.5 ELEVATED EXPRESSION OF DISTINCT CYTOKINES  
Induction of Cytokines in Colon Tissue 
The severity of the DSS-induced inflammation was further characterized by analyzing the local 
production of inflammatory cytokines. RNA was extracted from murine colons after repeated DSS 
treatments and RT-qPCR was performed to analyze cytokine induction in colon tissue during the 
experimental chronic colitis (see 2.8). 
 
Fig. 3-32: Cytokine expression in murine colon during chronic colitis 
A longitudinal piece of colon tissue (proximal to distal) was homogenized using the Tissue Lyser II (QIAGEN), RNA was isolated and 
TaqMan performed. a–g The relative expression of various cytokines in the colon compared to Gapdh is displayed. Each data point 
represents the average of a technical duplicate. Bars indicate the median. One-way ANOVA and Bonferroni post-tests were performed.  
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001  
Distinct cytokines were upregulated during chronic DSS colitis. RNA levels of the pro-inflammatory Il6 and Cxcl2/Mip2, but also the anti-
inflammatory Il10 were significantly elevated in the severely affected Nlrc5 koabort subgroup when compared to DSS-treated wt animals.  
The pro-inflammatory cytokines Tnfa, Il6, Cxcl2 and Il1b were induced upon DSS treatment in murine 
colons (Fig. 3-32 a–f). The level of induction was comparable between wt and kod21 mice, but the DSS 
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effect showed a strong interindividual variability. Also mRNA levels for the anti-inflammatory Il10 
were increased (Fig. 3-32 g). The Nlrc5 koabort animals showed significant upregulation of Il6, Cxcl2, 
Il1b and Il10 compared to the controls or the kod21 animals. The induction of Ifng, Il12a and Il10 was 
only weak. Ifng and Il12a mRNA levels did not show significant differences between water and DSS-
treated animals. 
 
Distinct cytokines were upregulated in colon tissue during chronic DSS colitis, but their induction was 
not as potent as observed during the DSS-induced acute inflammation (Fig. 3-21). 
 
Cytokine Levels in Murine Serum 
Systemic inflammation was further analyzed by determining cytokines levels in murine serum using 
multiplex assay (see 2.6), but no significant differences were found in the systemic induction of 
cytokines neither between the treatment groups nor between the genotypes during chronic colitis 
(Fig. 3-33). Il12a mRNA levels tended to be elevated in DSS-treated wt and kod21 animals when 
compared to their control groups. In contrast, Il12a was not upregulated in the koabort group after DSS 
treatment. 
 
Fig. 3-33: Serum cytokine levels during chronic colitis 
Mice were anesthetized by intraperitoneal ketamine/ xylazine injection and blood was taken by cardiac puncture. Blood was centrifuged 
using lithium heparin-gel blood collection tubes (Sarstedt) to obtain serum for further analyses. Cytokines were detected using multiplex 
assay (Bio-Rad). Measured serum concentrations are displayed in a–h. Data points represent individual mice. Bars indicate the median. Due 
to high variances the non-parametric Mann-Whitney Test was performed for statistical analysis.  
None of the analyzed pro- or anti-inflammatory cytokines showed a significantly altered serum concentration during chronic colitis. There 
were also no significant differences between wt and Nlrc5 ko mice. 
3.5.2.6 ALTERED SPLEEN WEIGHT IN NLRC5 KO AND WT MICE  
After the induction of the chronic DSS colitis, murine spleens were removed and weighted 
(Fig. 3-34 a). There were already slight differences between the genotypes comparing spleen weights 
of water-treated animals. Spleens of Nlrc5-deficient mice weighted approximately 35% more than 
their wt counterparts, although mice had comparable maturity.  
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Repeated DSS treatment resulted in 36% elevated spleen weight in wt animals, while no effect could 
be seen in the majority of kod21 mice. 
In the koabort subgroup a significant influence of DSS treatment was observed as spleen weight was 
reduced by 65% when compared to water-treated controls. Changes in spleen weight were independent 
of the DSS-induced body weight loss (Fig. 3-34 b). 
 
Fig. 3-34: Murine spleen weight during chronic colitis 
Spleens were removed and weighted. a The absolute spleen weight is depicted. Medians are written below. b Shown is the spleen weight in 
relation to the body weight. a+b Each data point represents an individual mouse. Medians are indicated by the bars. One-way ANOVA with 
Bonferroni post-tests was performed. *p < 0.05; **p < 0.01  
A significantly reduced absolute and relative spleen weight was measured in the Nlrc5 koabort subgroup during chronic DSS-induced colitis 
when compared to either DSS-treated wt or DSS-treated kod21 animals. 
3.5.2.7 ELEVATED MYELOPEROXIDASE EXPRESSION  
The expression of Myeloperoxidase in murine spleen tissue was analyzed by RT-qPCR after RNA 
processing (Fig. 3-35). Mpo mRNA was induced upon DSS treatment in wt as well as in ko animals. 
Both genotypes showed high variances in Mpo expression, but in contrast to the wt, ko animals with 
very low Mpo expression had one further common characteristic: they all had a very severe colitis 
phenotype with major weight loss (> 20%) and colon epithelial damage (> 50%) and had to be taken 
out of the experiment early. Hence, ko mice suffering from chronic colitis having low Mpo expression 
represented exactly the koabort group. 
 
Fig. 3-35: Expression of myeloperoxidase during chronic colitis 
Spleens were homogenized using the Tissue Lyser II (QIAGEN), RNA was isolated and TaqMan analysis performed. Displayed is the 
relative Mpo mRNA expression in comparison to Gapdh. Each data point represents the average of a technical duplicate. Bars indicate the 
median. One-way ANOVA with Bonferroni post-tests was performed. *p < 0.05  
Mpo mRNA was significantly induced during chronic colitis in wt mice, while in the severely affected Nlrc5 koabort only minor Mpo levels 
were detectable.  
3.5.2.8 EXPRESSION OF CD4 AND CD8 IN MURINE SPLEEN AND COLON TISSUE 
Adaptive immune responses arise in the late acute phase of colitis and persist during chronic colitis. 
They lead to an accumulation of lymphocytes within the colon (Hall et al., 2011).  
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Here, the expression of the T cell co-receptors Cd8 and Cd4 was analyzed in spleen and colon tissue 
from mice with DSS-induced chronic colitis using RT-qPCR (see 2.8). Both receptors were expressed 
in murine spleens and to a much lesser extend also in the colons (Fig. 3-36). 
In the control groups, Cd8 mRNA levels were slightly lower in spleens of Nlrc5-deficient mice when 
compared to the wt. During DSS-induced chronic colitis the Cd8 expression decreased significantly 
within the splenocytes and the differences between wt and ko persisted.  
The splenic Cd4 expression was slightly diminished in the spleens of control animals as well. During 
the DSS-induced inflammation Cd4 RNA levels in spleen tissue were potently reduced to similar 
levels in wt and Nlrc5 ko mice. 
The expression of Cd8 and Cd4 in the spleen was comparable to data obtained during acute colitis. 
 
Fig. 3-36: Expression of Cd8 and Cd4 in murine spleen and colon during chronic colitis 
Murine spleens and colon tissues were homogenized using the Tissue Lyser II (QIAGEN). RNA was isolated and TaqMan analysis was 
performed. Displayed is the relative expression of Cd8 (a, c) as well as Cd4 (b, d) compared to Gapdh. Each data point represents the 
average of a technical duplicate. Bars indicate the median. One-way ANOVAs with Bonferroni post-tests were performed. **p < 0.01  
The expression of Cd8 and Cd4 on murine splenocytes was reduced during chronic colitis. Cd8 level were diminished in Nlrc5 ko, while Cd4 
levels were comparable to the wt. 
The colon harbors only minor lymphocyte populations under healthy conditions, but during the 
proceeding inflammation lymphocytes invade the colon tissue.  
Under healthy conditions ko mice tended to have a slightly higher median Cd8 and Cd4 expression in 
the colon if compared to the wt.  
Upon DSS treatment Cd8 was upregulated in both genotypes, but a higher median expression was 
observed in ko mice. The expression of Cd4 was not altered in wt mice during the DSS-induced 
inflammation, while Cd4 was potently induced in half of the DSS-treated ko group.  
Overall there were very strong interindividual differences in mRNA expression, but the expression of 
Cd4 and Cd8 was not dependent on the abort day, therefore all ko animals were analyzed together 
without distinguishing between kod21 and koabort.  
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4 DISCUSSION  
Publications on the biological function of NLRC5 were strikingly inconsistent regarding e.g. protein 
expression, subcellular localization and protein function. Still, all of them implicated NLRC5 to 
participate in immune-relevant mechanisms. This functional discordance gave motivation to further 
study this NLR member and to clarify its functional relevance. We hypothesized that NLRC5 is 
involved in immunity. 
An Nlrc5 knockout mouse model was generated and the basal phenotype investigated. The Nlrc5 ko 
mouse was supposed to clarify if NLRC5 participates in the initiation or regulation of innate immune 
defense mechanisms, accordingly if NLRC5 plays a pro- or anti-inflammatory role.  
Further, I was interested to see if NLRC5 also participates in adaptive immune mechanisms. Although 
NLR-induced innate responses are known to be important for the subsequent initiation of adaptive 
effector mechanisms, only the NLR member CIITA had been shown to be directly involved in the 
generation of adaptive responses by then. With the identification of the co-transcriptional activity 
NLRC5 exerts on MHC class I encoding HLA genes (Meissner et al., 2010), a particular function of 
NLRC5 in the development of adaptive cytotoxic T cell responses can be suggested.  
 
NLRC5 was neither essential for normal development, survival nor reproduction as Nlrc5 ko mice 
were inconspicuous under SPF conditions. The ko was not lethal. Mice were born at normal mendelian 
ratio and they had an average life expectancy. Moreover, ko mice displayed a median body weight as 
well as normal macroscopic and microscopic organ structure (data shown for secondary immune 
organs, Fig. 3-4). 
4.1 NLRC5 EXPRESSION – IMPLICATIONS FOR POTENTIAL FUNCTIONS  
Several observations underlined an immune relevance of NLRC5. The protein was found to be 
ubiquitously expressed in humans and mice with predominant expression in immune tissues in both 
species. Levels were especially high in secondary and primary lymphoid organs as well as in organs 
bearing mucosal linings (Fig. 3-1). This is in agreement with Neerincx and Staehli (Neerincx et al., 
2010; Staehli et al., 2012). Others rather suggested the highest NLRC5 expression in primary 
lymphoid organs (Benko et al., 2010; Cui et al., 2010; Davis et al., 2010). The expression of NLRC5 
in immune organs is therefore indisputable and seems to rely on leukocytes, which are the 
predominant cell type in these tissues. Mucosa-lined organs as the lung with its bronchus-associated 
lymphoid tissue (BALT) and diverse sections of the bowel with the gut-associated lymphoid 
tissue (GALT) had the highest NLRC5 expression among non-immune organs (Fig. 3-1). This is also 
supported by others (Davis et al., 2010; Kuenzel et al., 2010).  
From this expression pattern several hypothetical functions can be presumed for NLRC5. Firstly, it 
can be hypothesized that NLRC5 is involved in the differentiation of naïve lymphocytes from 
hematopoietic precursors in the thymus or bone marrow. Secondly, the protein could be of structural 
relevance in immune tissues. And thirdly, NLRC5 might participate in the proliferation and 
differentiation of naïve lymphocytes to generate adaptive effector cells in secondary lymphoid tissues.  
 
Lymphocytes differentiate and proliferate in primary lymphoid organs, while they encounter antigens, 
clonally expand and mature to effector cells in the secondary lymphoid organs. NLRC5 does not seem 
to play an indispensable role for the generation of T and Β lymphocytes as B cell and T cell areas were 
histologically distinguishable in lymphoid tissues in Nlrc5-deficient mice (Fig. 3-4, Fig. 3-31). 
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Moreover, normal CD3+ T cell and CD19+ B cell populations were encountered in the spleen 
(Fig. 3-5).  
The group around D. Philpott reported a low NLRC5 expression in CD4+ CD8+ and 
CD4- CD8- thymocytes, which are generated from hematopoietic precursors in the thymus and 
represent the direct precursors of naïve CD4+ or CD8+ T lymphocytes. Hence, they presumed a 
potential role for NLRC5 during T cell development (Benko et al., 2010). However, these CD4+ CD8+ 
and CD4- CD8- thymocyte populations were observed to be normally sized in Nlrc5 ko mice, which 
does not support a specific role of the NLR member in lymphocyte generation (Yao et al., 2012).  
Beyond, the ubiquitous expression of NLRC5 in immune tissues makes it rather unlikely that the 
protein is functionally restricted to lymphocyte development in primary lymphoid tissues. 
 
Histological studies revealed that NLRC5 had no structural function in secondary lymphoid organs as 
Nlrc5 ko mice showed a normal spleen and lymph node architecture (Fig. 3-4). NLRC5 was 
dispensable for the proliferation of T and B lymphocytes in these organs as T and B cell areas existed 
in spleen, lymph nodes and lymph follicles in Nlrc5 ko mice (Fig. 3-4, Fig. 3-31). These areas showed 
a tissue-typical distribution and architecture. Secondary nodules, which represent ongoing B cell 
proliferation, were observed in lymph nodes. In addition, the general occurrence of CD3+ 
T lymphocytes and CD19+ B lymphocytes in murine spleens was not altered in the absence of NLRC5 
(Fig. 3-5). NLRC5 did not have an obvious effect on the development of lymphoid tissue as the 
formation and enlargement of lymph follicles in the colon of Nlrc5 ko mice was not altered to the wt 
during an inflammation induced immune response as the chronic colitis (Fig. 3-31).  
Additionally, Nlrc5-deficient mice displayed a normal spleen weight under baseline conditions, 
indicating a normal organ function (Fig. 3-3). Splenic dysfunctions like inadequate lymphocyte 
proliferation are usually reflected by changes of the organ weight or the overall architecture. 
 
Β and T lymphocytes occur throughout the body, but highest lymphocyte concentrations are found in 
secondary and primary lymphoid organs as well as in mucosa-associated lymphoid tissues. This 
correlates with the observed Nlrc5 mRNA expression pattern found in human as well as murine tissues 
(Fig. 3-1). Accordingly, it was assumed that NLRC5 is primarily expressed by immune cells, 
especially lymphocytes.  
Experiments on immortal cell lines did not support this hypothesis as NLRC5 was only moderately 
expressed under baseline conditions and levels were comparable between immune and non-immune 
cell lines (Fig. 3-2). Additionally, others found an equal NLRC5 mRNA expression in Jurkat, THP-1 
and HeLa cell lines (Neerincx et al., 2010), hence immune and non-immune cells. Some even 
observed severely diminished NLRC5 mRNA levels in Jurkat T lymphocytes and various tested B cell 
lines (Benko et al., 2010). 
 
IFNɣ treatment led to the induction of NLRC5 in all tested cell lines. The most potent increase was 
detected in immortalized T and Β lymphocytes (Fig. 3-2).  
IFNɣ is potently induced during infections with intracellular microorganisms as bacteria or viruses. It 
subsequently induces ISGs that convey immune relevant functions to defeat the encountered 
pathogens (Malmgaard, 2004; Müller et al., 1994).  
An induction of NLRC5 in diverse cell types by IFNɣ could indicate that NLRC5 is involved in those 
immune defense mechanisms. IFNɣ signals via the JAK/STAT pathway and activates STAT1 for 
nuclear import and transcriptional activity (Schroder et al., 2004). NLRC5 might itself be an ISG as 
two STAT1 binding sites were described within its promoter region (Kuenzel et al., 2010).  
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NLRC5 seems to exert its function in various cell types, but the rapid and potent induction in 
lymphoid tissue-derived cell lines by IFNɣ might further indicate a function that is particularly 
characteristic for lymphocytes. 
TNFα treatment did not affect NLRC5 protein levels (Fig. 3-2). TNFα signals via the NF-κB or the 
MAPK pathway and subsequently leads to the expression of distinct target genes. Here no evidence 
was found that NLRC5 is regulated by these particular signaling pathways. 
 
While NLRC5 was only moderately expressed in various immortalized cells and not particularly 
elevated in immune-derived lineages under baseline conditions (Fig. 3-2), some groups observed 
significantly altered levels among primary immune cells isolated from lymphoid organs. NLRC5 
mRNA was highly expressed in T helper cells, B cells, CTLs, natural killer (NK) and natural killer 
T (NKT) cells as well as MΦs and DCs (Benko et al., 2010; Neerincx et al., 2010; Staehli et al., 2012). 
These data support our findings that NLRC5 is mainly expressed in immune and immune-associated 
tissues, which are mainly comprised of these immune cells (Fig. 3-1). The data further reflect the 
elevated NLRC5 protein levels we detected in immune cell lines when compared to non-immune cells 
upon IFNɣ treatment, while levels were comparable under baseline conditions (Fig. 3-2). 
The group around Staehli further analyzed the expression of NLRC5 in various different human and 
murine T and B cell lines in comparison to the expression pattern in primary total spleen, isolated B or 
T lymphocytes (Staehli et al., 2012). Interestingly, all of the murine and most of the human immortal 
lymphoid lineages showed a decreased NLRC5 protein level when compared to primary lymphoid 
cells. Accordingly, this suggests a probable function for NLRC5 in the defense against mutated cells. 
The potent down regulation of NLRC5 in lymphoid tumors was a common pattern even between 
species and can indicate that a down regulation enables cancerous cells to escape immune surveillance. 
4.2 THE EXPRESSION OF MHC MOLECULES IS ALTERED ON NLRC5 DEFICIENT 
CELLS 
4.2.1 NLRC5-DEPENDENT MHC CLASS I EXPRESSION ON IMMUNE CELLS 
The surface expression of MHC class I receptors was significantly diminished in Nlrc5-deficient mice 
(Fig. 3-6, Fig. 3-7, Fig. 3-8, Fig. 3-10). This reduction was more pronounced on lymphocytes when 
compared to Mϕs and it correlated with the NLRC5 expression pattern (Fig. 3-2). The impaired 
MHC class I expression was not limited to one specific MHC I isotype (Fig. 3-7). 
NLRC5 could have an impact on the surface expression of MHC class I by different means. Firstly, 
NLRC5 might influence MHC class I peptide loading. Secondly, it could be involved in transport of 
assembled MHC I complexes to the plasma membrane. Thirdly, it might regulate the initial expression 
of genes coding for MHC class I, β2M or other involved components. 
 
Empty MHC complexes are retained in the ER and finally degraded. Defects in proteins that are 
involved in MHC I loading have been associated with a reduced MHC I surface expression. For 
instance, Tapasin-deficient mice show decreased MHC class I levels in combination with a reduced 
cytotoxic T cell response (Garbi et al., 2000). The impaired MHC I expression in Nlrc5 ko mice could 
be due to a similar mechanism if NLRC5 is involved in MHC I loading.  
Defects in MHC class I loading should not affect MHC class II expression as peptide loading onto the 
MHC II complex requires a different machinery (1.3.5). In this study the surface MHC II expression 
on Nlrc5-deficient BMDMs was not altered, but the overall MHC II+ cell population was elevated 
(Fig. 3-9). 
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After peptide loading, MHC I complexes need to be transported from the ER via the trans-Golgi 
network to the plasma membrane. A decreased MHC I surface expression in Nlrc5-deficient mice 
could also be due to a defect in intracellular transport pathways from the ER via the trans-Golgi 
network to the plasma membrane, which NLRC5 might be involved.  
A recently published study found NLRC5 to be localized to the Golgi apparatus when infected with 
Human rhinovirus (Triantafilou et al., 2013). Viral infections also lead to an upregulation of MHC I 
molecules on the cell surface (Herzer et al., 2003; Yossef et al., 2012). A functional implication of 
NLRC5 in a rapid membrane transport of newly loaded MHC I complexes can therefore be supposed. 
This would explain the impaired MHC class I surface expression observed in Nlrc5 ko mice. 
However, this hypothesis is only supported by a MHC class I-specific and not by a general NLRC5-
supported membrane transport as the expression of other surface markers (e.g. CD3, CD11b, Gr-1; 
Fig. 3-5) was not influenced by the Nlrc5 ko. 
 
MHC class I is ubiquitously expressed on nucleated cells and thrombocytes, but the expression levels 
vary between tissues and cell types. MHC I is especially elevated in immune-associated tissues as well 
as tissues with mucosal linings, while e.g. in the brain no protein is detectable (Human Protein Atlas, 
2015). Therefore, the MHC I expression pattern reassembles that of NLRC5, which indicates that both 
might be linked (Fig. 3-1).  
It was postulated that NLRC5 is a transcriptional regulator of MHC class I-coding HLA genes 
(Meissner et al., 2010). This has now been confirmed and mechanism of the nuclear import as well as 
gene transactivation have been studied in greater detail (Biswas et al., 2012; Meissner et al., 2012a, 
2012b; Neerincx et al., 2012; Robbins et al., 2012). 
4.2.2 NLRC5-INDEPENDENT MHC CLASS I EXPRESSION ON IMMUNE CELLS 
The surface expression of MHC Class I was significantly decreased in Nlrc5 ko mice. However, 
MHC class I was not equally reduced on Nlrc5-deficient immune cells. There existed two distinct 
MHC I expressing cell populations among Nlrc5-deficient splenocytes, while all wt cells expressed 
equal amounts of the surface receptor (Fig. 3-7 c, Fig. 3-8 a-c). Observing the co-expression of either 
CD8 or MHC class II on Nlrc5-deficient MHC class I+ lymphocytes revealed that e.g. CD8+ CTLs 
carried less MHC class I on their surface than MHC II expressing B lymphocytes (Fig. 3-8).  
As already mentioned, NLRC5 has been identified as a co-transactivator of genes coding for HLA-A-G 
and genes involved in MHC class I peptide presentation. This explains the severely diminished 
MHC class I expression in Nlrc5 ko mice, but neither the remaining basal MHC class I expression 
(Fig. 3-6, Fig. 3-7, Fig. 3-8), an altered expression among lymphocytes nor the residual ability to 
induce the expression of NLRC5 upon stimulation (Fig. 3-10).  
 
The data presented here indicate that at least one additional NLRC5-independent mechanism exists 
that regulates the transcription of MHC class I genes. This mechanism accounts for the persisting 
expression of MHC class I molecules in Nlrc5-deficient immune cells under baseline conditions.  
MHC I-inducing mechanisms seem to account differently for the MHC class I expression in distinct 
cell types. The expression of MHC class I in CTLs is particularly dependent on the regulation by 
NLRC5, which in turn leads to a potent MHC I decrease within this cell population in the absence of 
NLRC5. However, in MHC II+ cells an NLRC5-independent mechanism contributes more effectively 
to the transcription of MHC I-coding genes, which leads to an attenuated MHC I decline on Nlrc5-
deficient APCs, e.g. B lymphocytes (Fig. 3-8).  
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These findings are supported by others that also found an unequal reduction of MHC class I on the 
surface of different immune cell populations in Nlrc5 ko mice. They all observed the most prominent 
decline on CD4+, followed by CD8+ T lymphocytes. An intermediate reduction was seen on 
B lymphocytes and only a mild MHC I decrease found on Mϕs (Robbins et al., 2012; Staehli et al., 
2012; Tong et al., 2012). Some even observed no reduction of MHC class I on Nlrc5-deficient 
BMDMs as well as BMDCs (Biswas et al., 2012). These cell type-specific differences regarding the 
decline of MHC class I in Nlrc5 ko mice correlate with the NLRC5 expression pattern in wt mice. 
NLRC5 has the highest expression in T lymphocytes, followed by B lymphocytes, while 
hematopoietic cells of the myeloid lineage e.g. DCs and Mϕs only show a moderate expression (Benko 
et al., 2010; Neerincx et al., 2010; Staehli et al., 2012). 
 
Although the MHC class I surface expression was impaired in Nlrc5 ko mice, MHC class I could still 
be induced upon stimulation with PHA (Fig. 3-10). Even others reported that an Nlrc5 ko did not 
abolish the potential to induce MHC class I by stimulating cells with either IFNγ (Biswas et al., 2012; 
Robbins et al., 2012; Staehli et al., 2012) or LPS (Yao et al., 2012). These data support the idea of 
mechanisms that regulate the expression of MHC class I coding HLA genes in addition to NLRC5. 
 
CIITA is primarily known as transcriptional co-activator for MHC class II genes, but it was shown in 
vitro that it can also enhance the expression of MHC class I-coding genes (Gobin et al., 1998a; Martin 
et al., 1997). Under baseline conditions CIITA is solely expressed in Mϕs, DCs as well as 
B lymphocytes, which are referred to as professional APCs. They constitutively carry peptide-loaded 
MHC class II complexes on their surface (Singer and Devaiah, 2013; 1.3.5.1).  
An expression of CIITA and the subsequent CIITA-induced transcription of MHC class I-coding 
genes could account for a higher MHC I surface expression in Nlrc5 ko lymphocytes that co-express 
MHC class II in contrast to CD8+ co-expressing CTLs (Fig. 3-8). An alternating CIITA expression can 
therefore lead to the inhomogeneous MHC class I expression on distinct cell types in Nlrc5-deficient 
mice. 
Ex vivo differentiated Nlrc5-deficient BMDMs also showed a diminished MHC class I expression with 
two distinguishable populations. These are probably due to different developmental stages of the 
primary culture (Fig. 3-6). 
 
The remaining inducibility of MHC I on Nlrc5-deficient lymphocytes might be explained to an 
induction of CIITA by IFNγ. The stimulation of murine primary cultures with PHA led to the 
induction of IFNγ (Fig. 3-12). IFNγ potently induces CIITA in most other cell types besides APCs 
(Muhlethaler-Mottet et al., 1997; Steimle et al., 1994). CIITA can subsequently induce MHC class II 
in these cells. Simultaneously the expression of MHC class I-encoding genes is enhanced.  
The induction of CIITA could explain the remaining inducibility of MHC class I molecules in Nlrc5-
deficient cells upon stimulation as well as the expression of MHC class I-coding genes after a 
stimulation with either IFNγ or LPS as described above. 
CIITA is crucial for the basal expression of MHC class II molecules and their induction upon 
stimulation. In contrast, I could show here that NLRC5 is neither essential for a basal MHC I 
expression nor for the induction of MHC class I. Both can be conveyed by an additional mechanism, 
probably CIITA, instead. However, the expression of MHC class I molecules is significantly impaired 
in the absence of NLRC5 as this mechanism cannot rescue the impaired MHC I levels to a 
physiological level. 
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Although CIITA is likely to account for the cell-specific decline in MHC class I surface expression as 
well as the persisting inducibility of MHC I in Nlrc5-deficient immune cells, it cannot explain the 
remaining MHC I expression on CD8+ cytotoxic lymphocytes that was observed under baseline 
conditions (Fig. 3-8).  
CTLs do not constitutively express CIITA (Glimcher and Kara, 1992) and primary cultures were not 
stimulated to induce this NLR member. Accordingly, there has to exist yet another transcriptional 
regulator for the induction of MHC class I-encoding HLA genes. These genes contain an ISRE within 
their promoter region (Girdlestone, 1996). Therefore, they are ISGs, which are presumed to be directly 
induced by IFNs.  
MHC class I and NLRC5 are supposed to be induced by IFNɣ-mediated JAK/STAT signaling. 
NLRC5 can subsequently lead to the transcriptional co-activation of MHC I-encoding genes. 
Accordingly, the expression of MHC class I might be upregulated directly by IFNɣ signaling via the 
binding of STAT dimers to the ISRE and indirectly via an IFNɣ-mediated induction of NLRC5.  
The direct transcriptional regulation of MHC class I-encoding-genes by IFNɣ could explain the 
residual basal MHC I level in Nlrc5-deficient cells and also an induction of MHC I upon stimulation 
(Fig. 3-10). 
NLRC5 is potently induced already early after IFNγ treatment (Fig. 3-1). In future studies, both the 
temporal upregulation of MHC class I and NLRC5 upon IFNɣ stimulation could be monitored and 
compared to evaluate if there is a temporally shifted, but mutual induction of MHC class I by IFNɣ 
and NLRC5 and to what extent both mechanisms contribute to the overall MHC class I expression. 
Eventually, an Nlrc5/Ciita double ko mouse model might reveal if IFNγ has an impact on MHC 
expression, if additional MHC class I regulators might exist or if the expression of MHC molecules is 
entirely regulated by the two NLR members NLRC5 and CIITA. 
4.2.3 NLRC5 DEFICIENCY AFFECTS THE EXPRESSION OF MHC CLASS II 
The number of MHC class II+ leukocytes was elevated in the spleens of Nlrc5-deficient mice by about 
9% (Fig. 3-9). Within the leukocyte population monocytes, B lymphocytes and dendritic cells 
constitutively express MHC class II receptors. The population of B cells and macrophages/monocytes 
were normally developed in Nlrc5-deficient mice and cannot explain an enhanced MHC II+ population 
(Fig. 3-5). However, genes encoding MHC II proteins can also be induced by IFNɣ in other cell types, 
e.g. lymphocytes, granulocytes, endothelial and epithelial cells.  
 
The amount of MHC class II expressed on the surface of an individual cell was not altered between the 
genotypes (Fig. 3-9). This indicates that NLRC5 is not directly involved in the surface expression of 
MHC class II molecules. In contrast, CIITA is known to regulate the induction of both types of MHC 
molecules (Singer and Devaiah, 2013). 
Other groups also found evidence in vitro that NLRC5 does not regulate the induction of 
MHC class II-encoding genes (Meissner et al., 2010, 2012a, 2012b; Neerincx et al., 2012). Moreover, 
studies using Nlrc5-deficient mice revealed a normal MHC II expression within immune tissues as 
well as on immune cells (Biswas et al., 2012; Yao et al., 2012). It has been published that the N-
terminal NLRC5 domain conveys transcriptional activity for both, MHC class I and II-coding HLA 
genes when linked to a CIITA backbone. However, the physiological NLRC5 backbone is missing the 
MHC II transactivating ability (Neerincx et al., 2014).  
Taken together, the MHC II expression is not directly regulated by NLRC5. 
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An increased MHC class II+ cell population in the absence of NLRC5 can also be due to an altered 
regulation of CIITA. The impaired MHC class I expression in Nlrc5-deficient mice cannot be counter 
steered via the induction of NLRC5. To assure basal MHC class I expression and antigen presentation, 
CIITA might be induced in Nlrc5-deficient animals. CIITA could subsequently mediate the 
transcription of MHC class I-encoding genes. Simultaneously, MHC class II-encoding HLA genes are 
induced. CIITA can be expressed in various cell types. Hence, NLRC5 is not involved in the 
constitutive expression of MHC class II molecules on professional APCs. However, an impaired 
MHC class I expression might induce CIITA, which next to MHC I also leads to the expression of 
MHC II molecules in non-APCs and thereby augments the MHC class II+ cell population upon Nlrc5 
deficiency. 
This hypothesis must be further evaluated in future experiments. Data of Biswas et al. revealed a 
slightly elevated Ciita expression in Nlrc5-deficient splenocytes, however no upregulation of MHC II 
was observed (Biswas et al., 2012).  
4.3 NLRC5 DEFICIENCY LEADS TO A DIMINISHED CD8+ T CELL POPULATION 
During the analysis of splenic cell populations it was observed that the number of 
CD8+ T lymphocytes was significantly reduced in Nlrc5 ko mice, while there were no changes in any 
other analyzed immune cell population (Fig. 3-5, Fig. 3-8 g, Fig. 3-25, Fig. 3-36).  
CD8+ cells are predominantly cytotoxic T lymphocytes (CTLs). These are indispensable in adaptive 
responses towards intracellular pathogens as CTLs possess a tightly regulated mechanism to identify 
and eliminate infected cells via MHC class I-presented foreign antigens. In addition to adaptive 
immune responses the expression of MHC class I is further crucial for the development of single 
positive CD8+ thymocytes and their positive selection during T cell development in the thymus. CTL-
determined thymocytes only survive if they encounter and recognize a self peptide presented on a self 
MHC class I receptor (Janeway, 2005). An impaired MHC I expression can lead to an impaired CTL 
generation. Accordingly, the reduced splenic CD8+ T cell population in Nlrc5 ko mice might be due to 
the impaired MHC class I expression (Fig. 3-5).  
It can be speculated that differences in CTL numbers are even more pronounced during 
CD8+-mediated immune responses, because the proliferation of CTLs is initiated by 
MHC class I-presented antigens. CTL proliferation is expected to be impaired in the absence of 
NLRC5 due to a diminished MHC class I expression.  
Taken together, an NLRC5 deficiency significantly impairs the surface expression of MHC I, which 
can consecutively influence the generation of CD8+ T cells in the thymus and their expansion in 
secondary lymphoid organs. Interestingly, Biswas et al. observed a diminished proliferation of Nlrc5-
deficient CTLs even if the antigen was properly presented to CTLs by B lymphocytes (Biswas et al., 
2012). 
 
The effects of an Nlrc5 ko on MHC class I expression as well as the indirect influence on the CTL 
population assign the protein a function in adaptive cytotoxic T cell immunity. Therefore, it is 
assumed that Nlrc5 ko mice show an impaired adaptive response against intracellular pathogens. Due 
to diminished CD8+ T cell numbers intracellular microbes might be able to proliferate and spread more 
potently to neighboring cells, which subsequently leads an increased disease progression. These 
considerations were further supported by Yao et al., who systemically infected Nlrc5-deficient mice 
with L. monocytogenes and observed severely decreased CD8+ T cell numbers as well as increased 
bacterial loads in various organs (Yao et al., 2012). This underlines a defective cytotoxic capability in 
the absence of NLRC5. In contrast, Tong et al. rather observed reduced virus titers and a pronounced 
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survival of Nlrc5 ko mice during an infection with systemic Vesicular stomatitis virus (VSV) (Tong et 
al., 2012).  
4.4 NLRC5 DEFICIENCY DOES NOT AFFECT CD4+ T CELL NUMBERS 
While the decreased MHC class I expression led to a reduced CD8+ T population in Nlrc5 ko mice, 
elevated MHC II+ leukocyte numbers did not significantly alter the CD4+ T cell population (Fig. 3-5). 
Differentiation, proliferation and activation of CD4+ lymphocytes depends on the recognition of 
MHC class II-bound antigens presented on APCs. Basal MHC II expression was not altered in Nlrc5 
ko mice; therefore the differentiation and proliferation of CD4+ T cells might not be affected. 
However, an increased expression of MHC class II molecules on non-APCs can enhance the 
presentation of antigens to effector CD4+ T cells and thereby favor their activation. An enhanced 
activation of CD4+ effector cells is reflected in increased effector functions e.g. an elevated cytokine 
production.  
4.5 NLRC5 HAS A COMPLEX INFLUENCE ON CYTOKINE RESPONSES IN PRIMARY 
IMMUNE CELLS  
A function for NLRC5 on inflammatory signaling pathways has repeatedly been reported. Within this 
project the question was addressed if the protein influences the innate signaling cascade and thereby 
the induction of inflammatory cytokines. Several interesting observations affecting distinct pathways 
were made. 
 
1. Nlrc5-deficient BMDMs showed a reduced Ifnb mRNA expression upon stimulation with viral 
RNA analogues when compared to the wt (Fig. 3-11). In contrast, LPS stimulation led to a comparable 
Ifnb induction in both genotypes. Accordingly, NLRC5 seems to be required for a proper IFNβ 
expression induced by either viral ss or dsRNA.  
Throughout the literature an effect of NLRC5 on the induction of type I IFNs has been under debate, 
but a particular role has not been identified. Findings by T. Kufer and J. Ting et al. support our data as 
they report a decreased IFNβ induction upon poly(I:C) treatment or SeV infection in cells in which 
Nlrc5 was knocked down or knocked out (Neerincx et al., 2010; Robbins et al., 2012). Others 
observed no NLRC5-specific influence on the expression of IFNβ (Kumar et al., 2011; Staehli et al., 
2012; Yao et al., 2012) or even an increased IFNβ expression in Nlrc5 ko mice infected with SeV or 
VSV (Robbins et al., 2012; Tong et al., 2012). 
On the molecular level, NLRC5 might be involved in PRR downstream signaling pathways that lead 
to the transcription of Ifnb. LPS only induced a minor expression of IFNβ that did not differ between 
wt and ko. LPS is recognized by TLR4 and internalized TLR4 receptors can induce Ifnb via the 
MyD88-independent TRIF pathway as in TLR3 signaling (Tanimura et al., 2008). Hence, an NLRC5-
specific effect on the TRIF pathway is not likely.  
It can rather be speculated that NLRC5 has a positive effect on the IPS-1-dependent IFNβ induction 
via MDA5, RIG-I or NOD2. This is supported by the observation that NLRC5 interacts with TBK1. 
NLRC5 might regulate TBK1 activity and hence IRF3 phosphorylation (Kumar et al., 2011).  
In contrast, it was reported that NLRC5 overexpression inhibited the RIG-1 induced IRF3 
phosphorylation as well as ISRE activation by MDA5 and RIG-I (Benko et al., 2010; Cui et al., 2010). 
and that NLRC5 interacts directly with RIG-I and MDA5 to negatively regulate type I IFN signaling 
(Cui et al., 2010). This inhibitory effect of NLRC5 on the induction of IFNβ is neither supported by 
our in vivo data nor by those of other groups (Kumar et al., 2011; Robbins et al., 2012).  
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It can also not be ruled out that NLRC5 might be directly involved in the recognition of viral ss or 
dsRNA ligands to induce type I interferons and hence possess receptor functions as initially assumed 
for all NLR members. 
 
Type I IFNs are important for antiviral protection as they induce a set of ISGs that interfere with viral 
replication. IFNs act in an autocrine as well as in a paracrine manner. Hence, they induce an antiviral 
state in the infected cell as well as in yet unaffected neighboring cells. An alleviated expression of 
IFNβ in Nlrc5 ko mice might consequently lead to an impaired innate antiviral defense and to more 
widespread and aggravated viral infections. An impaired type I expression can subsequently lead to a 
diminished induction of the type II IFNɣ.  
 
2. We found that Nlrc5-deficient leukocytes expressed and secreted significantly diminished amounts 
of IFNɣ upon cell activation, although wt and Nlrc5-deficient cells were activated to a comparable 
extend as evaluated by the expression of the activation marker CD25 (Fig. 3-12 a-c).  
Our data were supported by other groups that observed an impaired production of IFNɣ in Nlrc5 ko 
mice after an infection with L. monocytogenes (Yao et al., 2012). Interestingly, there were no 
alterations in the expression of IFNɣ in a microarray performed with NLRC5 mutants (Meissner et al., 
2010). 
An impaired induction of type II IFNɣ in activated T lymphocytes can indicate defects in certain 
signaling pathways. Here, cells were stimulated with LPS to induce IFNβ. IFNβ binds the surfacial 
type I interferon receptor (IFNAR) and induces JAK/STAT signaling. Thereby, STAT1 becomes 
phosphorylated and phospho-STAT1 dimers bind the GAS element within the IFNɣ promoter and 
potently induce the production of IFNɣ (Rawlings et al., 2004). LPS induced the expression of IFNɣ in 
wt, but not in ko splenocytes. This was not due to an altered IFNβ production (Fig. 3-11), but might 
reflect an impaired IFNβ-mediated JAK/STAT signaling in Nlrc5-deficient mice. It was reported that 
the expression of STAT1 is not altered in Nlrc5 ko mice (Biswas et al., 2012). However, further 
experiments should be performed to study the induction of type I and II IFNs in Nlrc5 ko cells. 
Moreover, the components of the JAK/STAT signaling pathway and their phosphorylation status 
should be investigate to reveal if NLRC5 directly influences the IFN signaling. 
The impaired CD8+ T cell population observed in Nlrc5 ko mice (Fig. 3-5) might also account for an 
impaired IFNɣ production in mixed murine splenocyte cultures, as activated CTLs are a major source 
of the cytokine. Interestingly, CTLs in Nlrc5 ko mice were observed to produce normal amounts of 
IFNɣ upon activation, which indicates that the production of IFNɣ is not generally impaired in ko cells 
(Yao et al., 2012). This also supports the idea that a reduced CTL population rather than a deregulated 
JAK-STAT signaling pathway leads to a diminished overall IFNɣ production in a mixed immune cell 
culture.  
 
IFNɣ is predominantly secreted by T lymphocytes, NK as well as NKT cells. The cytokine is 
necessary for a potent activation of Mϕs to phagocytose and present digested peptides. Furthermore, it 
induces the expression of MHC molecules for antigen presentation. A deficient IFNɣ production in 
Nlrc5 ko mice can therefore impair the uptake and destruction of invading pathogens by Mϕs as well 
as the generation and presentation of antigens. As a consequence, innate immune responses might 
arise that are impaired in removing invading pathogens and that lead to a more widespread 
inflammation. In combination with the decreased MHC class I expression and a reduced CTL number 
the decreased IFNɣ levels could further favor the development of tumors in Nlrc5 ko mice (Ikeda et 
al., 2002). 
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3. Beyond its impact on the induction of interferons NLRC5 also influenced the production of NF-κB-
dependent cytokines and their maturation. 
 
A role of NLRC5 in the production of mature IL-1β has been indicated by different publications. The 
data presented here indicate that NLRC5 is involved in the generation of IL-1β as Nlrc5-deficient cells 
showed reduced IL-1β levels (Fig. 3-13).  
IL-1β is a pro-inflammatory cytokine. A diminished induction can lead to an impaired innate immune 
defense in Nlrc5-deficient mice as these might not be able to develop a potent inflammatory response. 
The group around J. Ting found evidence that NLRC5 positively regulates IL-1β signaling as part of 
the NLRP3 inflammasome (Davis et al., 2010), while others even claimed that NLRC5 inhibits IL-1β 
signaling (Benko et al., 2010). NLRC5 could be a part of the NLRP3 inflammasome as IL-1β levels 
were significantly impaired upon treatment with ATP in Nlrc5 ko cells (Fig. 3-13). However, the 
IL-1β production upon ATP stimulation was not entirely abrogated in the Nlrc5-deficient cells. This 
indicates that NLRC5 is either a dispensable component of the NLRP3 inflammasome or that there 
exists a distinct NLRC5-dependent mechanism to activate caspase-1, which can be induced by ATP. 
Our data indicate that NLRC5 might rather be necessary for a potent induction of the IL-1β propeptide 
by NF-κB than its cleavage into the mature form due to caspase activation as Il1b mRNA levels were 
decreased in Nlrc5-deficient cells (Fig. 3-13 a).  
 
Various groups did not find any NLRC5-specific effects onto the NF-κB signaling pathway 
performing in vitro experiments (Davis et al., 2010; Kuenzel et al., 2010; Meissner et al., 2010; 
Neerincx et al., 2010; Ranjan et al., 2014). Some again claim NLRC5 to inhibit NF-κB signaling as a 
reduced promoter activation and a diminished induction of NF-κB target genes were observed in Nlrc5 
overexpression studies (Benko et al., 2010; Cui et al., 2010; Kumar et al., 2011; Li et al., 2014). To 
further evaluate the impact of Nlrc5 on NF-κB signaling, BMDMs were stimulated with LPS and the 
induction of selected NF-κB target genes was measured.  
From our data no general effect can be concluded as distinct NF-κB target genes were differentially 
influenced by the Nlrc5-deficiency. Upon LPS stimulation Nlrc5-deficient BMDMs showed different 
effects depending on the monitored NF-κB target gene. While Il6 and Cxcl1 mRNA levels were not 
altered in the ko (Fig. 3-14 c, d), Tnfa mRNA was significantly elevated in Nlrc5 ko cells. However, 
the secretion of TNF-α was impaired in Nlrc5-deficient BMDMs (Fig. 3-14 a, b), which might rather 
be due to defects in TNF-α secretion than an impaired Tnfa induction in ko animals.  
Many contradictory observations exist that try to clarify the impact of NLRC5 in NF-κB signaling 
(Biswas et al., 2012; Kumar et al., 2011; Staehli et al., 2012; Yao et al., 2012; Tong et al., 2012; 
Kumar et al., 2011). A general influence of NLRC5 on NF-κB signaling and NF-κB-induced gene 
expression cannot be ruled out, but more dedicated future analyses are needed. 
4.6 INFLUENCE OF NLRC5 ON EXPERIMENTAL COLITIS IN VIVO 
NLRC5 was assigned a pro-inflammatory role from the preceding in vitro experiments.  
It was presumed that individuals with functional defects in Nlrc5 are more susceptible to infections as 
distinct innate as well as adaptive immune mechanisms were observed to be impaired in Nlrc5-
deficient mice. Inflammatory disorders were presumed to develop less aggravated. 
Since, NLRC5 has not been studied in the context of intestinal inflammation, its role in the onset, 
progression and chronification of colitis was evaluated here. This inflammatory disorder involves 
innate as well as adaptive mechanisms (Geremia et al. 2014). 
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During the initial characterization Nlrc5 ko mice were shown to have an impaired MHC class I surface 
expression, a diminished CD8+ population and a reduced production of IFNs and IL-1β. All of these 
factors are thought to be protective in IBD (Bär et al., 2013; Bisping et al., 2001; Fais et al., 1991, 
1994; Ligumsky et al., 1990; Mahida et al., 1989; Müller et al., 1998; Noguchi et al., 1995; Okazaki et 
al., 1993; Reinecker et al., 1993; Sasaki et al., 1992; Satsangi et al., 1987). Accordingly, Nlrc5 ko 
mice were expected to develop an alleviated colitis upon DSS treatment when compared to wt 
animals. 
4.6.1 MICE LACKING NLRC5 ARE MORE SUSCEPTIBLE TO DSS-INDUCED COLITIS 
Nlrc5-deficient mice developed colitis upon DSS treatment. The intestinal inflammation worsened 
after DSS withdrawal during regeneration phases in the acute as well as the chronic model. Some ko 
animals even had to be prematurely sacrificed as they suffered an extraordinary disease aggravation.  
 
The temporal onset of colitis upon acute DSS-treatment was comparable between Nlrc5-deficient and 
wt mice. However, ko animals developed a more pronounced disease, which was e.g. characterized by 
a premature drop out of 20% of DSS treated ko animals (Fig. 3-16). Regarding the clinical phenotype, 
Nlrc5 ko mice suffered from a more severe diarrhea, they showed more pronounced intestinal 
bleedings and had a greater body weight loss during the course of the experiment. This is collectively 
represented by the increased DAI (Fig. 3-17). DAI-specific clinical signs are caused by the severe 
epithelial destruction in the colon, which hinders a proper resorption of water from the feces and 
thereby leads to the disease-typical diarrhea. The impaired uptake of nutrients and electrolytes induces 
the severe body weight loss. The progressive inflammation further causes intestinal bleedings that 
were detectable as occult blood in the feces. 
Moreover, colon shortening was observed in all ko and wt mice during acute disease. The degree of 
shortening was comparable between the genotypes, although ko animals had a more pronounced 
epithelial damage in the colon as well as a more pronounced clinical disease. Therefore, they were 
initially assumed to show an increased colon shortening (Fig. 3-18). Colon shortening is a typical 
feature found in IBD patients. It has also been described for rodents suffering from DSS-induced 
colitis (Chassaing et al., 2014). Organ shortening reflects the severe local inflammatory processes, due 
to which the colon loses fluid and its flexibility as epithelial lesions are repaired by inflexible scar 
tissue.  
Histopathologically, Nlrc5-deficient mice showed a severely elevated epithelial destruction in the 
distal colon with a great loss of goblet cells and entire crypts during acute colitis (Fig. 3-19, Fig. 3-20). 
Inflammatory mediators like IL6 and KC were significantly elevated in colon and serum of ko mice 
compared to the wt (Fig. 3-21, Fig. 3-22).  
 
During the induction of a chronic DSS-induced colitis, Nlrc5-deficient and wt animals initially did not 
show alterations in the clinical phenotype. However, 40% of ko mice suddenly developed an 
exaggerated disease during the repeated regeneration phases and had to be sacrificed early (Fig. 3-27). 
They were analyzed separately as koabort subgroup as they showed significant differences regarding 
their disease pathology when compared to the more moderately affected ko animals, which were 
designated kod21. DSS-induced chronic colitis in these kod21 animals was comparable to that in wt 
animals with regard to all analyzed parameters.  
However, Koabort mice showed a more pronounced loss of crypts within the distal colon and an 
upregulation of distinct inflammatory mediators as IL6 and MIP2α in the colon (Fig. 3-32). The bowel 
of koabort animals was significantly shortened when compared to the control group or even kod21 Nlrc5-
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deficient mice, what also reflects the more aggravated disease and the rapid pathophysiological 
changes that justified this experimental subgroup (Fig. 3-29). 
 
Altogether, the loss of NLRC5 led to an increased susceptibility towards acute as well as chronic DSS-
induced intestinal inflammation, an observation that was contrary to the initial hypothesis. 
4.6.2 THE PRODUCTION OF INFLAMMATORY CYTOKINES WAS ELEVATED IN NLRC5-
DEFICIENT MICE UPON DSS TREATMENT 
Several inflammatory cytokines have been implicated in the onset and perpetuation of IBD (Neurath, 
2014). Thus, the expression of certain cytokines was evaluated locally in the colon as well as 
systemically in the serum.  
Under baseline conditions, the expression of cytokines was not altered in Nlrc5 ko mice. Acute as well 
as chronic DSS treatment led to a potent induction of cytokines in the colon (Fig. 3-21). Detected 
levels varied greatly between individual animals. In the acute disease the pro-inflammatory IL-1β, 
IL-6, IL-12, the anti-inflammatory IL-10 as well as the chemokines CXCL1/KC and CXCL2 were 
significantly upregulated in the colons of Nlrc5-deficient animals. During chronic colitis cytokines 
were induced equally in the colon of wt and kod21 mice, only the severely affected koabort animals 
showed an enhanced expression of IL-6, CXCL2, IL-10 and IL-1β in the colon.  
The elevated cytokine production in ko mice upon DSS treatment correlated with the degree of injury 
observed in the colon epithelium and the severity of disease.  
 
In IBD patients, an elevated expression of IL-1β in the gut has been observed. The cytokine is 
produced spontaneously by mononuclear cells within the lamina propria during active CD and UC, 
while it is not detectable in healthy controls (Ligumsky et al., 1990; Mahida et al., 1989; Reinecker et 
al., 1993; Satsangi et al., 1987). In murine DSS-colitis models IL-1β is also potently induced (Arai et 
al., 1998) and disease severity can be reduced by inhibiting the IL-1β production or signaling pathway 
(Kwon et al., 2005; Okada et al., 2011; Siegmund et al., 2001b). The pro-inflammatory cytokine is 
thought to increase the permeability of the intestinal epithelium by affecting tight junctions (Al-Sadi 
and Ma, 2007), which enables pathogens, commensals and food antigens to enter more easily. In 
addition, IL-1β increases the recruitment of granulocytes and diverse cells of the lymphoid lineage in 
the intestine (Coccia et al., 2012).  
The production of IL-1β by Nlrc5 ko cells was observed to be impaired in preceding in vitro 
experiments upon stimulation (Fig. 3-13). Therefore, Nlrc5-deficient mice were hypothesized to have 
a diminished IL-1β production in the gut, which was assumed to be protective in the development of 
the DSS-induced colitis. However, we observed an enhanced IL-1β production in the colon of ko 
animals compared to the wt (Fig. 3-21, Fig. 3-22). This further correlated with the development of a 
more severe colitis phenotype in Nlrc5-deficient mice (Fig. 3-17). IL-1β supports the ongoing 
inflammation by increasing the epithelial permeability and the recruitment of neutrophils to the site of 
inflammation. 
 
A more severe course of disease was also reflected by an increased production of IL6, CXCL1 (KC, 
murine IL-8 homologue), CXCL2 (MIP2a) and IL-10 in Nlrc5-deficient mice.  
CXCL1 and CXCL2 support the inflammation by activating and recruiting phagocytes from the blood 
to the site of injury or inflammation as they promote endothelial adhesion and diapedesis (Kobayashi, 
2006). IL-6 can enhance disease severity by activating various target cells e.g. APCs and T cells to 
produce specific mediators. The cytokine also prevents the apoptosis of effector T cells and therefore 
 Discussion 
84 
 
keeps the inflammation from ceasing (Neurath, 2014). IL-10 down-regulates the production of pro-
inflammatory cytokines. It is upregulated to limit intestinal inflammation. IL-10 levels correlate with 
the severity of colitis Mutations impairing IL-10 production or signaling are associated with IBD in 
humans and mice (Engelhardt and Grimbacher, 2014; Rennick et al., 1997).  
 
Although all Nlrc5-deficient mice had elevated levels of the cytokines discussed above two important 
inflammatory mediators were not altered between the genotypes during DSS-induced colitis. These 
were IFNɣ and TNFα. 
An enhanced intestinal IFNɣ production has been observed during IBD, especially in CD patients 
(Breese et al. 1993; Sasaki et al. 1992; Fais et al. 1991; Fais et al. 1994; Bisping et al. 2001a). There 
was also a therapeutical benefit observed if patients suffering from Crohn’s disease were treated with 
the humanized anti-interferon γ antibody Fontolizumab (Ghosh et al., 2006; Hommes et al., 2006). 
Several experimentally induced colitis models in rodents furthermore revealed a correlation of the 
intestinal inflammation and the IFNɣ production as colitis did not develop in the absence of IFNɣ (Ito 
et al., 2006; Powrie et al., 1994) or disease severity was significantly ameliorated, when the production 
of IFNɣ was inhibited or secreted IFNɣ was neutralized by monoclonal antibodies (Hans et al., 2000b; 
Obermeier et al., 1999; Okada et al., 2011). Lymphocytes in the lamina propria were found to 
spontaneously release IFNɣ in CD patients (Fais et al., 1991). These were identified to be CTLs, 
which are activated for cytokine secretion upon antigen recognition. They are a major source of IFNɣ 
during an adaptive response (Bisping et al., 2001).  
Due to the decreased MHC class I expression and the reduced CD8+ T cell numbers it was initially 
presumed that the activation of CTLs and thereby the release of IFNɣ was impaired in Nlrc5–deficient 
mice (Fig. 3-6, Fig. 3-7). An impaired expression of IFNɣ in Nlrc5-deficient splenocytes had already 
been observed in vitro upon stimulation (Fig. 3-12). IFNɣ activates endothelial cells, induces T cell 
proliferation and initiates the recruitment and activation of additional leukocytes into the gut 
(Koboziev et al., 2010; Noguchi et al., 1995). Therefore, we initially hypothesized that the impaired 
production of IFNɣ alleviates the DSS-induced colitis in Nlrc5 ko animals.  
However, we measured comparable IFNɣ levels in Nlrc5-deficient animals during DSS-induced colitis 
(acute: Fig. 3-21, Fig. 3-22; chronic: Fig. 3-32, Fig. 3-33). Ko mice were not protected from colitis by 
an impaired IFNɣ production as we presumed. In contrast, they even suffered a more aggravated 
disease.  
IFNɣ levels did not correlate with disease severity in this study (Fig. 3-17), which might reflect the 
inability of Nlrc5-deficient mice to produce proper amounts of IFNɣ in response to intestinal 
inflammation. An imbalance of disease severity and IFNɣ production might reveal that IFNɣ is usually 
upregulated during colitis, but that disease severity is not due to the elevated IFNɣ production.  
On the other hand one could also hypothesize that the aggravated disease in Nlrc5-deficient mice is 
especially due to the impaired IFNγ production. This is supported by the observation that 
mesenchymal stromal cells need to be activated by IFNγ to exert immunosuppressive properties. 
Activated mesenchymal stromal cells can thereby attenuate DSS-induced colitis in mice (Hommes et 
al., 2006). 
 
TNFα was also induced at comparable amounts in the colons of wt and Nlrc5 ko mice during DSS-
colitis, although ko animals suffered a more aggravated disease. The pro-inflammatory TNFα is 
known to be potently upregulated in IBD patients (Braegger et al., 1992; Breese et al., 1994; Komatsu 
et al., 2001) as well as in experimental colitis models in rodents (Perse et al., 2012; Yan et al., 2009). 
Today, humanized anti-TNFα antibodies (e.g. Infliximab, Adalimumab) are one of the most effective 
therapeutical options to treat IBD patients. 
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However, in Nlrc5-deficient mice TNFα levels did not correlate with the severity of the DSS-induced 
colitis. As with IFNγ it is tempting to speculate that this reflects the inability of Nlrc5-deficient mice 
to produce proper amounts of TNFα in response to intestinal inflammation and that the upregulation of 
TNFα might rather be a consequence, but not an initial cause during intestinal inflammatory diseases. 
 
In summary, the diminished production of IL-1β and IFNɣ in Nlrc5-deficient cells in vitro supported a 
pro-inflammatory role of the NLR member and favored the hypothesis of an alleviated colitis 
phenotype in Nlrc5-deficient mice. However, cytokine levels were not reduced in vivo and ko animals 
developed a more aggravated DSS-induced colitis. The enhanced production of cytokines that was 
observed in the colon of ko animal could be due to an elevated influx of inflammatory cells, an 
enhanced activation of local immune and non-immune cells or impaired regulatory mechanisms.  
The induced pro-inflammatory mediators perpetuate the inflammation. Further immune cell 
populations are recruited, which can subsequently account for the prominent epithelial destruction in 
Nlrc5-deficient mice. 
4.6.3 THE ENHANCED EPITHELIAL DESTRUCTION IN THE COLON OF NLRC5 KO MICE 
IS NOT DUE TO AN ELEVATED INFLUX OF INFLAMMATORY CELLS 
Histological analyses revealed that mice suffering from DSS-induced colitis show damages in the 
epithelium of the large bowel (Fig. 3-19, Fig. 3-30). During acute disease, the epithelial destruction 
was characterized by an extensive loss of goblet cells as well as entire crypts (Fig. 3-19, Fig. 3-20). It 
was strikingly more severe in Nlrc5 ko mice when compared to wt animals. In the chronic model, 
there was only a moderate and comparable epithelial damage in the colons of wt and kod21 animals, 
while the koabort group showed an extensive loss of crypts (Fig. 3-30). The enhanced epithelial 
destruction in this subgroup correlated with the severity of disease (Fig. 3-27, Fig. 3-28, Fig. 3-29).  
 
The primary epithelial destruction in DSS-colitis models is assumed to be mediated by cytotoxic 
effects DSS exerts onto intestinal cells. These impair the epithelial barrier and subsequently lead to the 
onset of inflammation in response towards the tissue injury and the intruding luminal antigens (Ni et 
al., 1996). Nlrc5-deficient mice developed a more severe epithelial damage in the distal colon when 
compared to wt animals. This could reflect an altered susceptibility towards the DSS-induced 
epithelial damage or the inability to efficiently cope with the induced epithelial damage. 
 
Beyond DSS, immigrating immune cells and resident non-immune cells can mediate an epithelial 
destruction during colitis. 
The level of IL-1β, CXCL1 and CXCL2 in the colon of DSS-treated Nlrc5 ko animals was 
significantly increased when compared to wt mice (Fig. 3-21; Fig. 3-32). These cytokines promote the 
chemotactic invasion of phagocytes (especially neutrophils) from the blood. Therefore an increased 
influx of inflammatory cells was assumed in the bowel of Nlrc5-deficient animals. Immigrating 
neutrophils can be involved in the severe destruction of the intestinal epithelium (Fournier and Parkos, 
2012; Fig. 3-19). 
Intestinal inflammation usually originates at the intestinal epithelium were pathogens, commensals as 
well as food constituents can enter if the epithelial barrier is disrupted e.g. by DSS. Subsequently, 
antigens are presented to intraepithelial immune cells, which become activated to secrete cytokines 
and induce the influx of immune cells into the site of inflammation. Depending on disease severity 
immigrating cells penetrate the lamina propria and subsequently intersperse the submucosa or even 
break through the muscular layers into the abdominal cavity. During disease onset predominantly 
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neutrophils, monocytes and DCs migrate into the colon, while after approximately five days also 
T and B lymphocytes are attracted to the site of inflammation (Perse et al., 2012). 
In our study an infiltration of inflammatory cells into the different layers of the colon wall was 
observed upon DSS treatment (Fig. 3-19, Fig. 3-30). However, the influx of immune cells into the 
damaged intestine was not altered between Nlrc5 ko and wt mice (Fig. 3-19, Fig. 3-30). During acute 
disease colons of ko mice even tended to be less interspersed with infiltrating cells. Inflammatory cells 
accumulated mainly in the lamina propria, while in several colons of wt mice they also migrated into 
the submucosa (Fig. 3-19). During chronic disease the migration of immune cells into the bowel was 
more pronounced as most animals showed transmural inflammation (Fig. 3-30). Wt, kod21, and koabort 
animals had a comparable influx and distribution of inflammatory cells, although the koabort group 
showed significantly higher cytokine levels and a more severe disease phenotype.  
The enhanced mediator production and the aggravated disease severity observed in Nlrc5-deficient 
mice did not correlate with the influx of inflammatory cells into the bowel, neither in the acute nor in 
the chronic model. This was an unexpected finding as the influx of inflammatory cells as well as their 
tissue distribution are usually used to evaluate disease severity in experimentally induced colitis 
models as they are assumed to correlate with one another (Wirtz et al., 2007). 
 
The influx of neutrophils into the bowel is an early event during colitis. The subsequent recruitment 
and activation of lymphocytes severely exacerbates tissue destruction and aggravates disease. 
Therefore, CD8+ and CD4+ lymphocyte populations were monitored during colitis.  
CD8+ effector cells are supposed to be involved in the pathogenesis of colitis as their numbers are 
increased in patients suffering from IBD (Bisping et al., 2001; Müller et al., 1998). CTLs are activated 
by MHC class I-presented antigens and contribute to the development and progression of IBD by 
different mechanisms. On the one hand, CTLs isolated from colons of IBD patients produce elevated 
amounts of IFNɣ and thereby perpetuate the local inflammation (Bisping et al., 2001). On the other 
hand, higher levels of the CTL-specific granule constituents perforin and granzyme A were detected in 
the lamina propria of colons from IBD patients (Müller et al., 1998; Waldner et al., 2010). Perforin 
lyses the target cell, which is bound via the TCR, while granzymes enter the cell and induce the 
programmed cell death. Accordingly, an increased cytotoxicity was observed in intestinal lesions of 
IBD patients. It contributes to the epithelial destruction during colitis and was shown to be 
MHC class I restricted (Okazaki et al., 1993). A deficient perforin production was reported to 
attenuate colitis, which underlines the role of CTLs in the course of IBD (Waldner et al., 2010).  
CTLs preferentially locate to sites within the bowel that face the intestinal lumen where they recognize 
MHC class I-presented antigens on IECs (Müller et al., 1998). Upon activation, CTLs induce cytolysis 
of the antigen-presenting IEC and thereby damage the intestinal epithelium. IECs constitutively 
express MHC class I. This surface expression is increased in IBD patients (Hershberg and Mayer, 
2000; Mayer et al., 1991). Within the intestine, IECs separate the host’s immune components from the 
non-self components within the gastrointestinal lumen. IECs present luminal antigens to intraepithelial 
lymphocytes and thereby activate intestinal CD4+ and CD8+ T lymphocytes (Bisping et al., 2001; 
Dotan et al., 2007).  
Due to the impaired CD8+ T cell population in Nlrc5 ko mice it was initially assumed that there is a 
reduced capacity to release perforin and granzymes compared to wt animals (Fig. 3-5). In addition, it 
was presumed that fewer antigens are presented to CD8+ T cell due to the reduced MHC class I surface 
expression (Fig. 3-6, Fig. 3-7). Collectively, an alleviated epithelial destruction and hence a reduced 
intestinal inflammation was expected in Nlrc5-deficient mice. 
CD8+ numbers in the spleen were diminished in Nlrc5 ko mice under basal conditions as well as 
during colitis (Fig. 3-5, Fig. 3-8, Fig. 3-25, Fig. 3-36). However, the CD8+ population in the colon was 
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comparable to wt animals (Fig. 3-36). The loss of crypts in the distal colon was more severe in Nlrc5-
deficient mice and the decreased presentation of antigens due to the impaired MHC class I expression 
did not alleviate the epithelial destruction (Fig. 3-17, Fig. 3-19). It can be speculated that an aberrant 
activation of CTLs in the bowel of Nlrc5 ko mice augments the cytotoxic death of IECs upon MHC I-
antigen presentation. An overactivation can account for an aggravated epithelial destruction and 
consequently a more severe colitis in ko mice.  
CD4+ T cell numbers were not significantly altered between the genotypes neither in the spleen nor in 
the colon (Fig. 3-5, Fig. 3-25, Fig. 3-36). In the course of disease we observed that CD8+ and CD4+ 
lymphocyte numbers decreased in the spleens of wt and ko mice (Fig. 3-25, Fig. 3-36). This is 
assumed to be due to their migration to the site of inflammation. Accordingly, the number of CD8+ and 
CD4+ cells within the colon expanded (Fig. 3-36). In addition to the chemotactic invasion of 
T lymphocytes from the spleen, an enhanced proliferation of naïve T cells in the gut-associated 
lymphoid tissue might account for an extending lymphocyte population in the bowel (Fig. 3-31). 
Accordingly, although CD8+ T cell numbers were diminished in Nlrc5-deficient mice, their 
proliferation and migration was not affected. A decreasing T cell population in the spleen and an 
increasing population in the colon during colitis have also been described by others (Hall et al., 2011; 
Perse et al., 2012).  
 
During future experiments it should be evaluated if there is a normal activation of CTLs in Nlrc5 ko 
mice during an intestinal inflammation. Therefore perforin and granzyme levels can be measured and 
the CD8+ IFNɣ-producing CTL population in the colon can be evaluated. 
4.6.4 AN ALTERED MHC EXPRESSION IN NLRC5-DEFICIENT MICE CAN FAVOR 
INTESTINAL INFLAMMATION BY DIFFERENT MEANS 
Food and microbial antigens can induce inflammation and initiate adaptive responses if their MHC-
presented antigens are recognized by CD4+ as well as CD8+ effector cells. A well established tolerance 
towards luminal antigens limits these immune responses and prevents from aberrant intestinal 
inflammation, which could easily become chronic as the sensitizing antigens do not fade. 
 
Genetic analyses revealed that certain human MHC class II coding HLA alleles are associated with UC 
or CD and emphasize an important role for MHC class II molecules in the development of IBD 
(Forcione et al., 1996; Stokkers et al., 1999). Additionally, certain MHC class II isotypes were found 
to be upregulated in active inflammatory lesions (Fais et al., 1987; Mayer et al., 1991). Therefore, next 
to specific HLA alleles, also a high MHC class II expression is associated with IBD. 
An increased MHC class II+ cell population was found among splenocytes in Nlrc5-deficient mice 
(Fig. 3-9). An elevated MHC class II expression presumably leads to an enhanced presentation of 
extracellular antigens towards CD4+ T lymphocytes. This can induce an enhanced proliferation and 
activation of CD4+ T cells and favor the development of adaptive responses. The proliferation and 
activation of CD4+ Th cells in the intestine is especially upregulated if the epithelial barrier is damaged 
(e.g. upon DSS treatment) and luminal components can enter the tissue. Their antigens are presented 
by MHC class II molecules e.g. on Mϕs, DCs or IECs (Dotan et al., 2007). 
Although Nlrc5 ko mice had an increased MHC class II population, we did not observe an altered 
proliferation of CD4+ T cells in ko mice, neither under baseline conditions nor upon DSS treatment 
(Fig. 3-9, Fig. 3-5, Fig. 3-25, Fig. 3-36).  
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Next to an elevated MHC class II expression also the impaired expression of MHC class II molecules 
on non-hematopoietic cells in the gut (e.g. IECs) is implicated in the onset of colitis (Thelemann et al., 
2014).  
Nlrc5-deficient mice had an increased MHC II+ cell population among immune cells. However, 
MHC II is not constitutively expressed in IECs, but needs to be induced by IFNγ (Fig. 3-9). In vitro 
experiments implicated that the production of IFNγ is impaired in Nlrc5-deficient cells (Fig. 3-12). 
Additionally, intestinal IFNγ levels were alleviated during chronic disease if correlated to disease 
severity (Fig. 3-21, Fig. 3-32). Impaired IFNγ levels can lead to a reduced MHC II expression on IECs 
and thereby to a decreased presentation of antigens to CD4+ T cells. In future experiments it should be 
evaluated if Nlrc5-deficent mice have a reduced expression of MHC II molecules on IECs and if they 
subsequently suffer from an impaired immunological tolerance. 
Oral tolerance is not induced centrally during lymphocyte development, but in the periphery upon 
antigen contact, predominantly by IECs (Westendorf et al., 2009). This peripheral tolerance is 
established by the differentiation of CD4+ cells into inducible regulatory T cells (iTregs), Th3 or type 1 
T regulatory (Tr1) cells. These regulatory cells suppress CD4+ as well as CD8+ T cell effector 
functions in a contact-dependent manner (iTreg) or via regulatory cytokines (Th3, Tr1) (Martin et al., 
2004; Mempel et al., 2006). Additionally, lymphocytes can become anerg if they recognize presented 
antigens, but do not receive a proper inflammatory co-stimulus. Anerg lymphocytes remain inactive 
also if they encounter the particular antigen again at a later time point (Janeway, 2005). A proper 
antigen presentation by IECs is important to establish oral tolerance towards the plethora of antigens 
derived from food and gut microbiota that are in constant contact with the intestinal epithelium 
(Marguerat et al., 1999). A tolerization of CD4+ cells requires MHC class II presentation of innocuous 
antigens in combination with regulatory or inhibitory secondary signals.  
An impaired oral tolerance favors intestinal inflammation and could contribute to the aggravated 
severity of colitis in Nlrc5 ko mice after DSS treatment. 
A spontaneous onset of a disseminate inflammation can occur if regulatory T cells are reduced or 
functionally dysregulated. The gastrointestinal tract is usually affected early as it is constantly 
stimulated by food and microbial antigens (Zenewicz et al., 2009). The population of regulatory 
T cells was found to be decreased in IBD patients, which favors an aberrant activation of T effector 
cells (Boden and Snapper, 2008).  
 
Beyond CD4+ regulatory T cells diverse CD8+ regulatory T cell populations exist. They only make up 
a small portion within the peripheral circulation, but are more frequent among intestinal epithelial 
lymphocytes (Wang and Alexander, 2009). CD8+ Tregs specifically regulate the effector functions of 
activated antigen-driven CD4+ T cells either by secreting regulatory cytokines or in a contact-
dependent manner by releasing cytotoxic granules (Jiang and Chess, 2000; Wang and Alexander, 
2009). Regulatory CD8+ T cells are found in the lamina propria of the healthy intestine. They are 
absent in IBD patients (Brimnes et al., 2005). It was shown that IECs from IBD patients cannot 
properly expand CD8+ Tregs in vitro. This might play an important role in mucosal tolerance and 
therefore in the pathogenesis of IBD (Mayer and Eisenhardt, 1990). 
In Nlrc5 ko splenocyte cultures CD8+ T cell populations were significantly diminished, but their 
numbers were not altered in whole colon tissue (Fig. 3-5, Fig. 3-36). However, CD8+ T regulatory 
cells in the lamina propria can still be impaired in ko mice as cell populations within the distinct 
sublayers of the colon tissue were not evaluated. A more detailed analysis of CD8+ T reg cells on 
isolated lamina propria samples of murine colons could reveal if this population is reduced in Nlrc5 ko 
animals. This could contribute to an enhanced susceptibility to develop intestinal inflammations. 
 Discussion 
89 
 
Existing CD8+ Tregs might furthermore be impaired in conveying their contact-dependent regulatory 
functions in Nlrc5-deficient mice as the expression of MHC I is severely reduced in these animals. 
Consequently, overshooting T cell effector functions might not be properly alleviated or inhibited and 
aberrant effector cells are not deleted. A normal MHC I expression especially on CD4+ T cells can 
therefore be crucial for a normal CD8+ Treg-mediated peripheral tolerance in the gut. Reduced MHC I 
expression as well as reduced CD8+ Treg numbers might account for the severe colitis phenotype 
observed in DSS-treated Nlrc5 ko mice.  
 
In future studies it will be promising to evaluate if CD4+ and CD8+ regulatory T cell populations are 
normally developed in Nlrc5-deficient mice. Decreased numbers can contribute to an aggravated 
development of DSS-induced colitis. 
4.6.5 NLRC5 KO MICE ARE SUSCEPTIBLE TO DEVELOP AN AGGRAVATED CHRONIC 
COLITIS ACCOMPANIED BY HYPOSPLENISM 
In this study we observed that distinct cytokines were significantly upregulated in the serum of Nlrc5-
deficient mice during acute colitis (IL-6, IL-1β, CXCL1), while in wt animals the acute DSS-treatment 
had no effect on serum cytokines (Fig. 3-22). In addition, the expression of Mpo, a cytokine produced 
by activated neutrophils and Mϕs, was elevated in the spleen of Nlrc5-deficient mice (Fig. 3-24). 
While IL-6 and IL-1β promote the development of a systemic inflammatory response, CXCL1 
activates and attracts phagocytes from the blood. The elevated Mpo expression in the spleens of ko 
animals therefore correlates with enhanced CXCL1 serum concentrations. 
 
During the acute DSS colitis wt mice developed splenomegaly, while spleen weight was not altered in 
Nlrc5-deficient animals. Spleen enlargement usually reflects an exaggerated spleen function. It 
indicates a systemic immune activation with a vivid lymphocyte proliferation in the spleen and the 
development of adaptive responses (Medscape, 2014). Spleen enlargement in the course of DSS 
treatment has already been reported and is believed to reflect the establishment of a systemic 
inflammation (Chassaing et al., 2014). Moreover, altered spleen sizes have repeatedly been observed 
in IBD patients. Splenomegaly as well as hyposplenism was reported. Splenomegaly effects especially 
CD patients, while hyposplenism was rather observed in UC (Muller and Toghill, 1995; Pereira et al., 
1987; Rozen et al., 1977; Ryan et al., 1978). 
Elevated serum cytokine levels and the pronounced splenic MPO expression reflect systemic effects of 
the DSS-induced intestinal inflammation. These developed earlier in Nlrc5 ko mice than in wt 
animals. This early systemic response can indicate that the local response is not efficient enough to 
cope with the DSS-induced injury or its subsequent effects. Furthermore, regulatory mechanisms 
might be impaired that can curtail an inflammation to the site of injury. Both would support an 
aggravated colitis phenotype as observed in ko mice. Although ko mice developed a prominent 
systemic innate response, they did not show spleen enlargement, which usually indicates the 
development of a systemic adaptive response. It can be speculated that Nlrc5 ko mice are impaired in 
generating proper adaptive responses to fight pathogens that invade via the defective intestinal barrier. 
An excessive inflammation might be induced to combat an infection by innate mechanisms, which 
casually leads to the exaggerated tissue damage in ko mice. 
 
During chronic disease, serum cytokine levels were comparable between Nlrc5-deficient and wt 
animals. The splenic Mpo expression was equally elevated in wt and kod21 mice and the spleen weight 
was alike in these two experimental groups. In contrast, in koabort mice a significantly diminished 
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induction of Mpo was observed in the spleen and the spleen weight was greatly reduced compared to 
wt or kod21 mice (Fig. 3-34; Fig. 3-35). 
A decreased spleen weight can indicate a collapsed spleen function (hyposplenism). The spleen is 
important for adaptive responses, as effector lymphocytes are generated and proliferate here. It is also 
the major reservoir for monocytes, which are key players in the innate response. Hyposplenism is a 
common complication in severely inflamed UC patients, which either suffered persisting active 
disease or a pronounced relapse. Patients with hyposplenism are more prone to bacterial infections, 
sepsis and intravascular coagulation due to the reduced spleen functionality, which recovered upon 
resection of the affected colon parts (Ryan et al., 1978). 
Analog it can be speculated here, that the early onset of the strong systemic innate responses in Nlrc5-
deficient mice during DSS-induced colitis leads to the exhaustion of the spleen function. This might 
subsequently result in organ resignation and the reduction of spleen weight.  
I hypothesize that the impaired spleen function contributes to the severe course of disease as well as 
the elevated mortality that was observed in koabort animals (Fig. 3-27, Fig. 3-28) as the impaired 
immune system is unable to properly cope with the epithelial damage and the arising inflammation 
within the intestine. 
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5 CLINICAL RELEVANCE & FUTURE PERSPECTIVES 
5.1 NLRC5 IS POTENTLY INVOLVED IN INNATE AND ADAPTIVE DEFENSE AGAINST 
INTRACELLULAR PATHOGENS 
From the initial characterization of Nlrc5-deficient mice it is presumed that individuals with functional 
defects in NLRC5 are more susceptible to infections with intracellular pathogens as their innate 
(decreased production of IFNs and IL-1β) as well as their adaptive (reduced MHC class I expression 
and CD8+ population) immune mechanisms are impaired. Accordingly, NLRC5 defects could favor 
the development of more widespread, longer lasting and recurrent infections. NLRC5 can therefore be 
assigned a pro-inflammatory role. 
 
In future studies it should be investigated if Nlrc5-deficient mice show alterations in immune defense 
mechanisms or disease susceptibility, when infected with intracellular pathogens (viruses, intracellular 
bacteria).  
It would be of interest if Nlrc5 ko mice develop normal IFN responses during viral infections or if the 
induction of IFNs and subsequently ISGs is impaired in those animals. The CD8+ CTL population and 
its activation status should also be analyzed and it should be investigated if alterations are due to a 
diminished MHC class I expression. Moreover, it can be evaluated if infected Nlrc5 ko mice develop a 
premature and prominent systemic inflammation possibly accompanied by hyposplenism as observed 
during chronic colitis. 
Altogether, these studies can reveal if a loss of Nlrc5 leads to a more widespread infection with 
intracellular pathogens, an impaired clearance of infected cells and a pronounced clinical picture. 
5.2 NLRC5: A NEW SUSCEPTIBILITY GENE FOR IBD OR INFLAMMATORY 
DISEASES? 
In addition to its pro-inflammatory role, NLRC5 might exert important regulatory functions. The data 
presented here reveal that functional NLRC5 protects from a fulminate course of colitis. This could 
also implicate a role of NLRC5 in the pathogenesis of IBD in humans.  
Several NLR family members have been associated with intestinal inflammation. While mutations in 
NOD2 are known to favor the onset of CD in humans (Hampe et al., 2001; Hugot et al., 2001; Ogura 
et al., 2001), other NLRs were shown to be protective in murine colitis models e.g. NOD1 (Chen et al., 
2008), NLRP1 (Williams et al., 2015), NLRP3 (Allen et al., 2010; Villani et al., 2009; Zaki et al., 
2010), NLRC4 (Carvalho et al., 2012), NLRP6 (Elinav et al., 2011) and NLRP12 (Zaki et al., 2011).  
Although Nlrc5 deficiency worsened the intestinal inflammation in the DSS-induced murine model, 
genome-wide association studies did not reveal any IBD-associated NLRC5 variants so far (Jostins et 
al., 2012).  
 
NLRC5 initiates the transcription of MHC class I-coding HLA genes. Studying Nlrc5 ko mice 
underlined the importance of proper MHC class I expression for intestinal homeostasis.  
Here we hypothesize that a decreased MHC class I expression and a diminished CD8+ Treg cell 
population in individuals bearing functionally defective NLRC5 variants might lead to an impaired 
intestinal tolerance. It was reported that regulatory CD8+ T cells are diminished in the lamina propria 
of IBD patients (Brimnes et al., 2005). Therefore, analyzing the role of MHC class I and its 
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transcriptional regulator NLRC5 for intestinal tolerance might advance the understanding of IBD 
pathogenesis. 
An inefficient tolerance towards gut antigens favors an aberrant activation of T effector cells, which 
can lead to a recurring or chronic intestinal inflammation as triggering antigens derived from food or 
microbiota persist within the bowel. More dedicated studies are needed to clarify the involvement of 
NLRC5 in gut tolerance. It should be investigated if Nlrc5 ko mice have an altered CD8+ and CD4+ 
regulatory cell population under baseline conditions, but also during DSS-induced colitis. 
Furthermore, the activation of these regulatory cells should be assed, e.g. by analyzing the secretion of 
regulatory or inhibitory mediators as TGF-β or IL-10.  
In addition, it should be analyzed if Nlrc5-deficient mice have an impaired expression of MHC II 
molecules on IECs and if this correlates with an impaired IFNγ production. An impaired MHC II 
expression could further impair the establishment of intestinal tolerance mediated by CD4+ T cells. 
 
If it shows that NLRC5 is involved in immunological tolerance in the gut the protein could also have a 
functional relevance on other surfaces of the body (e.g. within the lung). Accordingly, functional 
NLRC5 defects might favor the onset of various inflammatory disorders. 
5.3 NLRC5 MIGHT BE A PROMISING TARGET TO ENHANCE TUMOR IMMUNITY 
The presentation of endogenous antigens on MHC class I molecules in malignant cells and their 
subsequent lysis by CTLs underline the importance of NLRC5 regarding tumor immunity. 
Longitudinal studies on aging animals should be performed to evaluate if Nlrc5 ko mice are more 
prone to develop tumors due to their impaired MHC class I expression as a down regulation of 
MHC class I surface expression is a common mechanism of tumors to hide and escape the body’s 
immune surveillance (Bubeník, 2003). Understanding the mechanisms of MHC I expression and its 
induction by NLRC5 and other mechanisms (e.g. CIITA) can be of use for cancer research as a 
targeted MHC upregulation on malignant cells presumably enhances endogenous tumor immunity. 
5.4 FUNCTIONAL NLRC5 DEFECTS MIGHT INDUCE A CLINICAL PICTURE 
COMPARABLE TO BLS I 
This study revealed that a loss of Nlrc5 is associated with a more severe intestinal inflammation in a 
murine DSS-induced colitis model. It can be presumed that a functional NLRC5 defect in humans 
might cause a more complex clinical picture that involves not only inadequate inflammation (due to 
missing tolerance), but also widespread infections (due to ineffective innate and adaptive defenses 
towards intracellular pathogens) as well as susceptibility to malignant transformations (due to an 
impaired expression of abnormal cellular antigens). 
 
An impaired expression of MHC molecules in humans is known to cause severe combined immune 
deficiencies (SCID) that have various clinical signs. SCIDs in general are characterized by an impaired 
generation or activation of functional T or B lymphocytes due to various genetic mutations.  
A deficient MHC class I expression as seen in Nlrc5-deficient mice is designated Bare Lymphocyte 
Syndrome I (BLS I). The reduced MHC class I expression is usually caused by a defective TAP 
complex, but NLRC5 defects could have a similar clinical manifestation. Patients suffer from chronic 
or recurring inflammation in different compartments e.g. respiratory and gastrointestinal tract as well 
as the skin (Gadola et al., 2000). Interestingly, no BLS I phenotype has been shown so far to be caused 
by mutations in the NLRC5 gene, which might be due to a compensatory albeit reduced MHC class I 
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induction by NLRC5-independent mechanisms (e.g. CIITA). Accordingly, patients with defects in the 
NLRC5 gene might only develop an alleviated BLS I phenotype.  
MHC class II deficiency, which is referred to as BLS II is the more common SCID among the two 
MHC deficiencies. It is caused by mutations in genes involved in MHC II transcription e.g. CIITA, 
which lead to an impaired or abrogated MHC class II surface expression. As for BLS I, patients suffer 
from repeated severe infections e.g. within the gastro intestine, the respiratory tract and the skin.  
5.5 FUTURE PERSPECTIVES & CONCLUDING REMARKS 
NLRC5 is an important molecular switch to influence diverse clinical conditions due to its co-
transcriptional activation of MHC class I coding HLA genes. More detailed studies are needed to 
elucidate the role of NLRC5 (and thereby the importance of MHC class I molecules) in viral and 
bacterial infections, the establishment of immunological tolerance and inflammatory disorders as well 
as the development of cancer.  
Further research might unravel how NLRC5 impacts the production of IL-1β. NLRC5 was shown to 
be involved in IL-1β maturation. Although it was postulated that it might be associated with the 
NLRP3 inflammasome (Davis et al., 2010; Yao et al., 2012) there is still no model available that 
sufficiently describes interaction partners, activating ligands or regulatory mechanism. Our data rather 
imply an impact on the NF-κB-mediated induction of the IL-1β propeptide, but the mechanism needs 
to be elucidated. 
The impact of NLRC5 on the production of IFNs was not unraveled so far. The NLR member might 
have an important innate immune function in initiating antiviral responses as our data indicate that 
NLRC5 is involved in the induction of IFNs. Diminished IFNγ levels in the gut can impair local 
tolerance. IFNγ is necessary for the activation of mesenchymal stromal cells to exert their 
immunosuppressive functions. The cytokine further induces MHC class II molecules, which are 
needed to activate CD4+ T cells and prime regulatory lymphocytes. IFNɣ also inhibits the expression 
of IL-23, a cytokine implicated in the development of inflammatory disorders (Sheikh et al., 2010). It 
should be evaluated if the induction of IL-23 is altered in Nlrc5 ko mice and if this correlates with a 
decrease in IFNɣ. In future experiments it can be analyzed if the reconstitution of a normal IFNγ-level 
in Nlrc5-deficient mice attenuates the DSS-induced colitis and how it impacts IL-23 and the MHC II 
expression in the intestine. 
 
The presented results support a pro-inflammatory as well as a regulatory role for NLRC5 depending 
on the depicted mechanism the protein is involved. Furthermore, this study reveals the significance of 
a proper Nlrc5-mediated MHC class I expression to prevent severe intestinal inflammation. 
If we understand how NLRC5 is regulated this might be a powerful target to manipulate the 
expression of MHC class I molecules and thereby gain treatment options for distinct medical 
conditions. A selective upregulation of MHC class I can favor the clearance of infectious diseases and 
enhance endogenous tumor immunity, while a down regulation could be beneficial during chronic 
inflammation as well as for organ transplantations. NLRC5 could be the gateway. 
 
Before, CIITA was the only known NLR member with implications in adaptive immune regulations. 
With the identification of NLRC5 as the major co-transcriptional activator for MHC class I-coding 
HLA genes and its subsequent importance for adaptive immune responses, the significance of the NLR 
family beyond innate pathogen recognition becomes even more obvious.  
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6 SUMMARY 
The complex mammalian immune system comprises diverse synergizing mechanisms to protect 
organisms from constant potentially deleterious environmental effects, but also to establish tolerance 
towards innocuous influences. To understand disease pathogenesis and develop treatment strategies it 
is inevitable to elucidate and investigate the plethora of immune mechanisms.  
Here, the NOD-like receptor (NLR) NLRC5 was studied. NLRs are predominantly understood as 
cytoplasmic pathogen recognition receptors (PRRs), which initiate innate responses towards foreign 
pathogen-associated or endogenous danger-associated molecular patterns. No ligand is known for 
NLRC5 so far, but the protein is assumed to possess immune function. NLRC5 was initially reported 
to influence the expression of IFNs and NF-κB target genes as well as the production of IL-1β. 
However, its impact is controversially discussed. NLRC5 was identified to share several similarities 
with CIITA, an NLR member that functions as the major co-transcriptional activator for MHC class II-
encoding HLA genes and is therefore essential for adaptive immune processes. In analogy, NLRC5 
was reported to initiate the transcription of MHC class I-encoding HLA genes.  
This study aimed to define the contribution of NLRC5 to innate signaling pathways as well as to 
adaptive immune mechanisms. Therefore, Nlrc5-deficient (ko) mice were generated. They were viable 
and fertile and had no obvious immune defects under specific pathogen-free housing conditions.  
NLRC5 was predominantly expressed in immune tissues and potently induced by IFNɣ. In accordance 
with its role as transcriptional regulator, Nlrc5 ko mice had a severely decreased MHC class I surface 
expression. However, a residual, cell type-dependent MHC class I expression remained. Furthermore, 
MHC class I was still inducible in Nlrc5-deficient cells. This points to the existence of other MHC I 
regulating mechanisms. It is assumed that one of these mechanisms is the transcriptional activation of 
MHC class I-coding genes by CIITA.  
The decreased MHC class I levels led to an impaired generation of CD8+ T lymphocytes in Nlrc5-
deficient mice. In contrast, the MHC class II+ cell population was increased, but did not affect the 
number of CD4+ T lymphocytes. Next to these adaptive immune functions, NLRC5 was involved in 
innate immune signaling pathways. The protein was crucial for a proper induction of type I and II 
IFNs as well as IL-1β.  
The diminished CD8+ T cell population as well as the impaired production of IFNγ and IL-1β found 
during the characterization was presumed to render Nlrc5 ko mice less susceptible to an intestinal 
inflammation. In contrast this work revealed that ko mice develop an aggravated DSS-induced colitis. 
The pronounced phenotype correlated with an enhanced epithelial destruction and an upregulated 
production of inflammatory cytokines. However, there was no increased influx of inflammatory cells 
into the colon.  
Various mechanisms are discussed here that try to unravel the unexpected severity of DSS-colitis in 
Nlrc5-deficient mice. The severe epithelial damage in the intestine of ko animals is assumed to be due 
to an aberrant activation of local effector T lymphocytes. The diminished expression of MHC I 
molecules and an impaired CD8+ Treg population as well as decreased IFNγ level might hinder the 
establishment of proper intestinal tolerance and thereby favors an aberrant activation of mucosal 
lymphocytes and subsequently intestinal inflammation. 
Taken together, NLRC5 was found to be involved in pro-inflammatory innate signaling pathways and 
to have inflammatory as well as regulatory functions during adaptive immune processes.  
This study for the first time indicates a protective effect of NLRC5 during intestinal inflammation and 
discusses a role for this NLR member in the establishment of intestinal tolerance. Up to now 
investigations on an aberrant activation of intestinal effector lymphocytes during colitis concentrated 
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on the impact of CD4+ regulatory T cells, while here an important role of regulatory CD8+ T cells is 
presumed. 
Based on the here presented data, functional defects in NLRC5 are presumed to account for a 
decreased clearance of infected and malignant cells and to impair the establishment of immunological 
tolerance. Accordingly, mutations in NLRC5 might favor severe infectious and inflammatory diseases 
as well as cancer.  
 
Future experiments are needed to further investigate the role of NLRC5 for peripheral tolerance as 
well as for the course of infectious diseases and tumor development. Manipulating MHC class I 
surface expression e.g. via its transcriptional regulator NLRC5 could be a powerful therapeutical tool 
for diverse medical conditions as infections, chronic inflammations, tumors or even for 
transplantational medicine. 
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7 ZUSAMMENFASSUNG 
Das komplexe Immunsystem der Säugetiere umfasst diverse synergistische Mechanismen um den 
Organismus vor der konstanten Bedrohung durch potentiell schädliche Umwelteinflüsse zu schützen, 
aber auch um eine Toleranz gegenüber harmlosen Einflüssen zu etablieren. Um die Ursache von 
Krankheiten zu verstehen und neue Behandlungsstrategien entwickeln zu können, ist es unumgänglich 
diese Vielfalt an Immunmechanismen aufzudecken und zu erforschen. 
In dieser Arbeit wurde NLRC5, ein Mitglied aus der Familie der NOD-ähnlichen Rezeptoren, 
untersucht. NLRs werden überwiegend als zytoplasmatische Pathogen-erkennende Rezeptoren (PRRs) 
eingeordnet, die eine angeborene Immunantwort gegen Pathogen-assoziierte fremde oder Gefahren-
assoziierte endogene molekulare Strukturen initiieren. Ein Ligand für NLRC5 wurde bisher noch nicht 
identifiziert, trotzdem wird von einer immunologischen Funktion des Proteins ausgegangen. 
Anfänglich wurde ein Einfluss von NLRC5 auf die Expression von Interferonen und NF-κB Zielgenen 
sowie auf die Produktion von IL-1β berichtet. Dieser Einfluss wird jedoch kontrovers diskutiert. 
Außerdem konnte gezeigt werden, dass NLRC5 diverse Gemeinsamkeiten mit dem NLR Protein 
CIITA hat. CIITA ist der Ko-Transaktivator für die Transkription MHC II-kodierender HLA Gene und 
somit essenziel für adaptive Immunprozesse. Analog dazu wurde für NLRC5 beschrieben, dass es die 
Transkription von MHC I kodierenden HLA Genes initiiert. 
Diese Studie sollte untersuchen inwieweit NLRC5 zu angeborenen oder erworbenen Immunprozessen 
beiträgt. Dazu wurden Nlrc5-defiziente (Ko) Mäuse generiert. Diese waren lebensfähig und fertil unter 
spezifisch-pathogenfreien Lebensbedingungen. Sie wiesen keine erkennbaren Immundefekte auf.  
NLRC5 wurde vor allem in Immungeweben exprimiert und durch IFNɣ induziert. In 
Übereinstimmung mit seiner Rolle als transkriptioneller Regulator war die Oberflächenexpression von 
MHC I in Nlrc5 Ko Mäusen stark vermindert. Trotzdem bestand eine verbleibende MHC I Expression, 
die abhängig vom untersuchten Zelltyp war. Darüber hinaus war MHC I weiterhin induzierbar. Dies 
deuted auf die Existenz weiterer MHC I-regulierender Mechanismen. Es wird angenommen, dass einer 
dieser Mechanismen die transkriptionelle Aktivierung von MHC I-kodierenden Genen durch CIITA 
ist.  
Die stark reduzierten MHC I Spiegel in Nlrc5-defizienten Mäusen beeinträchtigten die Generation von 
CD8+ T Lymphozyten. Die MHC II+ Zellpopulation war hingegen vergrößert, was sich jedoch nicht 
auf die Anzahl CD4+ T Lymphozyten auswirkte. Neben diesen Einflüssen auf das adaptive 
Immunsystem wirkte sich NLRC5 auch auf die Signalwege der angeborenen Immunität aus. Das 
Protein war entscheidend an der Induktion von Typ I und II Interferonen sowie der Produktion von 
IL-1β beteiligt. 
Aufgrund der verminderten Anzahl CD8+ T Lymphozyten und der beeinträchtigten Produktion von 
IFNɣ und IL-1β wurde hier ursprünglich angenommen, dass Nlrc5 Ko Mäuse weniger empfänglich für 
die Induktion einer intestinalen Entzündung sind. Im Gegensatz dazu konnte in dieser Arbeit in DSS-
induzierten Kolitismodellen gezeigt werden, dass Nlrc5-defiziente Mäuse ein verstärktes 
Krankheitsbild entwickeln. Der ausgeprägtere Phänotyp korrelierte mit einer gesteigerten epithelialen 
Destruktion und der erhöhten Produktion inflammatorischer Zytokine. Es kam hingegen nicht zu 
einem vermehrten Influx von Entzündungszellen in das Kolon.  
Verschiedene Mechanismen werden hier diskutiert, die versuchen den unerwarteten Schweregrad der 
DSS-induzierten Kolitis in Nlrc5-defizienten Mäusen zu erklären. Es wird angenommen, dass der 
verstärkte intestinale Epithelschaden Nlrc5-defizienter Mäuse durch eine anormale Aktivierung lokaler 
T Lymphozyten ausgelöst wird. Die reduzierte Expression von MHC I-Molekülen und eine verringerte 
CD8+ regulatorische T Zellpopulation als auch verminderten IFNγ Spiegel können die Ausbildung 
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einer angemessenen intestinalen Toleranz beeinträchtigen. Dies begünstigt eine anormale Aktivierung 
mukosaler Lymphozyten und führt zur Ausbildung einer intestinalen Entzündung. 
Zusammenfassend konnte in dieser Arbeit gezeigt werden, dass NLRC5 an pro-inflammatorischen 
Signalwege der angeborenen Immunität beteiligt ist und sowohl inflammatorische als auch 
regulatorische Funktionen in adaptiven Immunprozessen hat. Diese Studie deutet zum ersten Mal auf 
einen protektiven Effekt von NLRC5 bei entzündlichen Darmerkrankungen hin und impliziert eine 
Rolle bei der Ausbildung der intestinalen Toleranz. Untersuchungen zur anormalen Aktivierung reifer 
intestinaler Lymphozyten während einer Kolitis konzentrierten sich bisher auf den Einfluss 
CD4+ regulatorischer T Zellen. Hier wird hingegen eine wichtige Rolle für die CD8+ regulatorische 
T Zellpopulation impliziert. 
Basierend auf den hier gezeigten Daten wird angenommen, dass funktionelle Defekte in NLRC5 zu 
einer verminderten Beseitigung infizierter und maligner Zellen führen, sowie die Ausbildung der 
immunologischen Toleranz beeinträchtigen. Dementsprechend könnten Mutationen im NLRC5 Gen 
schwere Infektions- und Entzündungskrankheiten sowie die Entstehung von Tumoren begünstigen. 
 
Es bedarf zukünftiger Experimente um die Rolle von NLRC5 in der peripheren Toleranz als auch im 
Verlauf von Infektionskrankheiten und in der Tumorentstehung zu untersuchen. Eine gezielte 
Einflussnahme auf die MHC I Expression an der Zelloberfläche z.B. über den transkriptionellen 
Regulator NLRC5, wäre ein wirksames therapeutisches Werkzeug für diverse medizinische 
Indikationen wie beispielsweise Infektionen, chronische Entzündungen, Tumore oder auch in der 
Transplantationsmedizin. 
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8.4 ABBREVIATIONS 
 
AD Acidic activation domain; also: acidic transactivation or acidic domain 
AIM2 Absent in melanoma 2 
ALR AIM2-like receptors 
APC Antigen presenting cell 
APC + antibody Allophycocyanin 
ASC Apoptosis-associated speck-like protein containing a CARD 
BIR Baculoviral inhibitory repeat-like domain 
BLS Bare lymphocyte syndrome 
BMDC Bone marrow-derived dendritic cells 
BMDM Bone marrow-derived macrophages 
bp Base pair 
BSA Bovine serum albumin 
CARD Caspase activation and recruitment domain 
CD Crohn´s disease; Morbus Crohn 
CD + number Cluster of differentiation 
cDNA Complementary DNA 
CIITA MHC class II transactivator 
CLIP Class II associated li peptide  
CLR C-type lectin receptors 
CMV Cytomegalovirus 
DAMP Danger-associated molecular pattern 
DC Dendritic cell 
DMEM Dulbecco’s Minimal Essential Medium 
DNA Deoxyribonucleic acid 
dsRNA Double stranded RNA 
DSS Dextran sulfate sodium 
DSZM German Collection of Microorganisms and Cell cultures               
(Deutsche Sammlung von Mikroorganismen und Zellkulturen) 
EDTA Ethylenediaminetetraacetic acid 
ES Embryonic stem cell 
FCS Fetal calf serum  
FELASA Federation European Laboratory Animal Science Association 
FITC Fluorescein isothiocyanate 
FRET Förster or fluorescence resonance energy transfer 
FSC Forward scatter 
GALT Gut-associated lymphoid tissue 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GAS IFNɣ activation sequence 
gDNA Genomic DNA 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GWAS Genome-wide association study 
HE Hematoxylin and eosin  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HET-E incompatibility locus protein from Podospora anserina 
HLA Human leukocyte antigen 
HRP Horseradish peroxidase 
HSV-1 Herpes simplex virus 1 
hu Human  
IBD Inflammatory bowel disease 
IEC intestinal epithelial cells 
IFN Interferon 
IFNAR Type I interferon receptor 
IgG Immunoglobulin G 
IKKα/IKKβ IκB kinase heterodimer 
IL Interleukin 
Iono Ionomycin 
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IRF Interferon regulatory factor  
ISG Interferone stimulated gene 
ISRE Interferon-specific response element 
IVC  Individually ventilated cages 
IκB Inhibitor of NF-κB 
KC  Keratinocyte-derived chemokine; CXCL1 
LMP2 Low-molecular-mass protein 2 
LPS Lipopolysaccharid 
LRR Leucine-rich repeat 
MALT Mucosa-associated lymphoid tissue 
MAPK Mitogen-activated protein kinases 
M-CSF Macrophage-colony stimulating factor 
MDA5 Melanoma differentiation associated gene 5 
MIP1a Macrophage inflammatory protein 1 alpha ; CCL3 
MMLV Moloney Murine Leukemia Virus 
MMM Mouse Macrophage Medium 
MPO Myeloperoxidase 
mRNA Messenger ribonucleic acid 
ms  Mouse 
MyD88 Myeloid differentiation primary response gene 88 
Mϕ Macrophage  
NACHT Acronym: NAIP, CIITA, HET-E, TP1 
NAIP Neuronal apoptosis inhibitor protein 
NBD Nucleotide-binding domain 
NDV Newcastle disease virus 
NFDM Non fat dry milk 
NF-κB Nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NK cell Natural killer cell 
NKT cell Natural killer T cell 
NLR NBD and LRR-containing gene family 
NLRA NLR family, AC domain containing 
NLRB NLR family, BIR domain containing 
NLRC NLR family, CARD domain containing 
NLRP NLR family, PYD domain containing 
NLS Nuclear localization signal 
NOD Nucleotide-binding and oligomerization domain 
number + h Hour(s) 
o/n Overnight 
OAS Oligoadenylate syntethase  
PAF Platelet-activating factor  
PAGE Polyacrylamid gel electrophoresis 
PAMP Pathogen-associated microbial pattern 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PE R-Phycoerythrin 
PHA Phytohemagglutinin 
PI Propidium iodide 
PMA Phorbol 12-myristate 13-acetate 
poly(I:C) Polyinosinic acid-polycytidylic acid; synthetic dsRNA 
PRR Pattern recognition receptors 
PYD Pyrin domain 
RANTES Regulated on Activation, Normal T cell Expressed and Secreted 
rh Recombinant human 
RIG-I Retinoic Acid-Inducible Gene 1 
RLR Retinoic Acid-Inducible Gene 1-Like Receptor 
rm Recombinant murine 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
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RPMI Roswell Park Memorial Institute medium 
RT PCR Reverse transcription PCR 
RT-qPCR Real Time quantitative PCR 
SDS Sodium dodecyl sulfate 
SEM Standard Error of the Mean 
SeV Sendai virus 
SPF Specific pathogen-free 
SSC Sideward scatter 
ssRNA Single stranded RNA 
TAE Tris base / acetic acid / EDTA buffer 
TAP Transporter-associated with peptide binding 
tapasin TAP-associated glycoprotein 
Taq Polymerase initially found in Thermus aquaticus 
TCR T cell receptor 
TEMED N,N,N′,N′-Tetramethylethylenediamine 
TGF-β Transforming growth factor beta 
TIR TOLL/IL1 receptor 
TLR Toll-like receptor 
TNBS 2,4,6-Trinitrobenzenesulfonic acid 
TNFα Tumor necrosis factor alpha 
TP1 Telomerase-associated protein 
Treg Regulatory T cell 
TRIF TIR-domain-containing adapter inducing interferon-β 
Tris Tris(hydroxymethyl)aminomethane 
UC Ulcerative colitis; Colitis ulcerosa 
VHH Victor Hensen House (animal facility) 
VSV Vesicular stomatitis virus 
ZTH Central animal facility 
β2M Beta-2-microglobulin 
